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CHAPTER 1
General introduction and thesis outline
CHAPTER 1
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URINARY DIVERSION
Acquired bladder pathologies
The urinary system can be subject to different pathologies affecting the kidneys, the ureters, 
the urinary bladder and/or the urethra. Pathologies related to the urinary bladder are most 
common, such as intersititial cystitis, bladder pain syndrome, severe trauma, neuropathic 
diseases or bladder cancer [1-3]. Urothelial bladder cancer is the main cause of bladder-
associated morbidity. Worldwide, it is the 7th most common cancer in men and the 17th 
most common cancer in women, with approximately 180.000 new diagnoses each year [4]. 
With tobacco use as main cause for bladder cancer it is expected that the burden of bladder 
cancer will even increase. This is the consequence of global changes in tobacco use, which is 
now shifting to developing countries [5].
In case of a single and small, but muscle-invasive bladder tumor it may be possible to treat 
patients by removing only a part of the urinary bladder (partial cystectomy). Nevertheless, 
in approximately 20% of patients with muscle-invasive bladder cancer, a complete removal 
of the urinary bladder (radical cystectomy) is required [6]. The subsequent challenge for 
surgeons lies in the reconstruction of an appropriate urinary diversion with gastrointestinal 
tissue (GIT) to allow urinary drainage in these patients [7, 8].
Congenital bladder pathologies
Next to acquired disorders, patients may suffer from congenital bladder abnormalities. In 
patients with spina bifida, limited or absent spinal innervation of the bladder can result in 
diminished viscoelastic properties of the bladder wall. In some of these severely disabled 
patients a urinary diversion with GIT is essential [9, 10]. Children with cloacal or bladder 
exstrophy represent a different patient group and may present with decreased bladder 
compliance and/or capacity [11, 12]. This small patient group is often subjected to either 
augmentation cystoplasty, the creation of continent reservoirs or catheterized stomas 
(Mitrofanoff or Monti technique) using segments of GIT [13, 14].
Urinary diversions
Three different reconstructive options exist for urinary diversions: 1) the ileal conduit, 2) a 
continent cutaneous reservoir, or 3) a continent orthotopic neobladder (Figure 1.1). The 
ileal conduit, or urostomy according to Bricker, is an incontinent diversion in which bowel 
tissue is used to bridge the ureters and an external urine collecting bag on the abdominal 
wall [15]. 
The external bag is applied to the skin opening on the abdominal wall to collect continuous 
draining urine. The cutaneous reservoir is a continent pouch, but requires intermittent 
catheterization through a stoma on the abdominal wall [10]. In contrast, a neobladder is 
directly anastomosed to the urethra and could allow normal voiding, although in some 
patients additional catheterization might be required [16].
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Figure 1.1: Reconstructive options for urinary diversion created with bowel tissue. A) ileal conduit. B) 
continent cutaneous reservoir. C) Neobladder. Adapted from: Brady Urology at John Hopkins Hospital.
Every type of urinary diversion is associated with consequences, complications and a 
reduced quality of life. The choice of urinary diversion varies between countries, surgeons’ 
experience and institutions [7, 17]. Patients should be encouraged to participate in the 
decision-making process, together with surgeons and nurse specialists, to find the most 
suitable urinary diversion for each individual patient [18]. Although some studies propose 
that continent diversions should be available for all patients, neobladders in particular are 
often only created in younger and healthier patients. The assumption of a better quality of 
life with continent diversion drives most surgeons to perform this surgery when possible, but 
may be as low as 15% of patients [17, 19, 20]. The ileal conduit remains the gold standard 
due to the lack of an established superior alternative and is still performed in the majority of 
patients [21].
Gastrointestinal tissue
In principle, any bowel segment can be used to reconstruct the urological system, but an 
ileal segment is most favorable [22, 23]. This autologous tissue is simple to mobilize, contains 
extensive mesentery and is abundantly present [24]. Long-term survival with acceptable 
quality of life can be accomplished with the use of ileal tissue [25, 26]. Nevertheless, healthy 
bowel tissue is necessary to make the reconstruction. Collection of ileal tissue may be 
difficult, if not impossible in patients presenting with complex clinical problems. In healthy 
individuals urinary tissue allows low-pressure storage and transport of urine, yet bowel 
tissue is responsible for the reuptake of key nutrients from stool. The incompetence of bowel 
tissue for urine transport may results in different complications. The use of bowel in pediatric 
patients in particular has disadvantages since it can have a tremendous effect on growth and 
bone density, as urine is resorbed through bowel mucosa causing metabolic disturbances 
[27-29]. Subsequent long-term complications and (re)hospitalization have a high impact and 
burden on healthcare systems.
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Ileal conduit – consequences and complications
Although the ileal conduit remains the gold standard in urological reconstruction, this 
approach is not without risk. The average age of patients receiving an ileal conduit is 66 years, 
representing an elderly patient population who often suffer from co-morbidities [17, 30, 31]. 
The surgical intervention to create the ileal conduit involves an extensive three-step approach: 
radical cystectomy, bowel resection and creation of the ileal conduit. It goes without saying 
that long hospitalization and recovery is required for these patients [32]. In 50-70% of these 
patients early complications occur. Readmission to the hospital occurs in 25% of patients 
within 90 days [33, 34]. Moreover, in 45% of the patients complications develop within 5 
years, and increasing to 94% after 15 years [34]. These complications are either related to 
the conduit itself or to the bowel surgery and include infections, stenosis, parastomal hernia, 
bleeding, bowel obstruction, fistulas, malabsorption, electrolyte imbalance and urolithiasis 
[2, 35-37] (Table 1.1). The causes for the complications may be related to the baseline frailty 
and presence of co-morbidities of this patient population [38].
Complications Short-term Long-term 
Urine leak 2% - 
Bowel leak 2% - 
Sepsis 3% 3% 
Kidney infection 3% 18% 
Wound infection 7% 2% 
Wound dehiscence 3% - 
Gastrointestinal bleed 2% - 
Abscess 2% - 
Prolonged ileus 6% - 
Conduit bleed 2% 10% 
Intestinal obstruction 3% 5% 
Ureteral obstruction 2% 6% 
Parastomal hernia - 2% 
Stomal stenosis - 30% 
Stone formation - 7% 
Excessive conduit length - 9% 
Metabolic acidosis - 13% 
Conduit infarction - 2% 
Volvulus (rotated bowel) - 7% 
Conduit stenosis - 3% 
Conduit-enteric fistula - <1% 
Table 1.1: Short- and long-term complications after use of bowel tissue in the ileal conduit. Adapted from 
Campbell-Walsh Urology, 10th edition, Section XV, Chapter 85, Table 85-5. Incidence as a percentage of the total 
number of reported cases from the literature.
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UROLOGICAL TISSUE ENGINEERING
Tissue engineering and regenerative medicine (TERM)
Design of a biological substitute may preclude the use of bowel in urological tissue 
engineering [39]. Omission of bowel tissue will prevent donor site-associated problems, may 
reduce operating time and the burden on healthcare costs [40, 41]. Different definitions have 
been developed to explain the field of tissue engineering. According to the Royal Netherlands 
Academy of Arts and Sciences, “tissue engineering and regenerative medicine (TERM) aims to 
functionally restore damaged tissues and organs by using (the characteristics of) tissues and 
cells” [KNAW, 2009] [42]. The National Institute of Health states it is “an interdisciplinary field 
of research and clinical applications to create living, functional tissue to repair or replace 
tissue or organ function lost, due to age, disease, damage or congenital defects” [NIH, 
2010] [43]. Transplantation and reconstruction surgery, materials science, cell biology and 
bioengineering are combined in this field of translational research and can be used to create 
biological tissue substitutes for urinary diversion.
Neobladders and bladder augmentation
The creation of a neobladder is considered the ultimate goal for TERM after radical 
cystectomy, since this would allow voiding at socially acceptable intervals and avoid external 
applications such as a stoma bag [44]. Two clinical trials have been initiated to evaluate tissue 
engineered neobladders. Implantation of neobladder in seven myelomeningocele patients, 
showed a very promising long term outcome in a phase I clinical trial [45]. Nevertheless, the 
results could not be substantiated in a consecutive phase II clinical trial for patients with 
neuropathic bladders [46]. Creation of a tissue-engineered neobladder is challenging; it 
requires a detrusor muscle and innervation to store urine at low pressure and allow complete 
voiding at socially acceptable intervals [47, 48]. Most preclinical research in bladder tissue 
engineering therefore aims to reconstruct only a part of the urinary bladder after partial 
cystectomy [49, 50].
Artificial urinary conduits
An artificial urinary conduit can be considered as an extended ureter to drain urine from 
the kidneys. The function will be mainly determined by its form and might therefore be 
relatively easy to design. A muscular layer in the conduit may be desirable for peristalsis, but 
is not absolutely necessary [24, 51]. The ileal conduit remains the gold standard technique 
for urinary diversion and is used in the majority of patients. Clinical implementation of an 
artificial urinary conduit using TERM techniques may therefore have a significant clinical 
impact [33]. Ideally, a functional artificial urinary conduit can be used in a large patient 
population and the results may be translated to regenerate other urological tissues, such as 
the (neo)bladder, ureter or urethra in the future [52-54].
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For many years, researchers have attempted to identify an alternative for bowel tissue in 
urinary diversion. The earliest designs relied on alloplastic materials, like silicone rubbers, 
latex and Teflon, but none presented with acceptable durability. The investigators concluded 
that a biocompatible and biodegradable material was required to maintain long-term 
function and durability [55]. The feasibility of an artificial urinary conduit created by TERM 
was first proposed 10 years ago in a rat study. A tubularized construct created from small 
intestinal submucosa (SIS) from porcine origin seeded with fibroblasts was subcutaneously 
implanted [56]. Since then, only a limited amount of studies have described similar 
approaches [39, 51, 57-59]. A pioneering study by Geutjes et al. proved the feasibility of the 
artificial urinary conduit in a large animal model [39].
Figure 1.2: TERM for the artificial urinary conduit. Development of a large tubular construct with biomaterials 
to mimic the extracellular matrix (ECM). Collagen alone may not be sufficient enough, therefore reinforcement 
strategies, like polymer meshes can be considered. Cells and/or bioactive factors (growth factors or peptides) 
can be incorporated to improve regeneration and/or vascularization. Vascularization is key for successful 
outcome of TERM. Additionally, materials need to be sterilized before they can be evaluated in large animal 
models.
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CONSTRUCT DESIGN
Biomaterials
Several key aspects of TERM need to be considered for the design of an artificial urinary 
conduit [33] (Figure 1.2). The basis of all TERM approaches for (re)creation of large tissues 
lies in the choice of an appropriate biomaterial, since they act as scaffolding material for 
tissue (re)generation [60]. A candidate biomaterial for the artificial conduit should provide 
structural and mechanical support to withstand pressure from surrounding tissue and 
allow watertight urine transport from the ureter to the exit on the abdominal wall in a urine 
collection bag [61]. Furthermore, the material should be biocompatible and biodegradable, 
avoid a major inflammatory response and stimulate tissue regeneration. Many different 
(bio)materials have been proposed for tissue engineering, including synthetic materials like 
polyglycolic acid (PGA) or poly(lactic-co-glycolic acid) (PLGA), decellularized tissues from 
autologous, allogeneic or xenogeneic tissue (i.e. bladder acellular matrix (BAM) or small 
intestinal submucosa (SIS)) and naturally derived matrices of which collagen is the most 
frequently used [45, 56, 59, 62].
Collagen is a structural protein, abundantly present in the human body to provide structural 
integrity for many tissues, such as the urinary bladder [63], through a triple-helical coil (fibril) 
of collagen molecules [64]. Over 26 different types of collagen have been identified in the 
human body, of which type I and II collagen are most prevalent. In urinary tissue, type I 
collagen is the most abundant type of collagen Artificial scaffolds containing collagen are 
known for their low antigenicity, excellent biodegradation, bio- and tissue compatibility and 
induction of cell differentiation. Importantly, when in suspension collagen can be molded 
in a variety of different forms and shapes. Collagen is therefore a preferred component to 
include when designing a tubular construct. Collagen-based materials are often used in 
TERM research for urological reconstruction, including bladder augmentation and urethra 
reconstruction [65, 66]. For the artificial urinary conduit, collagen scaffolds are too fragile 
and lack mechanical strength. Therefore, reinforcement strategies are necessary to form a 
hybrid tubular construct with adequate strength to provide the structural and mechanical 
support [39]. Several different reinforcement strategies have been proposed for large tubular 
constructs, including the addition of a compressed collagen layer or film, or synthetic 
polymer meshes or knitting [44].
Cells
When engineering urinary-like tissue it is important to mimic the original function of the 
tissue or organ and this may be improved by the introduction of a cellular component to 
the biomaterial of choice. The urothelial layer and the smooth muscle layer are the main 
components of urinary tissue (Figure 1.3). Rapid establishment of the urothelial cell layer 
is important as it forms a barrier that protects the underlining tissue or biomaterial from 
toxic urine and prevents degradation, stone formation, calcification and scar tissue [58, 67]. 
CHAPTER 1
18
Although acellular scaffolds have been reported to allow urothelium formation, this process 
may be enhanced by pre-seeding the biomaterials with urothelial cells [59, 68]. The muscle 
layer of the bladder is important for bladder function, but may be of less importance for the 
urinary conduit, since its acts as a passive drainage system. Nevertheless, its presence may 
enhance urinary flow by peristaltic contraction. Different cell types from different sources 
have been described to show improved urinary tissue regeneration, including bladder cells 
(urothelial cells (UC) and smooth muscle cells (SMC)) [66, 69]. Additionally, alternative cell 
sources have been proposed for patients with bladder cancer, such as mesenchymal stem 
cells from bone marrow (BMSCs) or adipose tissue (ADSCs) or urine-derived stem cells from 
the kidney’s pyelum (UDSCs) (Figure 2) [51, 57, 58]. 
Figure 1.3: Urinary tissue. A) schematic overview of urinary system with ureters, bladder, prostate and 
urethra. B) tubular bladder-tissue to be recreated in the artificial urinary conduit: an inner lining of urothelium, 
supported an extracellular matrix (ECM) containing a muscle layer. C) Theoretical design of a reinforced collagen 
construct seeded with urothelial cells (UC) and smooth muscle cells (SMC).
Vascularization
Of equal importance for a successful outcome is the presence of a perfused vasculature to 
provide the implanted cells or regenerating tissue with sufficient oxygen and nutrients [70]. 
Without such vasculature, tissue regeneration will be limited by diffusion and may even 
cause death of implanted cells [71]. Formation of a novel vasculature is an interplay between 
vasculogenesis (de novo vessel formation) and angiogenesis (sprouting from surrounding 
vessels). A frequently used technique to promote angiogenesis is the wrapping of implants in 
omentum, a well vascularized tissue, to mature the construct before or during implantation 
[59, 72]. Additionally, growth factors can be incorporated to attract endothelial progenitor 
cells and induce vasculogenesis [54, 73, 74]. However, the use of growth factors is debatable 
since release from the biomaterial may be difficult to control and growth factors may be 
washed out by the urine flow. This may lead to unwanted side effects.
Animal models and systematic reviews 
Design and evaluation of an artificial urinary conduit cannot and should not be limited 
to laboratory testing alone. To fully evaluate the performance of a large TERM construct 
A B C
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and allow translation to a clinical setting, preclinical testing in animal models is required 
[75]. A suitable animal model allows researchers and surgeons to evaluate the surgical 
characteristics and performance of the artificial conduit and should adequately predict the 
outcome in humans.
In clinical studies, the use of systematic reviews is widely accepted and has become 
an important aspect of evidence-based medicine. The application of this technique to 
preclinical (animal) studies is still in its infancy but is gaining ground as an essential part 
in the preparation of research proposals. Systematic search strategies and corresponding 
analyses of all preclinical evidence will maximize clinical translation and implementation. It 
will provide insights in how preclinical animal studies should be designed, conducted and 
analyzed [76].
Clinical implementation and sterilization
With clinical implementation in mind, other important aspects to consider are the packaging 
materials, the storage conditions, the shelf-life and the final sterilization techniques [28]. 
FDA-approved techniques, such as gamma(γ)-irradiation, ethylene oxide (EtO) degassing 
or wet/steam sterilization remove or destroy all forms of microbial life by either physical or 
chemical processes. Depending on the type of material and the choice of sterilization, the 
effect on biomaterial performance can be substantial [77]. It is therefore important to include 
a FDA-approved sterilization technique in early phases of research.
CHAPTER 1
20
THESIS OBJECTIVE & THESIS OUTLINE
The aim of this thesis was to systematically gather and analyze preclinical evidence on 
urological tissue engineering (urinary bladder and urinary diversion) and to develop an 
engineered artificial urinary conduit as a replacement for bowel tissue.
Part I: Systematic reviews for urological tissue engineering 
Systematic reviewing techniques were used to compile a database with all available 
studies regarding TERM for the urinary bladder and urinary diversion. In chapter 2, a 
systematic review regarding TERM for the urinary bladder was performed to make an 
unbiased comparison of preclinical results with clinical experience to provide insight in the 
translational value of preclinical experimentation. This relatively large field within urological 
tissue engineering may yield valuable information for new and uncultivated research areas, 
such as artificial urinary diversion. In chapter 3, a similar approach was used to create a 
more detailed overview of preclinical work on artificial urinary diversions. An evidence-based 
systematic review of the literature was performed to investigate all preclinical evidence with 
animal models evaluating TERM products for urinary diversion to identify a suitable animal 
model for this application.
Part II: The artificial urinary conduit
In part II, an artificial urinary conduit was designed using TERM strategies. In chapter 4, three 
differently reinforced collagen-based tubular constructs were evaluated for their potential 
use in urinary diversion. All three constructs were simultaneously connected to the porcine 
bladder to identify the optimal construct for the artificial conduit. Subsequently, the best 
construct from chapter 4 was used in a porcine model to create an artificial urinary conduit. 
Chapter 5 describes three different approaches for implantation: 1) direct implantation of 
the construct, 2) direct implantation of a cell seeded construct and 3) pre-implantation of 
the construct the subcutis to form an autologous graft, followed by translocation to create 
the conduit. For clinical application, materials require a validated sterilization method 
before the translation from animal models to patient can be made. However, the type of 
sterilization may affect material characteristics and functional outcome. In chapter 6, the 
most suitable biomaterial from chapter 4 was sterilized using two validated procedures. The 
in vitro behavior and in vivo performance as artificial urinary conduit was evaluated in an 
adult goat model.
The results and conclusions of these studies are summarized in chapter 7 in combination 
with future perspectives for further research and developments for the implementation of 
the artificial urinary conduit.
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ABSTRACT
To evaluate the potential of tissue engineering of the bladder a systematic review for 
preclinical studies in the current literature was performed. The outcomes of the preclinical 
studies were compared with the available clinical evidence to investigate the feasibility of 
tissue engineering for future clinical use.
Preclinical studies investigating tissue engineering for bladder augmentation were identified 
through a systematic search in PubMed and Embase (period: January 1st 1980 until January 
1st 2014). Primary studies in English were included if they performed bladder reconstruction 
after partial cystectomy using a tissue engineered biomaterial, in any kind of animal species 
with cystometric bladder capacity as an outcome measure. The outcomes were compared 
with clinical studies available on clinicaltrials.gov, and published clinical studies.
In total 28 preclinical studies were included, showing remarkable heterogeneity in study 
characteristics and design. Studies in which pre-operative bladder volumes were compared 
with post-operative volumes were considered the most clinically relevant group (18 studies). 
Bladder augmentation through tissue engineering resulted in a normal bladder volume in 
healthy animals with the influence of a cellular component being negligible. Furthermore, 
experiments in large animal models (pigs and dogs) approximated the desired bladder 
volume more accurately than in smaller species. The initial clinical experience was based on 
seemingly predictive healthy animal models with a promising outcome. Unfortunately, these 
results were not substantiated in all clinical trials, showing dissimilar outcomes in different 
clinical/diseased backgrounds. The translational predictability of a model with healthy 
animals might be questioned.
Through this systematic approach we present an unbiased overview of all preclinical 
studies that investigated the effect of bladder tissue engineering on cystometric bladder 
capacity. Preclinical research in healthy animals appeared to show the feasibility of bladder 
augmentation by tissue engineering. However, in view of the disappointing clinical results, 
based on healthy animal models, new approaches should also be evaluated in preclinical 
models with dysfunctional/diseased bladders. This may aid in the development of clinical 
applicable tissue engineered bladder augmentation with satisfactory long-term outcome.
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INTRODUCTION
Decreased bladder compliance and/or capacity due to bladder dysfunction e.g. neuropathic 
bladder, may require bladder augmentation. Current surgical techniques mainly involve the 
use of gastrointestinal tissues. Due to the physical properties of the tissue, complications 
such as metabolic disorders, bladder perforation, stone formation, infections, hematuria-
dysuria syndrome and potential development of cancer due to metaplasia might occur [1, 
2]. In order to avoid these complications and extensive surgical operations, new alternative 
therapeutic approaches are needed. Tissue engineering approaches could offer innovative 
options for bladder reconstruction by the use of biomaterials, supplemented with cells and/
or growth factors. This approach might result in the regeneration of bladder tissue or in the 
construction of a neo-bladder, which has been pioneered by Atala et al. [3].
In this systematic review we present a comprehensive overview of the current literature 
regarding preclinical bladder tissue engineering, with a quantitative and unbiased 
comparison of study outcomes. Cystometric bladder volume was used as an outcome 
measure to assess the effect of tissue engineering, since bladder volume is of paramount 
importance in the clinical situation. Furthermore, we discuss the available information of 
clinical experience with tissue engineered bladders.
MATERIALS & METHODS
Search strategy
We systematically searched PubMed and EMBASE (OvidSP) up until January 2014 to 
systematically identify preclinical studies for tissue engineering and bladder reconstruction 
[4, 5]. Synonyms for tissue engineering were combined with synonyms for bladder 
reconstruction, using MeSH (PubMed) and EMTREE terms (EMBASE) as well as free-text words 
from titles or abstracts ([tiab] or /ti,ab.) (Figure 2.1). Subsequently, results were filtered for 
animal studies, using previously designed animal filters [6, 7]. The reference lists of included 
studies and relevant reviews were screened for any missing studies. Furthermore, clinical 
trials regarding this subject were manually identified from clinicaltrials.gov and PubMed.
Study inclusion
After removal of duplicates and triplicates in End-Note (Thompson-Reuter, End-Note X5), two 
reviewers (VS and MS) excluded studies based on study titles that clearly were not related to 
the subject. Next, they independently screened the abstracts of the remaining studies in Early 
Review Organizing Software (EROS, IECS, Buenos Aires, Argentina, www.eros-systematic-
review.org), excluding studies based on 4 criteria: 1) no bladder reconstruction after partial 
cystectomy, 2) no tissue-engineered biomaterial 3) no animal model, and 4) review articles. 
Reviews were labeled, but not included for further analysis. Thereafter, the eligibility of 
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studies was investigated by a full-text assessment. Here, five additional criteria were used for 
the exclusion: 1) not an original article (e.g. conference abstract or editorial comment), 2) not 
published after 1980, 3) no cystometry data available and lack of mean, standard deviation/
standard error and number, 4) no diseased background and 5) not published in English. In all 
stages of the process, discrepancies were discussed until consensus was reached.
Figure 2.1: Search strategy. Synonyms for tissue engineering and synocyms for bladder reconstructions 
were combined and using MeSH terms (PubMEd) and EMTREE terms (EMBASE). Free text words from titles of 
abstriacts were added ([tiab] or /ti,ab.) Results were filtered by previously designed animal fitlers. 
Data extraction
Table 2.1 shows the general characteristics and outcomes of the included studies. The 
quality of the studies was assessed using a previously designed questionnaire (Figure 2.3, 
Sloff et al (2014), submitted). Cystometry data on bladder volume (mean bladder capacity, SD 
and number of animals) was used for meta-analyses. In case of more than one experimental 
group or time point, the most successful group, as indicated by the authors, at the end point 
was used in the analyses. The parameter of bladder volume was chosen because it has the 
highest clinical significance in bladder augmentation procedures; aimed at restoring bladder 
volume and protection of the upper urinary tract.
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Meta-analyses
Meta-analyses were performed for mean bladder volumes. Due to large differences in 
absolute bladder volumes between species, standardized mean differences (SMD) were 
calculated for the individual studies [8]. Since different species and biomaterials were used, 
considerable heterogeneity was expected. Therefore studies were organized according 
to study type (I-IV) and analyzed using a random effects model to obtain the overall effect 
size, 95% confidence (CI) interval and I2 (measure of statistical heterogeneity). Type I studies 
compared experimental bladder volumes with volumes of healthy control animals, type II 
studies compared pre-operative with post-operative measurements in the same animals, 
type III studies compared sham-operated animals to outcome, although the definition 
of sham-operated was unclear, type IV studies compared augmented animals with non-
augmented animals (primary closure) after partial cystectomy. Further subgroup analyses 
were only performed with type II studies, and included animal species and construct type 
(with or without cells). ReviewManager [Review Manager (RevMan) [Computer program]. 
Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.] 
was used for creating forest plots and performing meta-analyses.
RESULTS
Study inclusion and characteristics
Figure 2.2 shows the flowchart of study inclusion and exclusion. Finally, 28 papers were 
included for data synthesis and meta-analysis [9-36]. Exclusions during full-text assessment 
were mainly related to incomplete or lack of cystometry measurements. No additional 
references were found in the reference lists of the included studies or relevant reviews. Three 
papers were excluded from further analysis, since either the control group was represented 
as 100% without any SD or the experimental group consisted of only one subject [37-39].
The type of control group varied across studies, which were therefore categorized into four 
different types (Type I-IV, Table 2.1). The studies show a high degree of heterogeneity with 
respect to animal species, extent of cystectomy, follow-up, biomaterials and the use of cells 
and growth factors.
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Figure 2.2: Flow-chart of study inclusion. Study inclusion from PubMed and Embase.
Type of Study Animals Age/Weight Cystectomy Follow-up (months) Material 
Mauney 2011 I Mice (CD-1, ?) 6 weeks 1 cm2 2,5 Silk 
Adamowicz 2012 I Rats (Wistar, M) ? 0,7 cm2 ? Amniotic membrane + BMSC 
Lepper 2002 I Rabbits (?, M) 3,1-4,2 kg 16 cm2 3 Collagen 
Horst 2013 II Rats (Lewis, F) 200 g Partial 2 PLGA/BAM 
Jack 2009 II Rats (Rnu, F) 200-250 g 50% 3 PLGA + ADSC 
Wefer 2001 II Rats (SD, F) 3 months 50% 3 BAM 
Yang 2005 II Rabbits (NZ, F) 2,5-3,5 kg 40-50% 2 BAM 
Zhu 2010 II Rabbits (NZ, M) ? 40-60% 6 BAM + ADSC 
Zhu 2011 II Rabbits (NZ, ?) ? 60-70% 6 BAM 
Paterson 2002 II Minipigs (Yucatan, ?) 53-76 lbs 48 cm2 12 SIS 
Portis 2000 II Minipigs (Yucatan, F) ? 9 cm2 3 SIS 
Jayo 2008 II Dogs (Mongrel, M/F) ? 80% 24 PGA + SMC/UC 
Jayo 2008 II Dogs (Mongrel, M/F) ? 75% 9 PLGA + SMC/UC 
Kambic 1992 II Dogs (?/?) 25 kg 50% 4 Pericardium 
Kropp 1996 II Dogs (Beagle, M) 11-13 kg 35-45% 14 SIS 
Roth 2011 II Dogs (Beagle, M) 13,9 kg 40% 2,5 SIS + nanoparticles 
Sievert 2006 II Dogs (Mongrel, F) 1 year 50% 7 BAM 
Zhang 2006 II Dogs (Beagle, M) 12-13 kg 90% 9 SIS + SMC/UC 
Caione 2006 II Pigs (Landrace, F) 2 months Partial 3 SIS 
Hattori 2006 II Pigs (?,M) 15-18 kg 50% 3 Collagen 
Sharma 2011 II Monkey (Baboon, F) 18-20 kg 40-50% 2,5 SIS + MSC 
Chen 2010 III Rats (SD, M) 300 g 50% 3 Collagen + bFGF 
Kajbafzadeh III Rats (SD, M) 250-270 g 50% 3 BAM 
Yu 2007 III Rats (SD, M) 400-450 g 50% 2 Collagen-coated PCL 
Mimura 2010 IV Rats (SD, F) 337,9 ± 30,2 g 50% 2 Pericardium 
Piechota 1998 IV Rats (SD, M/F) ? 50% 4 BAM 
Piechota 1999 IV Rats (SD, M/F) 3 months 50% 4 BAM 
Koiso 1983 IV Rabbits (?,F) 2-2,5 kg 50% 12 Poly(Ɛ-benzyloxycarbonyl-l-lysine) 
Table 2.1: Study characteristics. Type I: healthy control. Type II: pre-operative control measurement. Type III: 
undefined sham operation. Type IV:non-augmented bladder after partial cystectomy is control. Abbreviations. 
SD=Sprague-Dawley, NZ=New Zealand, BMSC=bone marrow stem cells, PLGA=poly(lactic-co-glycolic)acid, 
BAM=bladder acellular matrix, ADSC=adipose derived stem cells, SIS=small intestinal submucosa, SMC=smooth 
muscle cells, UC=urothelial cells, MSC=mesenchymal stem cells and bFGF=basic fibroblast growth factor.
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Tissue engineering for bladder reconstruction
The quality of the included studies was sufficient (Figure 2.3), specifying the most important 
details on animal number, species, biomaterial, extent of cystectomy and follow-up period. 
Pooling the effect sizes of all study types was not sensible, because the use of different 
control groups required different interpretation of the results (Table 2.2). Nevertheless, 
heterogeneity (I2) was still high for individual study types, suggesting that besides control 
groups other factors including animal species, biomaterials and surgical techniques might 
play a role in causing study type heterogeneity.
Figure 2.3: Quality assessment of type II studies (pre-operative control). Blue = yes, red = no, green = unclear 
and purple = not applicable.
Meta-analyses for type I and II studies did not show a significant difference in bladder 
volume (SMD) between control, either healthy or pre-operative, and experimental animals. 
In the type III studies the sham control group was undefined but no significant difference 
was observed. In comparison, for type IV studies a significant effect was found: experimental 
animals presented with a larger bladder volume than the control animals in which a partial 
cystectomy without augmentation was performed (Figure 2.4).
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Study Type SMD [95% CI] I2 Included studies 
Type I 1,38 [-2,26 ; 5,03] 90% 3 
Type II 0,10 [-0,69 ; 0,89] 80% 18 
Type III 1,06 [-0,93 ; 3,04] 81% 3 
Type IV 5,54 [0,33 ; 10,74] 88% 4 
Table 2.2: Meta-analysis study Type I-IV. Abbreviations: CI: confidence interval, SMD is standard mean 
difference. Type I, II and III show a non-significant difference between control and experimental group. Type IV 
does show a significant difference between control and experimental group.
Figure 2.4: Forest plots study type I and II. Green squares are the outcome of each study (with a 95% 
confidence interval (CI)). The area of each square is proportional the study weight. The black diamant at the 
bottom represents the total effect size of the studies combined. 
Subgroup analyses
Bladder augmentation is performed to restore normal bladder volumes. In the type II studies, 
pre-operative values were compared with post-operative values, an approach also used in 
the clinic. Thus, this study type comes closest to the clinical situation and was therefore 
used for subgroup analysis. Subgroup analyses were performed for different animal models 
(Figure 2.5) and construct types (cellular and acellular, Figure 2.6).
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Figure 2.5: Forest plots animal studies (type II). Heterogeneity (I2) A:0%, B:95%, C:57% and D:73%. Green 
squares are the outcome of each study (with a 95% confidence interval (CI)). The area of each square is 
proportional the study weight. The black diamant in the bottom represents the total effect size of the studies 
combined.
Subgroup analysis showed that bladder reconstruction in rats resulted in a significantly 
larger bladder volume, in contrast to the overall effect found for all type II studies (Figure 
2.5A). This effect was not restricted to type II studies: in all the rat studies bladder volumes 
increased, regardless of type of control (2.77 [95% CI 0.78-4.77]). In the three rabbit studies 
the bladder volume was negatively affected, including a large 95% CI. This was mainly due 
to Zhu 2010 and Zhu 2011 (Figure 2.5B). Large animal models were limited to pigs and dogs 
but both correctly approximate the desired effect, as was observed in the combined type II 
Figure 2.6: Forest plots cellular and acellular constructs (type II). Heterogeneity (I2) A:83% and B:77%.
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studies (Figure 2.5C and D). Use of either species results in an I2<75%, which is lower than 
in the combined type II studies. Dogs show a narrower 95% confidence interval, with an effect 
closer to the desired type II effect than was observed in the pigs.
Furthermore, we investigated the effect of (pre-)seeding biomaterials on bladder volume and 
compared cellular constructs with acellular constructs (Figure 2.6). No significant difference 
was observed between the two subgroups (large overlap in 95% CI). A slight shift towards a 
smaller bladder volume was observed for the cellular constructs.
DISCUSSION
Bladder tissue engineering
Developments in preclinical research for urinary bladder reconstruction have resulted in 
two clinical trials in the past years [3, 40]. We performed a systematic search of the current 
literature to identify all preclinical research regarding tissue engineering for urinary bladder 
reconstruction, to investigate the reality of a tissue engineered bladder as a possible new 
therapy. Using predefined criteria, with cystometric bladder capacity outcome being one, 28 
studies were included. Bladder augmentation aims to restore bladder volume and thereby 
protect the upper urinary tract. This parameter has therefore the highest clinical significance 
and was therefore chosen to be evaluated. The heterogeneity between these 28 studies was 
high: different species and biomaterials were used. Based on control groups, the 28 studies 
were divided over 4 groups: I: healthy controls, II: pre-operative as control, III: undefined sham 
operation, IV: partial cystectomy with primary closure. Every type of control has specific 
(dis)advantages. In the type II studies the approach is analogous to the clinical case where 
increased bladder capacity is the primary goal of surgery. Therefore, the type II studies were 
used for further subgroup analysis.
Bladder capacity was used to compare the outcome of the different studies and predict the 
success of a tissue engineering approach in the clinic. In animal models the bladder volume 
should ultimately return to normal values after partial cystectomy and augmentation, 
resulting in a non-significant difference between healthy and experimental groups. The latter 
was true for the type II studies where animals served as their own control. This suggests 
that the same bladder capacity can be achieved after partial cystectomy followed by repair 
with a biomaterial, indicating the feasibility of tissue engineering for bladder augmentation. 
However, the variation within this study type was quite high (I2) with deviations in both 
positive and negative directions. Most likely this is the corollary of the inclusion of different 
animal species and biomaterials. In the type IV studies, the bladder volume did not restore to 
the original volume after partial cystectomy and primary closure of the defect. Comparison 
of type II studies with type IV studies indicates that the restoration of bladder capacity is 
indeed the consequence of the tissue engineering approach.
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Cells and bladder volume
The effect of (pre-)seeding tissue engineered constructs in bladder reconstruction remains 
subject of discussion within the field of tissue engineering. Although different groups have 
reported the advantageous effect of a cellular component, we show that in the evaluated 
animal models a cellular component does not result in a better bladder volume than acellular 
constructs [17, 41]. Acellular and cellular constructs resulted in similar final bladder volumes 
after augmentation. In fact, a slight decrease in bladder volume is observed in the group with 
cellular constructs. In this review, we only focused on bladder volume as the most important 
parameter. Although cells do not seem to aid in the preservation of bladder capacity, they 
might be necessary for (long-term) tissue regeneration. Whether cell seeding has a favorable 
effect on other essential parameters such as voiding patterns, bladder compliance and 
bladder histology is unclear, and is beyond the scope of this review as these parameters 
were not included. Only healthy animals were included in this review, and therefore only 
healthy cells were used for cell-seeding. Other cell sources might be considered to achieve 
a clinically satisfactory outcome when cell-seeded scaffolds are used. Alternatively, smart, 
acellular scaffold might be considered.
Animal models
Besides indicating the effectiveness of a tissue engineering approach, we aimed to identify 
an animal model that would adequately predict the behavior of tissue engineered constructs 
for bladder augmentation. Small animal species (such as rats and rabbits) do not appear 
to approximate the desired effect (Type II). In rats, bladder tissue engineering leads to a 
larger bladder volume after treatment regardless of study type (I-IV). This may be explained 
by the high regenerative capacity of the rat bladder: even after subtotal cystectomy without 
augmentation the bladder volume recovers completely [42]. The rabbit model shows a very 
heterogeneous pattern of outcomes with respect to bladder volume (Figure 2.5B). Formation 
of calcifications, a known drawback of this model [43], may explain the variation, but this 
was reported in only one out of three studies (Zhu 2011). Type II studies in large animals 
is limited to dogs and pigs, and both appear to be a representative animal model to study 
bladder tissue engineering, since normal bladder capacities are reached after augmentation. 
However, the use of dogs in experimental research remains subject to ethical discussion.
Clinical trials
In the first clinical study concerning bladder tissue engineering a seeded collagen or 
composite collagen-polyglycolic acid scaffold was used for augmentation cystoplasty in 
young patients with myelomeningocele [3]. This phase I study was based on their preclinical 
experience in dogs [37]. The outcomes did not show any cytotoxicity and indicated the 
safety of this approach, suggesting a promising future for this technique. Further research 
in two dog studies supported their findings: bladder capacity was regained 3-6 months 
after implantation of the construct [20, 21]. From both the clinical and preclinical data it 
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appears that both omental wrapping and bladder cycling were crucial to the success as 
this lead to larger post-operative bladder capacities. No major complications were reported 
in the (pre)clinical studies. Unfortunately, in a phase II clinical trial including ten patients 
with neuropathic bladder due to spina bifida, the results were disappointing. A seeded 
polyglycolic/polylactide scaffold adapted to the individual size was implanted onto the 
bladder. Many patients experienced multiple adverse events and most patients were 
converted to a traditional ileocystoplasty at the time of the publication [40]. Although the 
phase I and phase II trials were comparable in design, using the same clinical background, 
cell types, omental wrapping and bladder cycling techniques, the promising efficacy of the 
phase I study could not be substantiated in the phase II study. 
In contrast, repair of exstrophic bladders (a different disease status), with SIS alone in 5 
young patients aged 5-17 years showed a more favorable outcome. Here, they showed the 
development of a bladder wall covered with a multilayered urothelium fully covering the 
lamina propria, similar to normal urothelium. The smooth muscle wall was less developed 
when compared with the native detrusor wall and long-term continence was not achieved 
[44]. One might therefore question the predictive value of the preclinical experiments in 
healthy large animals [27, 40].
Diseased animal models
The different outcome of the phase II study in patients with neuropathic bladders may 
be explained by the disease status of the bladder. The harvested bladder material as a 
cell source or the regenerative capacity of the bladder itself might have influenced the 
regeneration process. This may have resulted in the unsatisfactory clinical outcome, whereas 
the preclinical studies suggested a favorable outcome. Whether the favorable outcome in 
the exstrophic bladder scenario was the result of the more potent regenerative capacity in 
young patients or superior quality of the urothelium of extrophic bladders in comparison to 
neuropathic bladder is unclear.
Although the number of studies in diseased animals is low, the exclusion of these studies 
might have biased our extrapolation of the preclinical results. Three studies investigating 
tissue engineering of a diseased bladder were identified. The rat studies report a positive 
outcome for tissue engineered bladder augmentation in a diseased model, but these results 
have to be viewed with caution given the inherent regenerative capacity of the rat bladder 
which might have influenced the outcome positively [45, 46]. Bladder augmentation after 
outlet obstruction in a large animal model was less effective than in a healthy animals, 
which might indicate the negative effect of disease status on bladder regeneration [47]. 
Furthermore, age might also influence the regenerative capacity of the bladder. In new-born 
lambs with a bladder exstrophy the regeneration pattern in diseased and normal bladders 
was similar [48]. However, the regenerative capacity in new-borns is more potent than in 
adults, which may have obscured abnormalities that may occur when older animals are 
studied. This might explain why a slightly better outcome in the clinical trial in patients with 
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exstrophic bladder was observed. The evidence in diseased animal models, though limited, 
suggests that the disease status might influence the regenerative capacity of the subject. 
Indeed, in vitro analysis showed that the proliferation and differentiation capacity of isolated 
urothelial and smooth muscle cells from diseased patients was diminished and altered 
compared to healthy individuals [49, 50]. The altered proliferation capacity observed in 2 
patients of the phase II clinical study suggests that this may have played a role in the clinical 
outcome and explain the disappointing outcome. Collectively the evidence appears to imply 
that the disease status influences outcome of bladder tissue engineering.
Study limitations and recommendations
A systematic review in combination with a meta-analysis is an adequate approach to 
objectively identify and analyze studies within a certain field of research. Using predefined 
selection criteria selection is objective, but it might result in the exclusion of indirectly 
relevant and high-quality papers, which is a drawback of this approach. The key parameter 
of this systematic review was bladder capacity, although other parameters including bladder 
compliance, voiding patters, and tissue regeneration using histological and morphological 
analyses are of equal importance. Furthermore, variables including biomaterials, growth 
factors and extent of cystectomy might influence study outcomes. To further investigate 
the efficacy of this approach, these parameters need to addressed to gain more insight into 
bladder tissue engineering.  As has been noted here, a successful preclinical outcome does 
not necessarily translate to a successful clinical trial. It is therefore important to design a 
preclinical study using the best predictive model available with an adequate diseased 
background to mimic the clinical situation. For bladder tissue engineering large animals with 
diseased bladders appear to present the best possible study model.
CONCLUSIONS 
The preclinical evidence suggests that tissue engineered bladder augmentation in healthy 
animals results in normal bladder capacity at follow-up. The advantageous effect of cell 
seeding with respect to bladder volume was not evident in the animal studies from the 
evaluated literature. Large animals models, like pigs and dogs appeared to be the best 
predictive models, but  the translational value of models with healthy animals appears to 
be questionable, since the regenerative capacity might be overestimated compared to the 
clinical setting. We believe that tissue engineering of the bladder may become a reality in 
the future, but to correctly predict the effect of tissue engineering for bladder augmentation, 
animal models with dysfunctional bladders should also be evaluated.
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ABSTRACT
Tissue engineering and regenerative medicine (TERM) approaches may provide alternatives 
for gastrointestinal tissue in urinary diversion. To continue to clinically translatable studies, 
TERM alternatives need to be evaluated in (large) controlled and standardized animal studies. 
Here, we investigated all evidence for the efficacy of tissue engineered constructs in animal 
models for urinary diversion. Studies investigating this subject were identified through a 
systematic search of three different databases (PubMed, Embase and Web of Science). From 
each study, animal characteristics, study characteristics and experimental outcomes for 
meta-analyses were tabulated. Furthermore, the reporting of items vital for study replication 
was assessed. The retrieved studies (8 in total) showed extreme heterogeneity in study 
design, including animal models, biomaterials and type of urinary diversion. All studies 
were feasibility studies, indicating the novelty of this field. None of the studies included 
appropriate control groups, i.e. a comparison with the classical treatment using GI tissue. 
The meta-analysis showed a trend towards successful experimentation in larger animals 
although no specific animal species could be identified as the most suitable model. Larger 
animals appear to allow a better translation to the human situation, with respect to anatomy 
and surgical approaches. It was unclear whether the use of cells benefits the formation of a 
neo urinary conduit. The reporting of the methodology and data according to standardized 
guidelines was insufficient and should be improved to increase the value of such publications. 
In conclusion, animal models in the field of TERM for urinary diversion have probably been 
chosen for reasons other than their predictive value. Controlled and comparative long term 
animal studies, with adequate methodological reporting are needed to proceed to clinical 
translatable studies. This will aid in good quality research with the reduction in the use of 
animals and an increase in empirical evidence of biomedical research.
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INTRODUCTION
Urinary diversion with gastrointestinal (GI) tissue remains the gold standard treatment for 
patients suffering from end-stage bladder disease caused by bladder cancer or congenital 
malformations, e.g. bladder exstrophy or spina bifida [1,2]. There are three approaches 
to create a urinary diversion in these patients. The first and most commonly used type 
among surgeons is the incontinent ileocutaneostomy; a urinary conduit with a skin-outlet. 
Alternatively, continent diversions can be formed non-orthotopically with a skin-outlet or 
orthotopically as a neobladder [3,4]. Although the use of GI tissue provides a satisfactory 
outcome in most cases, it can be associated with severe complications. These can be 
either related to the bowel surgery (obstruction, infections, fistulas, etc.) or to the urostomy 
implantation (metabolic disorders, stone formations, infections, etc.) [5,6].
A tissue engineering and regenerative medicine (TERM) approach may provide new 
possibilities by creating a man-made construct to replace GI tissue for urinary diversions. The 
implementation of such constructs could prevent invasive bowel surgery and the potentially 
life-threatening complications, therefore reducing health care costs. Several investigators 
have focused on the development of new materials for this purpose, including naturally 
derived materials, synthetic polymers and decellularized scaffolds [7-9]. These biomaterials 
can be applied with and without autologous cells, using the regenerative capacity of the 
body [10,11].
In the field of urogenital reconstruction, bladder domes for cystoplasty and uretheral 
reconstruction with man-made constructs have already been used in patients [12,13]. 
However, despite the progress in in vitro research and animal experimentation, clinical 
translation of TERM approaches for urinary diversion has been negligible. Translation 
from bench to bedside for these tissue engineered constructs starts with the analysis of 
biodegradability, biocompatibility and foreign body response, which is usually performed 
in small rodents. To engineer and regenerate specific tissues, evaluation should preferably 
be performed at relevant anatomical sites with appropriately sized constructs to permit easy 
clinical translation. Large animal models closely mimicking the human body are therefore 
desirable, but their use might be ethically debatable [14]. In general, the choice of an animal 
model is dependent on financial considerations, the investigators experience, ethical 
sensitivity and practical limitations. Even though other and better translatable models might 
be available [15]. To our knowledge a superior animal for tissue engineering and urinary 
diversion has not been identified yet.
To decide on the most suitable type of animal model an evidenced-based systematic review 
is essential, since it potentially increases the chance of successful clinical translation [16,17]. 
We therefore systematically searched the current literature for all types of studies on the 
efficacy of tissue engineered constructs in animal models for urinary diversion. The results 
were analyzed with respect to survival, side effects, functionality and urothelium formation, 
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to investigate whether there was sufficient evidence to decide if any animal model was 
superior for evaluating tissue engineered constructs for urinary diversion applications.
MATERIALS AND METHODS
Search strategy
We identified relevant studies, including peer reviewed articles and (congress) abstracts, 
through a systematic search of PubMed, EMBASE (OvidSP) and Web of Science up until the 
23rd of January 2013, following the approach as described by de Vries et al., and Leenaars et 
al. [16,17]. In all three databases synonyms for tissue engineering (e.g. tissue engineering, 
tissue engineered, regenerative medicine or biomaterials) were combined with synonyms for 
urinary diversion (e.g. orthotopic diversion, neobladders, continent or incontinent stomas). 
MeSH terms (PubMed) and EMTREE terms (EMBASE) were used when available and were 
combined with additional free-text words from titles or abstracts ([tiab] or /ti,ab.). For the 
complete strategy, see Figure 3.1. In PubMed and Embase (OvidSP), the results were filtered 
for animal studies, using previously designed ‘animal filters’ [18,19]. The included primary 
studies and relevant reviews on the subject were screened for additional relevant references.
Study selection
Only primary studies that evaluated tissue engineered construct for urinary diversion in 
animal models were included. From the retrieved set of papers, duplicates and triplicates 
were manually deleted from EndNote, considering the preference PubMed>EMBASE>Web of 
Science. Based on title/abstract, primary screening was performed by a single review author 
(MS), deleting articles that clearly did not involve tissue engineering or urinary diversion. In 
case of any doubt, articles were included for further screening. Secondary screening of title/
abstract was independently performed in Early Review Organizing Software (EROS, IECS, 
Buenos Aires, Argentina, www.eros-systematic-review.org) by two review authors (MS and 
RdV). The following inclusion criteria were used: 1) urinary diversion, 2) tissue engineering, 
3) (living) animals of any species, and 4) primary articles. In this step, a procedure was 
considered to be a urinary diversion if it involved a total/radical cystectomy or implantation 
of a stoma or pouch connected to at least one ureter. Articles that described a partial 
cystectomy, hemi-cystectomy or bladder augmentation were excluded, because they do not 
relate to urostomy. Tissue engineered constructs were defined as biomaterials or polymers 
that aided the (re)construction of tissues. Articles were either categorized as ‘included’, 
‘excluded’ or ‘more information necessary’ if important details were not included in the 
abstract. Any discrepancies were discussed and re-evaluated until consensus was reached. 
Full-text articles were retrieved and evaluated for definite inclusion/exclusion, based on the 
same criteria used for the secondary screening. The reference lists of the included studies 
and manually identified reviews on the subject were screened for any missed references. 
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Unfortunately, one of the included studies was published in Korean and we did not have the 
resources to have it translated [20]. The article was therefore excluded from this review.
Data extraction
From every included study, basic information (author, year of publication, etc.), animal 
characteristics (species, sex, etc) and study characteristics (biomaterial, follow-up, etc.) 
were extracted and tabulated by MS and RdV after reaching consensus (Table 3.1). The 
Figure 3.1: Search strategies. In PubMed, EMBASE and Web of Science, synonyms for tissue engineering and 
urinary diversion were combined. MeSH terms for PubMed and EMTREE terms for EMBASE were used as much as 
possible and combined with additional free-text words ([tiab or /ti.ab.) The results were filtered using published 
“animal filters”.
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outcome of the studies for the meta-analysis was assessed using extracted data on mortality, 
adverse effects, occlusion (blockade of urinary flow) and the formation of urothelium on the 
implanted construct (Table 3.3).
Methodological quality assessment
All included studies were feasibility studies only, i.e. no comparison was made between the 
new (tissue engineering) and classical treatment (GI tissue) or any other relevant control 
group. Therefore, performing a risk of bias-assessment was not possible, and we consequently 
focused on the quality of the reporting of data and outcomes of the studies (Table 3.2).
Meta-analyses
Meta-analyses were performed for the outcome measures functionality (absence of occlusion) 
and formation of urothelium in seven studies. One study did not describe the animal species 
and was therefore excluded [26]. Since appropriate control groups were not included in any 
of the studies, it was not possible to perform a standard meta-analysis using, for example, 
odds ratios. We therefore performed a meta-analysis of proportions, more specifically 
of the number of animals in which a functional construct or urothelium was formed as a 
proportion of the total number of treated animals. First, exact binomial confidence intervals 
were calculated for the individual studies. To circumvent continuity corrections (some 
studies had 0 events), an arcsine transformation of the proportions was carried out for the 
meta-analyses [21]. Because high heterogeneity was expected, the individual proportions 
were pooled using a random effects model. Given the low number of studies, a Hartung-
Knapp adjustment for random effects models was applied [22]. I2 was used as a measure of 
heterogeneity. The analyses were conducted in R (version 3.0.1; R Core Team 2012), using 
the metafor package [23,24]. To explore the potential influence of animal size on the effect, 
the studies were ranked according to the subgroups “large” (rabbits and larger) and “small” 
(rats and mice) models in the forest plots. The small group sizes prevented calculation of 
an overall effect per subgroup and therefore only visually derived tendencies are presented.
RESULTS AND DISCUSSION
Study inclusion 
Database searches yielded 573 references for PubMed, 855 references for Embase and 315 
references for Web of Science (Figure 3.2). After removal of duplicates and triplicates 1157 
references remained. During the primary screening in EndNote, 883 references that did 
not meet our inclusion criteria were removed. Secondary screening of the remaining 274 
references in EROS led to the removal of 206 references. Full text analyses of the remaining 
68 references resulted in the inclusion of only 8 studies: two abstracts, one poster and five 
full-text papers (Figure 3.3). Screening of the reference lists of these papers and manually 
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identified relevant reviews on the subject did not yield any new references. Thus, the final 
set included: Geutjes et al. (2012), Basu et al. (2012), Kloskowski et al. (2012), Liao et al. 
(2013), De Filippo et al. (2009), Bertram et al. (2009), Drewa et al. (2007), and Dørflinger et 
al. (1985) [11, 25-31]. Although the number of published studies on tissue engineering for 
urinary diversion in animal models appeared to be substantial, only these selected studies 
applied tissue engineered constructs for urinary diversion at relevant clinical sites in animal 
models. The recent increase in published papers on this subject is remarkable. Although all 
relevant databases were explored, we cannot exclude that some data reside within company 
protected domains. Moreover, studies tend to be published only when results are positive 
and statistically significant [32]. These two factors may have resulted in an incomplete data 
set and they may have introduced a publication bias in this systematic review. Due to the 
limited number of included studies, we were not able to estimate the risk and effect of this 
publication bias.
Study characteristics
Analysis of study characteristics revealed extraordinary diversity (Table 3.1). Various animal 
species, including pigs, minipigs, dogs, rats and rabbits, were used. They were implanted 
with constructs of either biodegradable polymers (poly(lactic-co-glycolic acid) (PLGA), 
polyglycolic acid (PGA) or collagen) or decellularized material (small intestinal submucosa 
Figure 3.2: Flow-chart of search and screening process. Primary screening exclusion was performed in 
End- Note. Criteria included: no urinary diversion, no tissue engineering or reconstruction of ureter or urethra. 
Secondary inclusion was performed in EROS. Criteria included: no urinary diversion, no tissue engineering, no 
animal study or no primary study.
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(SIS) and bladder acellular matrix (BAM)). Kloskowski et al., used a biodegradable polymer 
polycaprolactone (PCL) and decellularized aortic arches. Although three different approaches 
for urinary diversion are known (urinary conduit, abdominal pouch and neobladder), the 
included studies only created urinary conduits (5 studies) or neobladders (3 studies). An 
animal model for an abdominal pouch was not described.
There are three different study designs within the pool of included studies: studies that 
use cellular or acellular scaffolds and studies that compare these two constructs (Table 
3.1 and 3.4). The most frequently used study design was the comparison between cellular 
and acellular constructs (4 studies), investigating whether (pre-)seeding of the biomaterial 
resulted in a superior outcome. These studies generally isolated their cells from a bladder 
biopsy, although alternative sources like adipose tissue, peripheral blood and cell lines 
were investigated (Basu et al., Drewa et al., Geutjes et al. and Liao et al.). The other studies 
compared different materials (Kloskowski et al.), cell concentrations (Bertram et al.) or 
different experimental designs (Dørflinger et al.). Filippo et al. compared the behavior of  a cell-
seeded PLGA-based scaffold in cystectomized animals with its behavior in children enrolled 
in a Phase II trial for bladder augmentation. This diversity in animal species, biomaterial or 
study design complicates the interpretation of the results of this systematic review.
Since tissue engineering for urinary diversion is a relatively new area of research, the 
main focus of the studies was to determine the feasibility of implantation and subsequent 
behavior of the designed constructs. Follow-up time was less than a year in all cases, 
whereas constructs need to be functional throughout the remainder of a patients’ life time. 
Stoma complications can occur after several years in patients, and short follow-up in animals 
will not provide evidence on late complications. This indicates the necessity of appropriate 
control groups with the classical techniques and longer follow-up for at least 1 year.
Figure 3.3: Inclusion and exclusion of papers during secondary and full-text screening in EROS. After 
primary screening 274 papers were analyzed in EROS, resulting in the inclusion of 8 papers. Papers were 
excluded which were without urinary diversion, tissue engineering or animals or when they were reviews. For 
one study, we did not have the resources for translation.
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Quality assessment
The lack of control groups precluded a risk of bias-analysis. We therefore focused on 
the reporting quality of the studies (Table 3.2). Our specific interests were the animal 
characteristics, the composition, dimensions and preparations of the construct, the 
representativeness of the results and the adequate reporting of drop-outs.
The reporting was relatively poor in the abstracts compared to the full-text papers. Many 
abstracts omitted important details that are essential to compare different studies, including 
animal species, strain, number and sex, type of tissue engineered scaffolds, description of 
the composition, dimensions and preparations of the construct (Q1-Q9). This might have 
been partly the consequence of the word and space limitation for abstracts
All included studies appropriately described the predefined outcome measures and stated 
at which time evaluation took place. Only two studies commented on the representativeness 
of the figures for the overall study outcomes (Dørflinger et al. and Drewa et al.) (Q10-Q13). In 
total, three papers were complete in their reporting of the study design (Drewa et al., Geutjes 
et al., and Liao et al.).
Although guidelines for standardized reporting of animal experimentation have been 
described, these have not yet been generally accepted [33,34]. We observed that in some 
studies, especially in the abstracts, these guidelines were not implemented. It is crucial to 
further improve methodological reporting to aid future research, even in abstracts.
Data synthesis
To determine the efficacy of the tissue engineered constructs, we focused on the outcome 
measures: formation of a functional conduit or reservoir and the formation of urothelium 
in the regenerated tissue, evidenced by histology (Table 3.1). Some studies performed 
additional analyses, including immunohistochemistry, urograms or pyelograms (Table 
3.1), but these were not considered here. Because constructs can only be functional in the 
absence of major complications (including mortality), we first looked at the survival of the 
animals and adverse effects. Survival of the animals was regarded as the first indication for 
the safety of a construct and represented a condition for the efficacy of a construct. Secondly, 
since urine needs to exit the body adequately, the formation of a reservoir or conduit with a 
urothelial lining was deemed essential. 
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Adverse effects and mortality
Experience shows that even in some situations animals might die of unrelated causes, with 
more likelihood in larger experimental groups. A clear and detailed description of the drop-
outs will increase the credibility of the study. Surprisingly, two studies did not explicitly report 
on the mortality rate, but the studies suggest that all animals survived the procedure in good 
health (Basu et al, and Bertram et al.) They imply that a functional urinary conduit with 
urothelial linings is formed in all animals without any adverse effects (Table 3.2, Q14-Q17 
and Table 3.3). Such a successful score was not described in any of the other studies, which 
raises the possibility that the success rate was overestimated. The reported mortality of the 
other studies ranged between 60% in the pioneering study in 1985 (Dørflinger et al.) to 13% 
in the most recently published paper (Liao et al.), suggesting the application of improved 
constructs or improved surgical techniques over the years. Geutjes et al. is the only study that 
reports on both related and unrelated deaths.
All studies report on inflammation of the construct and the surrounding tissues, although 
this does not necessarily constitute a negative effect. Some degree of inflammation may 
guide tissue regeneration, remodeling and the formation of blood vessels. The formation 
of a vasculature structure in large constructs still remains a major problem in tissue 
engineering [35,36]. Other common adverse effects found in the majority of the studies were 
hydronephrosis and hydroureters, prevention of which remains the biggest challenge for 
tissue engineers. The designed constructs were not able to control urinary pressure, leading 
to reflux to the kidney and the aforementioned conditions.
The formation of stones in urinary diversions is one of the complications in using GI tissue. 
Remarkably, only one study, performed in pigs reported the formation of calcifications 
(Geutjes et al.). The absence of stones, particularly in the included rabbit study, is unexpected 
(Liao et al.). Implantation of a tissue engineered patch in the bladder wall of rabbits resulted 
in a high incidence of stone formation and encrustation, indicating that this animal model in 
particular is prone to develop stones [37,38]. Although a different biomaterial was used in a 
different setting, no stones were formed up until two months in the study performed by Liao 
et al. In humans, it takes months to years to develop urinary stones and perhaps the follow-
up time in these studies is too short (<1 year) to detect stones [39]. Obviously, due to the 
difference in diet composition, flow speed, composition and pH of  urine in different species, 
urinary stones might not develop in some animals. Long-term follow-up is necessary to 
exclude encrustation or stone formation.
Efficacy
We conducted meta-analyses for the outcome measures functionality and urothelium 
formation (Figures 3.4A and B). The aim of these meta-analyses was not to obtain a 
precise point estimate, but rather to get an impression of the quantitative relations between 
the results of the individual studies and to detect trends [40]. The heterogeneity between 
the studies was very high (I2=96% for functionality and I2=95% for urothelium formation). 
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Although this did not justify pooling of the results, nevertheless, overall proportions were 
calculated for functionality and urothelium formation (69% [CI: 18 – 100%] and 65% [CI: 17 – 
98%], respectively). Due to the large heterogeneity and small number of studies, these overall 
proportions should be interpreted with caution. To prevent misinterpretations, overall 
proportions are only shown as dotted vertical lines in the forest plots.
Successful formation of functional conduits with full urothelial linings, the primary goal 
of all studies, varied between the studies. Only small numbers of functional conduits and 
urothelial coverage were observed by Dørflinger et al., Drewa et al. and Kloskowski et al. In 
contrast, Liao et al. showed that in 4/5 cases a functional conduit was formed with urothelial 
linings. The large heterogeneity and small number of studies complicates identification of 
the underlying cause of the different results. We can only speculate whether these were the 
consequence of the biomaterial, the animal model or confounding factors.
Figure 3.4 Forestplots for functionality (A) and urothelium formation (B). Forest plot of 7 studies. Filippo et 
al. was excluded for both meta-analyses since the study does not report on the type of animal, functionality and 
urothelium formation. * indicates studies with large animal species. Grey quares are the outcome of each study 
(with a 95% confidence interval (CI)).
Animal models
The small number and heterogeneity of the studies did not permit subgroup analysis for 
different animal species. However, the forest plots (Figures 3.4A and B) from the meta-
analyses suggested a tendency towards better results in large animal models compared to 
small animals. Although we cannot exclude the effect of confounding factors, this supports 
the idea that future research should focus on larger animals. Larger animals have a more 
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similar anatomy to the human body than, for example, rodents, and allow for evaluation at 
clinical relevant sites with constructs of a comparable size. Moreover, surgical techniques 
and materials are more comparable to the human setting, therefore mimicking the human 
situation as closely as possible. In 1985, the first report on the use of a construct to tissue 
engineer a urinary diversion as a replacement for GI tissue in large animals was published 
(Dørflinger et al.). Even though the mortality rate was high, a functional reservoir could be 
formed showing the feasibility of this approach. In later studies small animals were used 
(Kloskowski et al. and Drewa et al.) but the success rate in these studies was low. This might 
be explained by the surgical challenge with a higher risk of complications in smaller animals.
The extraordinary heterogeneity in animal studies has previously been reported by Roosen 
et al. [41], who reviewed different animal models for the classical types of urinary diversion 
using GI tissue. A uniform conclusion regarding the most suitable animal model could not 
be drawn and the author advised to view the results with caution, when translating these for 
clinical implementation.
Cellular and acellular scaffolds
The studies that compared acellular and cellular scaffolds investigated the effect of (pre)
seeding on tissue regeneration (Table 3.1 and 3.4). Basu et al., Liao et al. and Geutjes et 
al. expanded autologous cells from a biopsy. Basu et al. stated that (pre-)seeding of the 
scaffolds provided an additional advantage, although this was not substantiated. The same 
conclusion was drawn by Liao et al., but here the authors clearly report that the drop-outs 
and adverse effects in the acellular group were higher. Geutjes et al. observed  no difference 
between cellular and acellular constructs.
In the study by Drewa et al., scaffolds were seeded with 3T3 fibroblast from mouse origin, 
followed by  implantation in rats. Not surprisingly, this resulted in an excessive inflammatory 
response and consequently a better outcome for the unseeded group.
The presence of a cellular component can trigger M1 macrophages, resulting in fibroblast 
deposition. In contrast, acellular scaffolds activate the M2 macrophages, which leads to 
reconstruction and regeneration of tissues [35]. Some researchers have reported that scaffold 
(pre-)seeding provides an additional advantage for tissue regeneration, since regeneration 
is less dependent on cellular in-growth [42,43]. Since the effect pre-seeding is outside the 
scope of this systematic review, a meta-analyses was not performed. Therefore, based on 
the available information, it is unclear whether (pre-)seeding of the scaffolds provides an 
advantage for tissue reconstruction in urinary diversions.
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Reference Acellular Cellular 
Basu 2012 8/8 24/24 
Drewa 2007 2/3 1/3 
Geutjes 2012 4/4 5/6 
Liao 2013 4/6 24/24 
Table 3.4: Cellular vs. Acellular: Amount of functional conduits formed in comparative studies with cellular and 
acellular groups. * was tabulated after correspondence with the first author. 
Concluding remarks
Based on this systematic review the most adequate animal model for urinary diversion  is still 
undefined. Only a limited amount of studies could be identified despite the comprehensive 
search strategy, all showing large heterogeneity. It appears that the predictive value of a 
particular animal model was not a decisive factor in the studies performed. Nevertheless, the 
forest-plots suggested a trend towards successful experimentation in larger animal models, 
supporting the idea that future research should focus on the evaluation of constructs in 
larger animal models which more closely mimic the human body than small (rodent) animal 
models. Bladder augmentations and urethral replacements have been successful in dogs [44-
47]. Although the results of the earliest study were disappointing (Dorflinger) this might be 
explained by the tissue engineering strategy. Use of  a more sophisticated tissue engineering 
approach did lead to satisfactory results (Bertram). In view of the former, evaluation of 
urinary diversion constructs in dogs might be a valid alternative.
Despite the limited amount of data available on this subject, a phase I clinical trial was initiated 
for implantation of a (pre-)seeded tissue-engineered urinary conduit in cystectomized 
patients [48]. Whether it is acceptable to expose patients to a new device which has not been 
investigated in a long term and multicenter animal study remains a matter of debate. Critics 
of animal experimentation might say that it is difficult to find a representative animal model 
to improve clinical translation. In order to improve translational practice, a re-evaluation of 
preclinical practice is warranted, in which systematic reviews and meta-analyses of animal 
studies can provide a valuable tool [49].
This systematic review focused on the identification of an appropriate animal model to 
investigate tissue engineering for urinary diversion. Remarkably, only feasibility studies 
were identified, which are necessary to evaluate potentially valuable techniques. To 
obtain a more thorough estimation of the feasibility and applicability, a large variety of 
approaches should be investigated and should include different biomaterials, growth 
factors and large animal models. Evaluation of the functionality and advantages of newly 
developed constructs should include appropriate controls and evaluate long-term effects 
and outcomes to investigate safety and efficacy of these constructs. Moreover, standardized 
assessment methods are desirable. The ultimate control would be the use of GI tissue, the 
golden standard technique currently used in the clinic. Assessment of these preclinical 
experiments should focus on both functionality and tissue regeneration, using urodynamic 
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measurements and histological evaluations. To continue to clinically translatable studies, 
standardization of (large) controlled and comparative studies with adequate methodological 
reporting is required as laid down in existing guidelines [33,34].
Animal experimentation remains subject to ethical debate and -among others- for animal 
welfare reasons it is therefore essential that research is properly conducted and reported. 
Nevertheless, the reporting of the methodology and representativeness of results was rather 
poor in the reviewed studies. Improvements in this area are urgently needed for ethical, 
scientific and economic reasons, and will allow researchers to repeat studies reliably and 
make an unbiased decision on the most correct animal model for their future experiments. 
The scientific community should adopt the existing guidelines for standardized reporting of 
animal experimentation and implement them in journal author guidelines, which should be 
enforced by editors, to improve standardized reporting in full-text articles. This will aid in 
good quality research with more relevant output for the clinic and reduction of the use of 
animals in biomedical research.
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ABSTRACT 
The use of bowel tissue for urinary diversion can be associated with severe complications 
and regenerative medicine may circumvent this by providing an engineered conduit. In this 
study, a novel tubular construct was identified for this purpose.
Three constructs (Ø=15 mm) were prepared from type I collagen an either (i) a semi-
biodegradable Vypro II polymer (COL-Vypro), (ii) a fast-biodegradable Vicryl polymer (COL-
Vicryl) or (iii) an additional collagenous layer (COL-DUAL). After freezing, lyophilisation and 
cross-linking, all constructs showed a porous structure with a two-fold higher strength for the 
polymer-containing constructs. These constructs were connected to full bladder defects of 
eleven female pigs and evaluated after one (n=4) or three months (n=5).
With respect to surgical handlings, the polymer-containing constructs were superior. All 
pigs voided normally without leakages, and survival rate was 82%. For the implanted COL-
Vypro constructs (8/9), stone formation was observed. COL-DUAL and COL-Vicryl showed 
better biocompatibility and small remnants were only found one month post-implantation. 
Histological an immunohistochemical analysis showed the best regeneration for COL-Vicryl 
with respect to epithelium, muscle pedicles an elastin formation was best developed in the 
COL-Vicryl.
In this study, COL-Vicryl constructs were superior in both biocompatibility and bladder tissue 
regeneration and have high potential for artificial urinary diversions.
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INTRODUCTION
The uretero-ileo-cutaneostomy, or urinary diversion according to Bricker, is an often used 
choice of treatment in the management of end-stage bladder disease [1, 2]. Urinary conduits 
are necessary for approximately 30% of patients with bladder cancer (~430.000 new cases 
estimated worldwide) [3]. A (contemporary) conduit may also be needed to divert urine in 
severe congenital malformations, e.g. bladder exstrophy or spina bifida [4, 5].
The urinary conduit is formed using autologous bowel tissue, but in some cases, this may 
lead to severe complications [6-8]. These complications can be related to the invasive bowel 
surgery or to the application of the urinary conduit itself [9, 10]. To decrease the risk for short 
and long term complications, and therefore improve the quality of life of the patients, new 
and safer treatment options for urinary diversions are currently being explored. A method to 
create an artificial conduit without the involvement of the GI tract would be of great value.
A feasibility study to develop artificial urinary conduits was first demonstrated in a rat model, 
using tubularized small intestinal submucosa (SIS) [11]. Subsequently, more groups reported 
the preparation of artificial conduits in small animals. These conduits were composed of 
synthetic or natural-based materials (polyglycolic acid (PGA)/poly(lactic-co-glycolic acid) 
(PLGA), collagen or bladder acellular matrix (BAM)) [12, 13].
Collagen-based scaffolds have been extensively investigated in preclinical research for 
urological tissue engineering, including bladder augmentation and urethra (re)construction 
[14-16]. Unfortunately, for these applications, collagen scaffolds are known to be quite fragile. 
In particular, the mechanical strength of large diameter and porous tubular constructs is 
insufficient and requires reinforcement. In a previous study, a large tubular-shaped collagen 
construct reinforced with a semi-degradable Vypro II polymer mesh (Ethicon) was used as 
a conduit in a large animal model [17]. Although a urinary conduit was formed in vivo, the 
incompatibility of the polymer mesh resulted in stenosis and fibroblast deposition, indicating 
that alternative reinforcement strategies were needed to improve both the regenerative and 
functional outcome.
In this study, we developed two new reinforced tubular constructs for the potential use in 
urinary diversion applications. The tubular constructs contained either a biodegradable 
polymer knitting (Vicryl), or an additional layer of compressed collagen and were compared 
in vivo to the original collagen-Vypro II polymer construct. Within the framework of reduction 
of animal use, these three tubular constructs were connected simultaneously to surgically 
created defects in the bladder to identify the optimal biomaterial for the artificial urinary 
conduit with respect to biocompatibility and regeneration.
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MATERIALS AND METHODS
Material preparation
Three different reinforced tubular collagen constructs were prepared with a length of 10 
cm and a luminal diameter of 15 mm: two collagen-polymer constructs (COL-Vicryl and 
COL-Vypro) and one dual-layered collagen construct (COL-DUAL). To obtain the polymer-
containing constructs, Vypro II (Ethicon) and Vicryl (polyglactin 910, Ethicon) meshes were 
tubularized around a stainless steel mandrel (ø 17 mm) and sutured with interrupted 4-0 
Vicryl Plus (Ethicon) sutures. The tubularized meshes were combined with a 0.7% (w/v) 
homogenized type I collagen suspension in a polystyrene cylindrical tailor-made mold. A 
stainless steel mandrel (ø 15 mm) was introduced in the lumen of the polymer meshes and 
kept in place by a tailor-made cap [17-19].
The COL-DUAL constructs were prepared by compressing a lyophilized 0.7% (w/v) type 
I collagen tubular construct, by rolling the mandrel over the luminal side until a 0.2 mm 
thickness was reached. Subsequently, a 0.7 % (w/v) type I collagen suspension was 
applied and allowed to connect to the inner layer during 30 min at room temperature [19-
21]. All constructs were further processed through a standard freezing, lyophilization and 
carbodiimide cross-linking protocol [20]. After additional freezing and lyophilization, the 
dried scaffolds were sterilized by 25 kGray γ-irradiation [22] (Synergy Health, Etten-Leur, The 
Netherlands).
Material characterization
The morphology and ultra-structure of the constructs were microscopically evaluated by 
scanning electron microscopy (SEM). The degree of cross-linking was determined using a 
2,4,6-trinitrobenzene sulfonic acid (TNBS) assay, indicated by the reduction of free amine 
groups after cross-linking [18]. The tensile strength was evaluated using the Texture analyzer 
TA.XT HD Plus (Stable Micro Systems, Surrey, United Kingdom) and expressed in Newton. 
In brief, pre-wetted were cut into 10 mm (w) x 30 mm (l) x 1 mm (thickness) and clamped in 
tensile clamps for subsequent analysis (COL-Vypro n=26, COL-Vicryl n=22, COL-DUAL n=24).
Animals and study design
This study was approved by the Ethical Committee on Animal Research of the Radboudumc, 
Nijmegen, The Netherlands. All procedures were performed using the guidelines from the 
Institute of Laboratory Animal Research [23]. In total, eleven female Landrace pigs (± 50 kg) 
were used and divided in two groups: n=5 for evaluation at one month and n=6 for evaluation 
at three months. Randomization of animals and blinded evaluation was not performed, 
due to the clear differences in physical appearances and weight. All pigs received the three 
different tubular constructs which were implanted into the bladder dome. The animals 
received restricted diet and water ad libitum and were individually housed after surgery. 
When possible, animals were placed in groups.
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Surgical procedure
All sutures were purchased from Ethicon. Pigs were anesthetized and received an 8 Charrière 
bladder catheter (Bard Medical, Covington, Georgia, USA). First, the bladder was emptied and 
250 mL of saline was instilled through the catheter to localize the bladder during surgery. A 
median incision of 15 cm was made above the pubic bone and after opening the peritoneum, 
the bladder was localized, lifted and tethered using 6-0 Prolene sutures.
Three separate defects were created in the dome using diathermia electro surgery (Valleylab, 
Minneapolis, Minnesota, USA), spaced approximately 6 cm apart in a triangular fashion. 
The three different scaffolds (5 cm length) were attached to the inner bladder wall by dual-
layered sutures, before closing the distal end (both 4-0 Vicryl running sutures) (Figure 
4.1). The defects and constructs were randomly selected by surgeons and an independent 
third person, respectively, to prevent any bias to positioning of a particular construct. A 12 
Charrière suprapubic Foley catheter (Bard Medical, Covington, Georgia, USA) with 5 mL saline 
was inserted through the bladder wall and attached using 4-0 Vicryl sutures. All constructs 
were covered with fibrin glue (Tissuecol® Duo 500, Baxter, Vienna, Austria) to prevent early 
urinary leakages. The watertight anastomosis was confirmed by the installation of 200 mL 
saline using the bladder catheter. Non-absorbable 6-0 Prolene sutures, spaced 1 cm from the 
constructs, were used for reference.
To prevent peritonitis due to unexpected leakages, the peritoneum was closed using 4-0 
Vicryl sutures, keeping the bladder retroperitoneally. The abdominal cavity was closed using 
Figure 4.1: Experimental procedure. Three tubular constructs were connected to surgically created holes in 
the bladder wall (COL-Vypro, COL-DUAL, COL-Vicryl). Bladder is instilled with 200 mL saline.
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0 Vicryl running sutures for the fascia, 2-0 Vicryl running sutures for the subcutis and CT-1 
Vicryl interrupted sutures for the skin. Finally, the suprapubic catheter was fixed to the skin 
between the hind legs, using CT-1 Vicryl sutures. The catheter was removed after ten days.
Follow-up and evaluation
After one or three months, the pigs were anesthetized as previously described and an 8 
Fr bladder catheter (Bard Medical, Covington, Georgia, USA) was inserted through the 
urethra. The bladder was drained and instilled with 1:1 Xenetix® 300 iodinated contrast 
fluid. Radiological images of the bladder by cystogram were obtained with the BV-25 
C-arm image intensifier (Philips, Eindhoven, The Netherlands). The pigs were sacrificed 
through an overdose of intravenous pentobarbital, after which the bladder was excised and 
macroscopically inspected. Samples of the base of the implantation sites in the bladder and 
pieces of the normal bladder were fixed in 4% (v/v) formaldehyde in phosphate buffered 
saline (PBS) 7.4 and paraffin embedded.
Histology and scoring
Cross-sections of the implantation site were paraffin-embedded, sectioned (5 µm), mounted 
on glass-slides (Superfrost®Plus, Thermo-Scientific, Waltham, MA, USA) and stained 
with hematoxylin and eosin [24]. Both the regeneration and inflammatory response were 
independently scored by two observers (MS and PG). Any discrepancies were discussed and 
re-evaluated until consensus was reached. Subsequently, representative slides were used for 
further evaluation by Masson’s Trichrome and immunohistochemical staining.
Immunohistochemistry
Expression of Pancytokeratin (Panck), Vimentin (Vim), α-Smooth Muscle Actin (SMA), Desmin 
(Des) and Smoothelin (Smo) was analyzed by immunohistochemistry on paraffin-embedded 
material. Heat induced antigen retrieval was performed for Panck and Smo with sodium 
citrate pH 6: slides were boiled for 10 min and cooled for 1 h at room temperature. For all 
stainings, endogenous peroxidase activity was blocked by incubation in 1% (v/v) H2O2 in 
PBS for 30 min. Slides were incubated with 5% (v/v) normal goat serum for 10 min followed 
by mouse-anti-human monoclonal IgG antibodies for 1 h (Table 4.1). After washings with 
PBS, the sections were incubated with BrightVision Poly-HRP antibody (ImmunoLogic, 
Duiven, The Netherlands) including 10 % (v/v) normal swine serum (preincuabted for 30 min). 
After washings with PBS, sections were developed with Bright-DAB (ImmunoLogic, Duiven, 
The Netherlands), counterstained with hematoxylin (Boom, Meppel, The Netherlands) and 
mounted. 
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Antibody Specificity Dilution Target Company 
AE1/AE3 Pancytokeratin (PanCK) 1:800 Epithelial cells Santa Cruz Biotechnology 
D33 Desmin (Des) 1:400 Muscle cells Biogenix 
V9 Vimentin (Vim) 1:1000 Fibroblast Biogenix 
R4A Smoothelin (Smo) 1:75 Mature muscle cells Santa Cruz Biotechnology 
1A4 Smooth muscle actin (SMA) 1:2000 Myofibroblasts Sigma-Aldrich 
Table 4.1: Monoclonal mouse antibodies used for immunohistochemistry.
RESULTS
Material characterization
A macroscopic and microscopic overview of the tubular constructs is shown in Figure 4.2. 
After sterilization and pre-wetting, all constructs retained an open lumen with a diameter of 
15 mm. Ultrastructural analysis by SEM demonstrated full incorporation of the polymers in 
the porous collagen wall of the constructs (Figure 4.2D, F). The pore-size ranged between 
100-200 µm. The COL-DUAL construct demonstrated two connected collagen layers with 
different pore sizes: 100-200 µm for the outer layer and 50-150 µm for the inner compressed 
layer (Figure 4.2E).
Tensile strength analysis, indicated by the maximum force, was superior for the polymer-
containing constructs (COL-Vypro 9.4 ± 6.6 N and COL-Vicryl 15.3 ± 4.6 N). The COL-DUAL 
constructs was significantly lower in comparison to the COL-Vicryl constructs (7.2 ± 2.2 N, 
p<0.0001). Cross-linking was successful as indicated by decrease in free amine groups and 
was comparable for the polymer-containing constructs, (COL-Vypro 198 nmol/mg, 37% 
cross-linking and COL-Vicryl 194 nmol/mg, 40% cross-linking) but was less for the COL-DUAL 
(253 nmol/mg, 17% cross-linking).
According to all surgeons, the suture properties of the mesh-containing constructs were 
superior compared to the COL-DUAL constructs. This resulted in an easy and watertight 
anastomosis. Suturing of the COL-DUAL often led to rupture of the material and subsequent 
leakage of urine.
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Figure 4.2: Material characterization. Macroscopic evaluation (A, B and C, 1 unit = 1 cm) shows incorporation 
of the polymer mesh into the collagenous matrix (COL-Vicryl and COL-Vypro) and a compressed porous layer 
on the luminal side with a porous outer layer for the COL-DUAL. Scanning electron microscopy (D, E and F, bar 
=1 mm) of the collagen constructs shows that all constructs maintain an open lumen after wetting. Lu = lumen, 
arrow in D and F indicates the polymer, arrow in E indicates border between layers.
In vivo evaluation
The survival rate of the animals in this study was 82%, with one related death (obstruction 
of the lower urinary tract one day after surgery) and one unrelated death (tracheal rupture 
after intubation). All pigs were able to void without any apparent changes after removal of 
the suprapubic catheter. One animal showed temporary swelling of the wound area, but no 
other adverse events or leakages were observed. Radiological evaluation did not show any 
bladder abnormalities (data not shown). During explantation, we observed that all bladders 
were moderately adhered to the surrounding tissues at the implantation site (i.e. muscle and 
fat). In all cases, the surgically created defects and the lumen of the constructs were closed. 
Macroscopic differences of the COL-Vicryl and COL-DUAL constructs at both time points were 
minimal, with slightly less contraction in the regenerating area of the COL-Vicryl construct. 
No calcifications of COL-Vicryl or COL-DUAL have been observed. In contrast, in 8 out of 9 
animals the COL-Vypro construct was calcified (Figure 4.3), either on the inside (4 animals) 
or on the outside of the bladder (4 animals). In one animal the material was extruded and no 
longer attached to bladder tissue. 
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Figure 4.4: Two different examples calcifications at the COL-Vypro implantation site in the bladder. Both soft (A) 
and solid (B) calcifications were observed.
Histological analysis
One month after implantation of the COL-Vicryl and COL-DUAL constructs, tissue regeneration 
and remodeling was in an early phase (Figure 4.3 and Table 4.2). Both bladder defects were 
covered by a thin layer of epithelial cells and loose connective tissue was formed with by 
small foothills of muscle pedicles.
Differences between COL-Vicryl and COL-DUAL became more apparent three months post-
implantation. The regenerated tissue of the COL-Vicryl showed more mature bladder tissue 
with muscle pedicles along the entire defect and coverage by a multi-layered epithelium 
(Figure 4.4 and Table 4.2).
Figure 4.7: Histological analysis at one and three months post-implantation of cross-sections at the 
base of implantation. Bar = 600 um and 50 um in close-up. The COL-Vypro construct shows a negative print 
of the polymer, some microvasculature and muscle in growth at the rims of the defect. The COL-DUAL showed 
urothelial coverage, a moderate immune response with little in growth and microvasculature. The COL-Vicryl 
construct also showed urothelial coverage, but more muscle cells and microvasculature with a moderate 
immune response at both time points.
A B
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A. Tissue Regeneration
COL-Vypro COL-DUAL COL-Vicryl 
Epithelium 1 month 
3 months 
+/- 
+ 
+ 
++ 
+ 
++ 
ECM organization 1 month 
3 months 
+/- 
++ 
++ 
++ 
+ 
+++ 
Neo-vascularization 1 month 
3 months 
++ 
++ 
++ 
++ 
++ 
++ 
Muscle formation 1 month 
3 months 
+/- 
++ 
++ 
++ 
+ 
+++ 
B. Tissue Reaction
COL-Vypro COL-DUAL COL-Vicryl 
Hyperplasia 1 month 
3 months 
+++ 
+++ 
+ 
+ 
+ 
+ 
# Cell layers 1 month 
3 months 
0-3
1-5
0-5
2-5
2-5
3-5
Scaffold remnants 1 month 
3 months 
+++
+++
+/-
+/-
-
- 
Granulocytes 1 month 
3 months 
+
+ 
+/-
+/-
+
+/-
Lymphocytes 1 month 
3 months 
+++ 
++ 
++
++
++
+
Macrophages 1 month 
3 months 
++ 
+ 
+ 
+ 
+ 
+/-
Giant Cells 1 month 
3 months 
++ 
+ 
+ 
+ 
+ 
+/-
Table 4.2: Scoring profile. All histology slides, stained by hematoxylin and eosin, were scored (n=4-5) creating a 
representative profile for each construct. Items were organized in (A) tissue regeneration and (B) tissue reaction. 
Items were scored – (not present), +/- (sporadically present), + (moderately present), ++ (abundantly present) or 
+++ (excessively present).
The immunohistochemistry of COL-Vicryl (Figure 4.5) revealed fully differentiated smooth 
muscle cells (Des and Smo-positive cells) at the rims of the defect and in the middle of the 
regenerating area. This was lacking for the COL-DUAL group (Figure 4.6). Masson’s Trichrome 
staining showed more aligned collagen fibers in the ECM and more elastin fibers were clearly 
present along the newly formed muscle pedicles in COL-Vicryl (Figure 4.4, 4.5 and 4.7). 
In both constructs, the newly formed epithelium was Panck-positive, but the differentiation 
status of these cells remains unknown due to the absence of antibody specific reactivity 
for CK20 and UroIII (results not shown). In addition, Vim- and SMA-staining, indicating 
myofibroblasts and new vessels, was homogenously distributed along the defects of both 
the constructs and did not change in time. Multiple accumulations consisting of lymphocytes 
were present at one month for both constructs. At three months, only in the COL-DUAL group, 
these cells were still clearly present in the subepithelium.
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Figure 4.7: Immunohistochemistry COL-Vicryl. Masson Trichrome staining (bar = 1000 µm, collagen = green, 
muscle cells = red, nuclei = brown and elastin = black) and immunohistochemistry of the COL-Vicryl cross-
section after 3 months at the base of implantation. Microvasculature (bar = 100 µm) is present in the centre 
of the defect. Urothelial coverage is shown by Panck staining. Homogeneous Vimentin staining indicates the 
presence of fibroblasts. Many of these cells are in a myofibroblastic stage (aSMA). However, we do observed 
some SMC differentiation halfway of the construct, indicated by Desmin (Des) and Smoothelin (Smo) positive 
cells (bar = 500 µm).
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Figure 4.7: Immunohistochemistry COL-DUAL. Masson Trichrome staining (bar = 1000 µm, collagen = green, 
muscle cells = red, nuclei = brown and elastin = black.) and immunohistochemistry of the COL-DUAL cross-
section after 3 months at the base of implantation. Here, more inflammatory regions below the urothelial 
layer are observed, which is indicated by Panck-positive cells. Microvasculature (bar = 100 µm) is present in the 
centre of the defect. Homogeneous Vim-staining indicates the presence of fibroblasts. Many of these cells are 
in a myofibroblastic stage (aSMA). However, we did observe some SMC differentiation halfway of the construct, 
indicated by Des-positive cells. Only a minority of cells was fully differentiated, indicated by Smo-positive cells 
(bar = 500 µm).
Figure 4.7: Elastin fibers. Visualization of elastin fibers and extracellular matrix three months post-implantation 
(bar = 50 µm). Collagen = green, muscle cells = red, nuclei = brown and elastin = black. COL-Vicryl implantation site 
shows aligned collagen fibers and most elastin fibers around newly muscle pedicles.
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One month after the implantation of the COL-Vypro, little or no tissue regeneration was 
present in the defect area. The tissue was disorganized and a negative imprint of the Vypro 
polymer was visible after both one and three months (Figure 4.4). Another significant 
observation was the aberrant and incomplete epithelial layer. The cell coverage was limited 
and hyperplasia was observed in combination with large amount of inflammatory cells 
along the entire defect (Table 4.2B). In addition, Masson’s Trichrome staining revealed that 
fibrotic tissue dominated in the COL-Vypro regenerated area, without elastin fibers (Figure 
4.7). Differentiated muscle cells were completely absent and neovascularisation was only 
formed at the rim of the defect (Figure 4.8).
Figure 4.8: Immunohistochemistry COL-Vypro. Masson’s Trichrome staining (bar = 1000 µm, collagen = 
green, muscle cells = red, nuclei = brown and elastin = black.) and immunohistochemistry of the COL-Vypro 
cross-section after 3 months at the base of implantation. Microvasculature is present at the rims of the defect. 
Urothelial coverage is present but aberrant, indicated by PanCK positive cells. Homogeneous Vim-staining 
indicates the presence of fibroblasts. Many of these cells are in a myofibroblastic stage (aSMA). Only a minority 
of these cells are Des-positive, and no Smo-positive cells were observed (bar = 500 µm). 
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DISCUSSION
The (re)construction of hollow tubular structures, like the ureter, urethra or the artificial 
urinary conduit using bowel, remains associated with donor site morbidity and severe 
complications. After a radical cystectomy, a urinary conduit is required to drain urine from 
the kidneys and facilitate an external drainage system to protect the upper urinary tract from 
ureterohydronephrosis. Regenerative medicine can be used to develop an artificial urinary 
conduit to omit the use of bowel and retain normal kidney function.
In an initial study, a construct prepared from collagen and a semi-biodegradable Vypro II 
polymer mesh (COL-Vypro) was implanted as a urinary conduit in pigs. Although a lumen was 
formed, some cases showed stenosis and excessive scar tissue formation as a consequence of 
the non-biodegradable properties of the polymer mesh [17]. Due to the poor biocompatibility 
with bladder tissue in combination with a poor clinical outcome, we concluded that the 
Vypro II polymer mesh was unsuitable for urological tissue engineering and the identification 
of novel reinforcement strategies is necessary.
In this study we evaluated two novel tubular constructs produced with different 
reinforcement strategies and biomaterials, and compared these to the previously studied 
COL-Vypro construct. The Vicryl mesh was chosen as a first suitable alternative, since in a 
comparative study in a porcine model the Vicryl mesh showed less fibroblast deposition 
and inflammation compared to the Vypro mesh [25]. Secondly, the COL-Dual construct was 
presumed to be a suitable alternative, since both COL-DUAL and COL-Vicryl constructs have 
been successfully used in the repair of diaphragmatic defects in animal models [21, 26]. In 
agreement with those observations, both constructs also indicated good biocompatibility 
with bladder tissue in vivo, in our study. However, the addition of the biodegradable Vicryl 
polymer mesh showed superior outcome with respect to tissue regeneration.
Formation of a epithelial layer is essential to protect the underlining tissues from harmful 
and toxic urine [27]. Besides epithelial coverage, functional bladder tissue should also 
contain a strong muscular layer with elastin fibers to induce elasticity for filling and 
emptying. Histological and immunohistochemical analysis demonstrated that epithelium, 
muscle pedicle and elastin formation was superior in the COL-Vicryl compared to the other 
constructs. For the COL-DUAL, maximal tissue regeneration did not improve after one month 
while the COL-Vicryl construct induced a prolonged and better regeneration profile at three 
months.
COL-DUAL constructs demonstrated a more pronounced inflammatory response in 
comparison to the non-compressed collagen construct in the COL-Vicryl. We hypothesize 
that the increased inflammatory response might have been the consequence of an increased 
collagen mass rather than collagen cross-linking [28]. Indeed, the inflammatory response 
induced by the COL-Vicryl construct was less pronounced. Altogether, the COL-Vicryl 
construct showed prolonged and better regeneration at three months, proving its suitability 
for the artificial urinary conduit.
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With respect to the production and characteristics of the novel constructs, several remarks 
could be made. Production of COL-DUAL constructs involved manual compression of the 
inner layer and additional freezing and lyophilization, thereby introducing variability. The 
cross-linking and tensile strength was lowest for the COL-DUAL construct (17% vs. 40% in 
COL-Vicryl and 37% in COL-Vypro). The consequence of this became more apparent in the 
surgical procedure: creation of a watertight anastomosis was difficult since the biomaterial 
easily ruptured during surgery.
Vicryl is a copolymer of 90% glycolide and 10% lactide, which is inert, non-antigenic and 
induces only a minor tissue reaction, making it a good temporary support for the healing 
of soft tissues [29]. Furthermore, the commercial availability and FDA approval allows fast 
clinical implementation of this novel tubular construct. In the clinic, Vicryl meshes are already 
successfully used for abdominal wall repair, breast reconstruction, pelvic floor reconstruction 
and as organ bags for temporary tissue support [30-32].
Collagen remnants were rarely found in any of the cases at either one or three months. This 
indicates that the collagenous component of all construct types degraded within one month, 
independent of the applied mechanical compression in the COL-DUAL construct. The fast 
degradation of these two construct might be related to the animal model; pigs are known for 
their rapid regeneration. The COL-Vicryl construct degraded 2.5x more rapid than anticipated. 
Normally, Vicryl is completely absorbed within 70 days and after three weeks only 50% 
of its initial strength is retained [29, 33]. The enhanced degradation rate of the COL-Vicryl 
might have been the consequence of exposure to urine since in an acidic environment the 
hydrolysis of the polyglycolide polymer (Vicryl) increases [34]. Moreover, the materials in this 
study were sterilized using gamma irradiation techniques, a common method of sterilizing 
collagenous medical products. Gamma irradiation does not influence the porous structure, 
cytocompatibility or the strength of collagen construct [22]. Nevertheless, the influence on 
mesh integrity and/or degradation rate should be further investigated.
In two systematic reviews we concluded that tissue engineering for urinary diversion or 
bladder augmentation should be performed in large animals, preferably in dogs or pigs [35, 
36]. In this study, a porcine model was chosen to compare the three different biomaterials in 
one animal, thereby eliminating inter-animal variability. Importantly, this approach leads to 
a reduction in number of animals. 
After connecting the three tubes to the porcine bladder wall, a watertight anastomosis was 
created allowing fluid influx. However, this was not continuous as is the case in a urinary 
diversion model. Within one month, none of the constructs had an open lumen, probably 
due to the limited space in the abdomen, contractility of the bladder wall and/or compliance 
of the constructs. Additionally, the absence of a continuous flow through the constructs 
might also have attributed to this.
In a canine model, the lumen did not close when an esophageal defect was bridged by a 
collagen-coated Vicryl mesh [37], thereby confirming the importance of flow. Nevertheless, 
a thorough analysis of bladder tissue regeneration could be made, and therefore select 
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the ideal biomaterial for artificial urinary diversions. To evaluate the total regenerative and 
functional outcome of the COL-Vicryl construct, this biomaterial should be implanted as an 
artificial urinary diversion, preferably in a large animal model. 
CONCLUSIONS
The polymer-containing collagen constructs were easy to prepare, which resulted in 
large tubular construct with adequate strength allowing fast and watertight anastomosis. 
Histological analysis indicated the best regeneration of bladder-like tissue for the construct 
with a Vicryl polymer mesh. We therefore conclude that a collagen-based construct, 
reinforced with a fast-degradable a clinical applicable Vicryl polymer mesh has excellent 
potential for application as an artificial urinary conduit. 
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ABSTRACT
A readily available artificial urinary conduit might substitute autologous bowel in standard 
urinary diversions and minimize bowel-associated complications. However, the use of large 
constructs remains challenging, as host cellular ingrowth and/or vascularization is limited. 
We investigated large reinforced collagen-based tubular constructs in a urinary diversion 
porcine model and compared subcutaneously pre-implanted constructs to cell seeded and 
basic constructs.
Reinforced tubular constructs were prepared from type I collagen and biodegradable Vicryl® 
meshes through standard freezing, lyophilization and cross-linking techniques. Artificial 
urinary conduits were created in 17 female Landrace pigs with i) a basic (untreated) construct 
(n=7), ii) a construct seeded with autologous urothelial and smooth muscle cells (n=5), or iii) 
a free graft formed by subcutaneously pre-implantation of a basic construct. All pigs were 
evaluated after one month.
Survival rate was 94%. At evaluation, one basic and one cell seeded conduit was occluded, 
whilst urinary flow was maintained in all conduits created with pre-implanted constructs. 
Pre-implantation of the basic construct resulted in a vascularized tissue construct, which 
could be used as a free graft to create an artificial conduit. The outcome was favorable when 
compared to the other conduits: urinary drainage was better, hydroureteronephrosis was 
limited and tissue regeneration was improved.
Subcutaneous pre-implantation of a basic reinforced tubular construct, resulted in a 
vascularized autologous graft which may potentially replace bowel in standard urinary 
diversions. This study introduces a straightforward, two-step procedure to create artificial 
urinary conduits in a large animal model.
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INTRODUCTION
Incontinent urinary conduits from ileum are often required in patients with muscle invasive 
bladder cancer or complex congenital disorders [1, 2]. These conventional conduits are 
created from well-vascularized ileum, with peristaltic movement to ensure urinary flow to 
protect the upper urinary tract from high pressure [3]. Although the Quality of Life (QoL) of 
patients after reconstruction is quite satisfactory, complications at the bowel donor site or in 
the conduit itself often occur [4, 5]. The collection of the intestinal tissue may be difficult, if 
not impossible in patients presenting with complex clinical problems.
A tissue-engineered conduit functioning at least as well as the current standard may reduce 
operating time and prevent bowel surgery with associated donor site complications [6]. 
Similar to conventional conduits, artificial conduits should allow continuous urinary flow 
to protect the upper urinary tract from hydroureteronephrosis and allow placement of 
ostomy pouches [7]. Ideally, the implanted material should also preclude fibrosis and induce 
formation of urothelium to protect the newly formed conduit tissue.
To mimic bowel tissue in the standard urinary conduit, large tubular constructs are 
required to create an artificial conduit in humans or equivalently sized animals [8, 9], but 
creation of such conduits is challenging. Supplementary strategies such as cell seeding or 
establishment of a vascular structure may be unavoidable to prevent conduit contraction 
and hydroureteronephrosis [10, 11].
A previous proof-of-principle study showed the feasibility of the construction of an artificial 
urinary conduit in a large animal model, but it was clear that material improvements were 
necessary [6]. A superior tubular construct was developed containing collagen type I and a 
biodegradable polymer knitting [12]. This construct was used in the present study to create 
artificial urinary conduits using three different implantation methods in a porcine model: 1) 
direct implantation of a basic construct 2) direct implantation of a basic construct seeded 
with autologous urothelial and smooth muscle cells and 3) pre-implantation of a basic 
construct to create an autologous tissue tube that could be used as a graft for the conduit. 
Functional outcome, hydroureteronephrosis, macroscopic and microscopic inspection were 
used as outcome parameters to evaluate each approach.
MATERIALS AND METHODS
Basic construct preparation and evaluation
Reinforced tubular constructs (l = 10 cm, ø = 15 mm, from here on referred to as “basic 
construct”) were prepared from a 0.7% (w/v) type I collagen sponge and tubularized Vicryl® 
polymer meshes for reinforcement (VM74, Polyglactin 910, Style 12, Ethicon) [12]. In brief, 
the Vicryl® polymer mesh was manually tubularized using 4-0 Vicryl® interrupted sutures 
(Ethicon) and combined with 50 mL 0.7% collagen suspension in a silicon cylindrical mold. 
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A stainless steel mandrel was inserted to maintain an open lumen, which was kept in place 
by a tailor-made cap. After standard techniques of freezing, lyophilization and cross-linking 
by EDC/NHS [13], constructs were packaged in blisters containing 70% ethanol (v/v) for 
sterilization by 25 kGray γ-irradiation (Synergy Health). Cross-linking was evaluated by a 
trinitrobenzene sulfonic acid assay [14]. Construct morphology was assessed using scanning 
electron microscopy (SEM, JEOL 6310). Before in vivo use, the constructs were washed at 
least three times in buffered saline until no ethanol washout was visible anymore.
Animals and study design
Experiments were approved by the Ethical Committee on Animal Research of the 
Radboudumc, Nijmegen, The Netherlands [15]. We included 17 three-month old female 
Landrace pigs (± 50 kg), receiving restricted diet and water ad libitum. Animals were 
individually housed after surgery and placed in groups when possible. Randomization and 
blinding was not possible due to clear differences in physical appearances and weight. The 
experimental design is depicted in Figure 5.1. In ten pigs, a bladder biopsy (n=10, 1x1 cm2) 
was harvested under general anesthesia through a 5 cm median abdominal incision and 
stored for cell isolation and culture (Table 5.1).
Figure 5.1: The experimental design. Ten pigs underwent initial bladder biopsies and were subsequently 
assigned to the basic construct or cell seeded construct group (basic construct seeded with urothelial and smooth 
muscle cells, n=5) according to cellular yield. Seven pigs were assigned to pre-implantation (extraperitoneal or 
subcutaneous), two of the extraperitoneal implanted pigs were converted to group the basic construct group. 
One animal died of peritonitis.
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Cell isolation and culture
The transport of biopsies, cell isolation and cell culture has been described previously [6]. 
Straight after biopsy, tissues were stored in transport medium (Hank’s Balanced Salt Solution 
(HBSS, Gibco) with Ca2+ and Mg2+, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES, Gibco), 1 µg/mL Aprotinin (Gibco), and 10.000 u/mL penicillin and 10.000 µg/mL 
streptomycin). Tissues were enzymatically treated with 2.4 U/mL Dispase II (Sigma, in HBSS 
without Ca2+ and Mg2+, 10 mM HEPES, 1 µg/mL Aprotinin and 10.000 u/mL penicillin and 
10.000 µg/mL streptomycin) and stored o/n at 4°C. Subsequently, the urothelial layer was 
mechanically removed by scraping the tissue with forceps. To obtain a single cell suspension, 
urothelium was further treated with 100 U/mL Collagenase IV (Sigma, in HBSS with Ca2+ and 
Mg2+, 10 mM HEPES and 10.000 u/mL penicillin and 10.000 µg/mL streptomycin). UCs were 
suspended in KSFM and seeded in PrimariaTM flasks.
For SMC isolation, the remaining tissue was cut in small pieces (1x1 mm2) and treated with 
0.5 mg/mL Liberase Blendzyme (Roche) (in HBSS with Ca2+ and Mg2+) for 90 min at 37°C. To 
obtain a single cell suspension, a 70 µm cell strainer was used. SMCs were then resuspended 
in SMCM and seeded in normal tissue culture flasks.
Urothelial cells (UCs) were cultured in PrimariaTM Flasks (Falcon, BD) with keratinocyte 
serum-free medium (KSFM) containing 0.5 ng/mL epidermal growth factor, 5 ng/mL bovine 
pituitary extract, 30 ng/mL cholera toxin (All Gibco, Thermo Fischer Scientific) and 10.000 
u/mL penicillin and 10.000 µg/mL streptomycin. SMCs were cultured in Smooth Muscle 
Table 5.1: Suture protocol. All sutures were purchased from Ethicon.
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Cell Medium (SMCM), 1% SMCM growth supplements, 2% fetal calf serum and 10.000 u/mL 
penicillin and 10.000 µg/mL streptomycin (All Sciencell) in normal culture flasks (Corning 
Inc.).
Cell seeded constructs
Biopsies (n=5) with the highest cellular yield were used to create cell seeded constructs. Basic 
constructs were pre-incubated in Smooth Muscle Cell Medium (SMCM) and subsequently 
immersed in a 25 mL suspension of 40-50 x 106 smooth muscle cells (SMC, P3) in SMCM 
and rotated at 2 rpm at 37°C for cell adherence overnight. Subsequently, both ends of the 
construct were closed with 4-0 Vicryl® sutures (Ethicon), and 4-5 x 106 urothelial cells (UC, 
P2) in Keratinocyte Serum-Free Medium (KSFM) were injected into the lumen and allowed to 
adhere for 8h at 37°C. The constructs were turned after 4h. After cell adherence, the sutures 
were removed and the seeded constructs were further cultured in 50% SMCM and 50% KSFM 
for 7 days until implantation. The mixed medium allowed proliferation of both cell types. Cell 
coverage and cell ingrowth was then determined by SEM and immunohistochemical analysis 
on snap-frozen samples. Cell-seeded constructs were used in an autologous setting.
Pre-implanted constructs
A 4 cm flank incision was made above the shoulder of the right hind leg. A pocket towards 
the cranial end was created below the first muscle layer (panniculus carnosus) under the skin 
(n=4) or between the fourth muscle and peritoneum (n=3). A basic construct was slid over a 
silicon mandrel and inserted into the pocket (Table 5.1, Figure 5.2). After one month, the 
autologous conduit was harvested through the same incision and used for implantation. A 
small biopsy was fixed in 4% (v/v) formaldehyde in PBS and paraffin embedded.
Implantation of the artificial urinary conduit
Implantation of the artificial urinary conduit was performed as previously described (Table 
5.1) [6]. In brief, the right ureter was extraperitoneally approached through a median 
abdominal incision of 15 cm above the pubic bone. The ureter was cut and spatulated for 
a tension-free side-to-end anastomosis to the construct. The distal end of the construct 
was connected the skin (ø 2.5 cm, Figure 5.6A). The flexible construct (Ø 1,5 cm) was easily 
fitted to the skin opening in most cases. In case of the autologous pre-implanted tissue, the 
material was spatulated to match diameters. An 8 Fr ureteral catheter (Vygon) was inserted 
and removed after maximally 10 days. Pigs received amoxicillin 20 mg/kg I.M. during surgery 
and Albipen LA (ampicillin) 15 mg/kg S.C. every 48h after surgery.
Artificial conduit characterization
After one month, pigs were sacrificed by a pentobarbital overdose. Radiological images were 
taken with the Veradius Mobile C-arm with FD (Model 718130, Philips) after instilling contrast 
fluid (Iomeron, Bracco Imaging) into the conduit with an 8 Fr ureter catheter (Vygon). Kidneys, 
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urinary bladder, ureters, conduit and skin outlet were excised and macroscopically inspected. 
Subsequently, samples were fixed in 4% (v/v) formaldehyde in PBS and paraffin embedded.
(Immuno)histochemical analysis and scoring
Paraffin-embedded samples were sectioned (5 µm), mounted (Superfrost®Plus, Thermo-
Scientific) and stained with hematoxylin (Klinipath) and eosin (Boom) (H&E) [16]. Tissue 
regeneration and inflammation was scored using H&E by two independent observers 
(MS, PG). Discrepancies were discussed and re-evaluated until consensus was reached. 
Representative slides were used for Masson’s Trichrome staining and immunohistochemistry.
Fluorescence immunohistochemistry
Fluorescence immunohistochemistry was performed as described before [17]. Snap-frozen 
samples in Tissue-Tek (Sakura) were cut (5 µm), mounted on glass slides (Superfrost®Plus, 
Thermo-Scientific), fixed for 10 min in acetone and dried for 2 hours. After PBS washings, slides 
were pre-incubated with 10% normal goat serum in 1% BSA/PBS for 30 min. Subsequently, 
slides were incubated for 1 hour with primary antibodies against collagen type I and RCK103 
or α-Smooth Muscle Actin (SMA) in 1% BSA/PBS (Table 5.2). After PBS washings, Alexa-488 
and Alexa-594 secondary antibodies were incubated for 1 hour, followed by a nuclear DAPi 
(Merck) staining. Slides were mounted and stored at 4°C.
Immunohistochemistry
Expression of cytokeratin 7 (Ck7), α-Smooth Muscle Actin (SMA) and Desmin (Des) was analyzed 
by immunohistochemistry on paraffin-embedded material [12]. After deparaffinization and 
PBS washing, endogenous peroxidase activity was blocked by incubation in 1% (v/v) H2O2 
in PBS for 30 min. After PBS washings, slides were incubated with 5% (v/v) normal goat 
serum for 10 min followed by mouse-anti-human monoclonal IgG antibodies for 1 hour 
(Table 5.2). After washings with PBS, the sections were incubated with BrightVision Poly-
HRP antibody (ImmunoLogic) including 10 % (v/v) normal swine serum (pre-incubated for 
Figure 5.2: Pre-implantation surgery. (A) Preparation of the construct and (B) implantation of the construct in 
the subcutaneous pocket below the panniculus carnosum.
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30 min). After washings with PBS, sections were developed with Bright-DAB (ImmunoLogic), 
counterstained with hematoxylin (Klinipath) and mounted (Permount, Fischer Scientific) on 
glass slides (Superfrost®Plus, Thermo-Scientific).
Antibody Specificity Target Dilution Company 
COL1A1 Collagen Type I (Col-I) Collagen scaffold 1:100 Santa Cruz Biotech 
RCK103 Basal Cell Keratin (BCK) Urothelial cells 1:1 MUbio products 
OVTL12/30 Cytokeratin 7 (Ck7) Urothelial cells 1:200 Monosan 
RKSE60 Cytokeratin 10 (Ck10) Keratinized stratified epithelium 1:5 MUbio products 
V9 Smooth Muscle Actin (SMA) Myofibroblasts/Muscle cells 1:8000 Sigma-Aldrich 
R4A Desmin (Desm) Muscle cells 1:400 Biogenix 
Alexa 488 Goat-a-rabbit Secundary Ab 1:200 Invitrogen 
Alexa 594 Goat-a-mouse Secundary Ab 1:200 Invitrogen 
Table 5.2: Antibodies used for immunohistochemistry.
Quantification
Cross-sectional slices (5 µm) of the proximal ureters were stained by H&E and analyzed for 
hydroureter formation (=area/perimeter) using ImageJ software (Version 1.46r, National 
Institutes of Health). Color images were converted to 8-bit images and artifacts in the 
urothelium were manually adjusted for luminal area and perimeter measurements. Data is 
presented as mean with Standard Error of Mean and analyzed with Prism software (Version 
5.03, Graphpad Software Inc). Mann-Whitney U test (two-tailed) was used to compare affected 
with healthy ureters. P-values < 0.005 were considered statistically significant.
RESULTS
Material characteristics
The sterilized and packaged tubular construct, is shown in Figure 5.3. Ultrastructural analysis 
by SEM indicated a porous structure with incorporation of the Vicryl® polymer in the collagen 
wall. Cross-linking was successful, and showed a 35% decrease in free amine groups.
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Figure 5.3: Material characterization. (A) Macroscopic representation of reinforced tubular constructs after 
packaging and γ-sterilization. SEM analysis at low (B) and high (C) magnifications show a porous (100-500 µm 
pores) collagen sponge with Vicryl® polymer incorporation (arrows).
 
Figure 5.4: Cell seeded construct before implantation. (A-B) SEM analysis shows cellular coverage of the 
inside and outside of the collagen scaffold after 7 days of culture. (C-D) Immunohistochemistry confirms cell 
identity of urothelial cells: (RCK103), smooth muscle cells (αSMA) and *=lumen.
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Cell seeding efficiency
Both the luminal side and the outside of the construct were covered with a layer of viable 
cells, as evidenced by SEM analysis (Figure 5.4). The luminal side was covered by Basal Cell 
Keratin (BCK)+ epithelial cells and αSMA+ smooth muscle cells were dispersed throughout 
the scaffold.
Pre-implantation
The pre-implantation procedure itself was successful in all cases. However, pre-implantation 
near the peritoneum (n=3) resulted in extreme adherence of the fully regenerated construct 
to the surrounding tissue. The force required to isolate these constructs resulted in ruptured 
tissue unsuitable for grafting. Therefore two animals were converted to the basic construct 
group. In the third animal an artificial urinary conduit could be created, but this animal 
died of peritonitis two weeks later as a consequence of the harvesting procedure. The 
subcutaneous pre-implantation approach was more successful and resulted in an ‘easy to 
harvest’ free graft of autologous tissue. This graft consisted of a dense, vascularized wall (2 
mm thick, αSMA+ pericytes surrounding blood vessels) without scaffold remnants and only 
a minor inflammatory response (Figure 5.5). Although the tissue collapsed after removal of 
the silicon mandrel, suture to ureter and skin was straightforward, allowing formation of a 
urinary conduit in all cases (n=4).
Figure 5.5: Pre-implant. (A) Autologous conduit with silicon mandrel (shown by insert) after 1 month pre-
implantation. Cross-section of the 2 mm thick wall by H&E (B) and αSMA staining for pericytes supporting newly 
formed vasculature (C) show a fibrous graft with a well-developed vascular structure. No scaffold remnants were 
observed. *=lumen.
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In vivo evaluation
With the exception of one animal with a peritoneal pre-implant, all other animals survived all 
procedures, resulting in a 94% survival. Urinary flow was present in all animals after surgery 
and was maintained in 15/17 animals until evaluation: one basic and one cell seeded construct 
was occluded. After one month, the conduit length was reduced to approximately 2,5 cm 
(75% reduction) and the skin outlet was reduced to approximately 2 mm (90% reduction) 
in all animals (Figure 6A-B). The conduit diameter at the conduit-ureter anastomosis was 
similar to the native ureter and a continuous lumen until the skin-exit was present. Based 
on X-ray analysis, no differences in construct behavior between the groups were obvious. 
Hydroureteronephrosis was observed in all animals, albeit in different degrees (Figure 6C). 
Kidney and ureter evaluation
Severe hydroureteronephrosis was observed in all animals receiving a basic construct with 
or without cells, although the severity appeared to be somewhat less in the latter (Figure 
5.7A-H). Affected kidneys were larger than control kidneys: ±15% for basic constructs and 
±35% for cell seeded constructs. Areas of severe fibrosis and dilation of the renal pelvis was 
observed in both groups. Histological analysis showed loss of kidney structure (i.e. glomeruli 
and tubuli) and infiltration of inflammatory cells. Furthermore, ureters were significantly 
dilated compared to unaffected healthy ureters (Figure 5.7I).
In the pre-implanted group, kidneys were of similar size as the healthy control (±5% larger) 
and showed improved structure compared to the other treatment groups without major 
inflammation, dilation of the tubuli or loss of glomeruli. Only small fibrotic areas were 
present. No significant difference between the ureters of the pre-implanted construct and 
healthy ureters was observed (Figure 5.7I).
Figure 5.6: Artificial urinary conduit. A) The conduit exit Ø 25 mm with catheter immediately after surgery. Arrow 
indicates urinary flow. B) The conduit exit Ø 2.5 mm, 1 month after surgery. C) Radiological evaluation showing the 
occlusion of the skin-exit (S), ureter (U) and kidney (K). An 8 Fr catheter was inserted for the contrast agent and was 
completely embraced by conduit.
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Figure 5.7: Kidney and ureter evaluation. Macroscopic (A, C, E and G) and microscopic (B, D, F and H) evaluation 
of kidneys, showing different degrees of hydronephrosis. (I) Statistical analysis of H&E section of cross-section 
of proximal ureters, comparing ureter dilation (=luminal area/luminal perimeter). ** p<0.005, ns=not significant.
Artificial urinary conduit evaluation
One month after implantation, construct remnants were absent. Regardless of the construct 
used, a dense conduit was formed with a functional αSMA-positive vasculature containing 
red blood cells (Figure 5.8). In the basic and cell seeded group outgrowth of epithelium 
(Ck7+) and muscle (Desmin+) was minimal and limited to the ureter-conduit transition zone 
(Figure 5.9, 5.10 and Table 5.3). Inflammation in these groups was slightly increased 
compared to the pre-implanted group.
Conduits created with a subcutaneously pre-implanted construct contained a lumen covered 
with Ck7+ epithelium throughout the entire construct from ureter to skin, with occasionally 
multilayered areas in all animals. The epithelium was negative for Ck10 (data not shown). 
Desmin+ muscle pedicles were observed up until halfway the artificial conduit from the 
ureter (Figure 5.11 and Table 5.3).
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Figure 5.8: Artificial urinary conduits. H&E stainings of the middle of artificial urinary conduits, longitudinally 
opened. (A) basic artificial urinary conduit. (B) cell seeded artificial urinary conduit. (C) conduit created from 
the subcutaneously pre-implanted construct. αSMA=pericytes supporting vasculature, Ck7=epithelial cells, 
Desmin= ingrowth of smooth muscle cells, *=lumen
Ureter - conduit Conduit cross-section Conduit - skin 
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Basic construct +/- + + sp sp ++ sp + + - - ++ sp +/- + - - +
Cell-seeded construct sp + + sp sp + - + + - - + - + + - - +
Pre-implanted construct sp ++ + +/- + + - + + +/- + +/- sp + + - + + 
Table 5.3: Semi-quantitative analysis of conduits. The complete conduit was analyzed from all animals. 
Histology slides, stained by hematoxylin and eosin, were scored creating a profile for each construct and 
sample area. Items were scored as follows: – (not present), sp (sporadically present), +/- (moderately present), + 
(abundantly present) or ++ (excessively present).
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Figure 5.9: Artificial urinary conduit created from basic constructs. Histology and immunohistochemistry 
of (A) conduit-skin transition and (B) Ureter-conduit anastomosis. n=native ureter, c=conduit lumen, s=skin, 
*=maximal epithelial growth. Dotted line indicates anastomosis. Ck7=epithelial cells, Desmin= ingrowth of 
smooth muscle cells, *=lumen.
Figure 5.10: Artificial urinary conduit created from cell-seeded constructs. Histology and 
immunohistochemistry of (A) conduit-skin transition and (B) Ureter-conduit anastomosis. n=native ureter, 
c=conduit lumen, sskin, *=maximal epithelial growth. Dotted line indicates anastomosis. Ck7=epithelial cells, 
Desmin= ingrowth of smooth muscle cells, *=lumen.
Figure 5.11: Artificial urinary conduit from subcutaneously pre-implanted tissue – longitudinal sections. 
Histology and immunohistochemistry of (A) conduit-skin transition and (B) ureter-conduit anastomosis (the 
middle piece was used for figure 5). n=native ureter, c=conduit lumen, s=skin, *=lumen/maximal growth of 
epithelium. Dotted line indicates anastomosis. See Figure 12 for control morphology of porcine skin epidermis 
and ureter urothelium. 
A
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Figure 5.12: Morphological appearance of healthy bladder urothelium and skin epithelium. Histology and 
iImmunohistochemisty (insert) on biopsies from porcine ureter (A) and skin (B). PanCk staining=epithelium 
(insert).
DISCUSSION
This study describes a two-step surgical approach with an engineered reinforced collagenous 
construct to potentially replace bowel tissue in urinary diversions. Subcutaneous pre-
implantation of a reinforced tubular construct resulted in a fully autologous and vascularized 
tube. The tube was used as a free graft to create an artificial urinary conduit in a large animal 
model. The conduit functioned adequately as demonstrated by urine drainage, limited 
hydroureteronephrosis and partial regeneration of urological tissue.
Subcutaneous pre-implantation can be performed using a minimal invasive procedure. The 
pre-implantation permits construct remodeling and the occurrence of an initial inflammatory 
response without interference of toxic urine passage, which might be detrimental when 
constructs are remodeled. The remodeled tubular construct provided a template for 
epithelial growth and minor muscle formation when implanted as a conduit. The inner 
lining of the conduit was completely covered with Ck7+/Ck10  cells, indicating that cells of 
urothelial origin had repopulated the conduit and not skin epidermal cells.
The autologous tissue grafts created by subcutaneous pre-implantation contained a perfused 
vasculature, as indicated by the presence of red blood cells in the vascular lumen. Isolation 
of the tissue grafts required disruption of the vascular structure before transposition as a free 
graft could occur. The hypoxic signals that have undoubtedly occurred after implantation of 
the free graft may have induced angiogenesis and inosculation. Nevertheless, isolation of 
these grafts was easy and safe, in contrast to the tubes pre-implanted near the peritoneal site: 
these tubes ruptured and could not be used to create an artificial conduit. Pre-implantation 
in the omentum might be considered as an alternative, since the vascular structure can be 
preserved during transposition. However, this approach is much more invasive and often 
results in an extremely fibrous graft with abdominal (bowel) adhesions [18-20].
Urinary conduits are primarily created to preserve kidney function. Therefore, 
hydroureteronephrosis was used as a primary outcome parameter in this study. Kidneys 
of animals receiving the cell seeded or basic construct showed severe hydronephrosis. The 
enhanced inflammatory response and absence of any biological cues might have contributed 
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to the emergence of fibrosis and contraction, inducing the hydroureteronephrosis. 
Moreover, the lack of immediate nutrient and oxygen supply may have intensified the 
hydroureteronephrosis in the cell seeded group [21]. When kidneys were connected to the 
pre-implanted constructs, the hydronephrosis was limited and even absent in some cases. 
Possibly, inosculation might have contributed to rapid perfusion leading to diminished 
fibrosis and contraction to prevent urine backflow to the kidney.
Apart from the different degrees of hydronephrosis, the development of hydroureteronephrosis 
might be attributable to other causes. First, the conduit exit is a direct access port for 
bacteria to the kidney, instigating hydroureteronephrosis. Second, within the first week 
after surgery, the catheter was removed due to scouring and nibbling of the animals, 
limiting the catheterization time (10 days). Afterwards, the animals became more inactive 
and preferred to lay down with a remarkable preference for the flank with the conduit exit. 
These are general problems related to (large) animals and may be difficult to prevent. Finally, 
young animals were chosen as they are relatively easy to handle and large (>300 kg) adult 
pigs present almost insurmountable technical difficulties. The young piglets have a fast 
regenerative capacity which might have influenced the functional outcome: one month after 
implantation, the conduit skin-exit was reduced to ~10% of its original diameter. This may 
have caused stricture formation, build-up of pressure and subsequent hydronephrosis [22]. 
Although long-term follow-up would be preferable, the extension of the follow-up period 
was not possible due to the risk of complete closure of the skin exit - already observed in 
two animals after one month. This would have resulted in inadmissible animal suffering and 
complete loss of the kidney. A comparable study in a different, adult animal model might be 
necessary to evaluate long-term outcome and to mimic the target (elderly population) more 
closely.
Sterilization of the reinforced collagen construct was performed by gamma irradiation, a 
method known to be harmless to the collagen structure [23]. Surprisingly, one month after 
(pre-)implantation, material remnants of collagen or the polymer mesh were rare. Gamma 
irradiation is commonly used to create Vicryl® Rapide, a suture material that is absorbed 
within 14 days[24]. The original strength and integrity of the mesh might be maintained 
with an alternative sterilization method such as ethylene oxide gas. The prolonged material 
support may improve outcome by prohibiting contraction.
Cell seeding is deemed a useful approach in tissue engineering, although this approach 
requires tissue biopsies and involves GMP regulations [25]. Additionally, isolation of healthy 
urinary bladder cells may be compromised in case of bladder cancer and therefore other 
cell sources should be considered [26]. In a porcine cystectomy model implantation of a cell 
seeded biodegradable polymer template lead to regeneration of urinary-like tissue, whereas 
non-seeded templates were mainly composed of fibrous connective tissue [10]. In this study, 
we did not observe improved outcome with cell seeded constructs: the epithelial lining was 
limited and similar to the basic constructs. In the pre-implantation group, the inner lining of 
the constructs was completely covered with epithelial cells, demonstrating that population 
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is possible. Conceivably, epithelial outgrowth may have been facilitated by the presence of 
natural extracellular matrix in these conduits. 
Such rapid establishment of the epithelial lining is essential to protect the supporting 
tissue for urine toxicity. This could be further enhanced by combining cell seeding with pre-
implantation. The existing vasculature might allow survival of the seeded cells due to fast 
inoculation. In previous studies, cells or even minced tissue were seeded onto pre-implanted 
tubular constructs to aid epithelium formation [27]. In rabbits a cell seeded tubularized 
construct was pre-implanted in the omentum and used as an artificial conduit. A multilayered 
urothelium was formed, resulting in improved outcome [28]. Alternatively, it may be possible 
to recreate a peristaltic muscle layer for active urinary flow by construct conditioning in a 
bioreactor [29]. 
The time between diagnosis of invasive bladder cancer and radical cystectomy should be 
limited and should not be beyond 3 months [30]. Therefore, a subcutaneous pre-implantation 
performed soon after diagnosis through a low-risk and minimal-invasive procedure in the 
(outpatient) clinic might be feasible. Pre-implantation of a reinforced tubular construct is a 
next step and promising approach to create a functional artificial urinary conduit. Long-term 
evaluations and further optimization is required in large adult animals. 
CONCLUSIONS
This study describes a two-step surgical approach with reinforced tubular collagen 
constructs that can potentially serve as an alternative for bowel tissue in urinary conduits. To 
create adequate artificial urinary conduits with urinary flow and partial tissue regeneration 
an existing vasculature in the remodeled construct seems to be essential. Nevertheless, the 
limited hydroureteronephrosis emphasizes that further optimization is required to examine 
which approach can be used to develop a readily available artificial urinary conduit.
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ABSTRACT
Clinical implementation of novel TERM products requires a validated sterilization method. In 
this study, we investigated the effect of γ-irradiation and EtO-degassing, on in vitro and in vivo 
behaviour of hybrid tubular constructs for the purpose of creating artificial urinary conduits.
Constructs were prepared from type I collagen and Vicryl® polymers, and sterilized by 25 
kGray of γ-irradiation or EtO degassing. In vitro degradation was assessed by incubation in 
goat urine and simulated body fluid (SBF) up to 28 days. For in vivo evaluation, constructs 
were subcutaneously pre-implanted in goats for 1 month. Artificial urinary conduits were 
created using pre-implanted γ- (n=2) or EtO-sterilized (n=6) constructs and evaluated after 
3 months.
Macroscopic and microscopic appearance of the γ- and EtO-sterilized constructs was similar. 
Incubation in urine resulted in fast degradation of the Vicryl® polymer and decreased strength 
(<7 days). Incubation in SBF was less invasive and strength was maintained for at least 14 days. 
Subcutaneous pre-implantation showed that the effect of sterilization is considerable. A well-
vascularized graft was formed in both cases, but the γ-irradiated construct was mechanically 
more comparable to the native ureter and showed advanced tissue remodelling. Preliminary 
results indicate that functional implantation as artificial conduits, the γ-irradiated construct 
demonstrated improved outcome compared to EtO-sterilized constructs.
This study shows that sterilization affects the functional outcome and cannot be predicted 
by in vitro analyses alone. Clinical translation of biomaterials can only be achieved when 
sterilization methods are included in a full panel of in vitro and in vivo analyses.
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INTRODUCTION
Recent advances in the field of tissue engineering and regenerative medicine have led to the 
application of advanced tissue engineered products (skin grafts, tracheas, cartilage, bladder 
augmentations) in different patient groups, albeit that patient numbers were limited [1-4]. 
The majority of research within this field is still at the preclinical stage and novel biomaterials 
are still being developed for a variety of indications. Evaluation of novel biomaterials varies 
from mechanical characterization and degradation studies to cyto- and biocompatibility 
assays [5, 6]. In general, the first step in in vivo evaluation is limited to subcutaneous 
implantation in small animals [7, 8]. For evaluation in larger animals, and in particular for 
successful clinical translation and implementation, standardized production with medical 
grade materials is required. One of the essential steps in this process is sterilization of 
constructs using a validated sterilization procedure [9]. The choice of sterilization method 
may affect the mechanical and biological features, for instance due to the aggressiveness 
of the sterilization procedure [10]. It is therefore important to evaluate the final sterilized 
medical grade products in vitro and in vivo, preferably when functionally implanted in large 
animals [11, 12].
For preclinical application of biomaterials, gamma(γ)-irradiation and ethylene oxide 
degassing (EtO) are the most frequently used sterilization methods [13]. With γ-irradiation 
wet materials can be sterilized, which eliminates additional processing. Materials can 
therefore be packaged in ethanol at -80°C, which is necessary for long-term sterility and 
storage. However, during γ-irradiation of wet materials free radicals are formed, leading 
to altered material properties [9]. Ethylene oxide (EtO) is a highly diffusive alkylating agent 
and adequate EtO degassing is needed to permit diffusion of remaining toxic derivatives, 
like chlorohydrin and ethylene glycol. [14]. Compared to γ-irradiation, EtO degassing is a less 
invasive sterilization technique and this may result in a material with prolonged strength and 
support. It may therefore be a preferred technique for polymeric materials [15, 16].
Urological tissue engineering often uses γ-irradiated collagen-based biomaterials to 
reconstruct parts of the urological tract [17-19]. For instance, artificial urinary conduits may 
be used in bladder cancer patients requiring radical cystectomy or in patients with severe 
congenital bladder abnormalities [20, 21]. Recently, a γ-irradiated hybrid tubular construct 
from type I collagen and a biodegradable Vicryl® polymer mesh was used to create an artificial 
urinary conduit in a porcine model [22]. Interestingly, a functional conduit with urinary flow 
could be created after subcutaneous pre-implantation, although severe shrinkage and skin 
contraction was observed. The implanted material was completely remodelled and did not 
provide sufficient structural integrity to prevent contraction. We hypothesized that this could 
have been the consequence of two important aspects. Firstly, young (porcine) animals were 
used, known for their fast growth, specific skin properties and regeneration [23]. Secondly, 
and most importantly, the choice of sterilization technique may have extensively influenced 
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the final outcome since γ-sterilization enhances Vicryl® biodegradability from 2 months to 
less than 1 month [24]. 
In this follow-up study, we evaluated the full impact of two validated sterilization procedures, 
i.e. γ-irradiation and EtO degassing, on material characteristics and functional outcome of 
hybrid tubular constructs. We compared the effect of these two methods on in vitro behaviour 
and in vivo performance as artificial urinary conduits in an adult animal (goat) model.
MATERIALS & METHODS
Tubular hybrid construct preparation
Tubular hybrid constructs (l = 10 cm, Ø = 15 mm) were prepared in a cleanroom facility (EMCM 
B.V., Nijmegen, The Netherlands), using a previously described protocol [25]. In brief, a 0.7% 
(w/v) type collagen suspension was combined with a tailor-made tubularized Vicryl® polymer 
mesh (VM74, Ethicon, Somerville, NJ, USA) in a silicon mold. A stainless steel mandrel (Ø 15 
mm) was inserted to create a lumen in the tubular construct. After freezing and freeze-drying, 
scaffolds were strengthened by chemical cross-linking using EDC/NHS [26]. Subsequently, 
constructs were either packaged in blisters with 70% ethanol for sterilization by a standard 
dose of 25 kGray of gamma (γ)-irradiation (Synergy Health, Venlo, The Netherlands), or further 
processed for sterilization by ethylene oxide degassing (EtO, Synergy Health, Netherlands). 
This required additional freezing and freeze-drying and subsequent packaging in blisters. 
Cross-linking efficiency was determined by trinitrobenzene sulfonic acid assay [27] and 
construct morphology was assessed by scanning electron microscopy (SEM, JEOL 6310) and 
histology by hematoxylin (Klinipath, Duiven, The Netherlands) and eosin (Boom, Meppel, The 
Netherlands) (HE).
Tensile strength analysis
The mechanical characteristics of the wetted tubular constructs were evaluated using a 
tensile tester with a 2.5 kN load cell (Z2.5 TN, Zwick/Roell, Ulm, Germany). A circular ring 
test was performed on ring pieces of the constructs (height (h)= 5 mm). The hooks of the 
apparatus were placed in contact with the upper and lower areas opposite each other, 
spaced 18.45 mm apart for the COL-Vicryl-EtO (n=14) and 22.53 mm for the COL-Vicryl-γ 
(n=11). The upper hook was then moved upwards with a crosshead speed of 50 mm/sec 
until rupture. Samples were compared to native goat ureters, the primary anastomosis site 
for the artificial urostomy, which acts as an extended ureter. Ureters from two different goats 
were similarly analyzed, spaced 1.27 mm apart (n=12). The measurements were normalized 
by wall thickness and height of the rings, to calculate the ultimate tensile strength (UTS) and 
Young’s modulus. Data is presented as mean with Standard Deviation and analyzed with 
Prism software (Version 5.03, Graphpad Software Inc, La Jolla, CA, USA). A one-way ANOVA 
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with a Tukey multiple comparisons test to compare the means of every group to every other 
group.
Degradation assay
A degradation assay was performed in goat urine and simulated body fluid (SBF) and 
analyzed for 28 days. The goat urine was centrifuged at 2000 g for 10 min at 4°C, filter 
sterilized and kept at 4°C until use. SBF was created as described [28]. In brief, SBF was made 
in a plastic beaker with 700 mL demi-water and the consecutive addition of the following: 
9.23 mM NaCl (Merck, Darmstadt, Germany), 0.56 nM NaHCO3 (Sigma-Aldrich, St. Louis, MO, 
USA), 0.41 mM Na2CO3 (Boom, Meppel, The Netherlands), 0,30 mM KCl (Sigma-Aldrich, St. 
Louis, MO, USA), 0.10 mM K2HPO4•3H20 (Merck, Darmstadt, Germany), 0.15 mM MgCl2•6H20 
(Merck, Darmstadt, Germany), 200 mL 0.2 M NaOH (Merck, Darmstadt, Germany), 7.51 mM 
HEPES (Invitrogen, Thermo Scientific, Waltham, MA, USA), 0.26 mM CaCl2 (Sigma-Aldrich, St. 
Louis, MO, USA), 0.05 mM Na2SO4 (Sigma-Aldrich, St. Louis, MO, USA). The mixture was then 
warmed until 36.5°C and adjusted to pH 7.4 with 1.0 M NaOH (Merck, Darmstadt, Germany). 
The precipitation potential of the SBF was checked on broken glass at 37°C. In contrast, the 
mixture should not precipitate at 4°C on plastic. COL-Vicryl-EtO and COL-Vicryl-γ tubes were 
cut into 5 mm (h, height) rings and incubated in 6-well plates (Corning, Corning, New York, 
USA) at 37°C. N=3 was used for each time point (day 0, 3, 7, 14 and 28) and both conditions. 
The constructs were evaluated by HE and tensile strength analysis using circular ring tests, 
with the set-up as described above. COL-Vicryl-EtO and COL-Vicryl-γ rings in urine were 
spaced 21.05 ± 1.75 mm and 21.81 ± 0.40 mm apart, respectively. COL-Vicryl-EtO and COL-
Vicryl-γ rings in SBF were spaced 24.84 ± 1.50 mm and 21.63 ± 1.27 mm apart, respectively.
Animals and study design
The animal experiment was approved by the Ethical Committee on Animal Research of the 
Radboud University Medical Center, Nijmegen, The Netherlands (RU-DEC 2014 233). We 
included nine adult Saane goats (2-3 years, ± 60 kg), receiving restricted diet and water ad 
libitum. Animals transported with a ‘buddy’ goat, but were individually housed with nose 
contact after surgery and placed in groups when possible at the animal farm. Randomization 
and blinding was not possible due to clear differences in physical appearances.
Subcutaneous pre-implantation
Subcutaneous pre-implantation was performed as previously described [22]. Under general 
anesthesia, subcutaneous pockets were created on the right flank below the muscle layer 
of the skin, through a 5 cm incision above the shoulder of the right hind leg. In 6 animals a 
COL-Vicryl-EtO construct was pre-implanted and in 3 other animals both the COL-Vicryl-EtO 
and COL-Vicryl-γ were pre-implanted. Constructs were extensively washed in PBS, slid over a 
silicon mandrel and attached to the mandrel using CT-1 Vicryl® sutures (Ethicon, Somerville, 
NJ, USA). The construct was then inserted into the pocket and attached to the fascia with 
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CT-1 Vicryl® sutures (Ethicon). The skin incision was subsequently closed with 2-0 Vicryl® 
(Ethicon) for the subcutaneous fat and the skin. Goats received Albipen LA (ampicillin) 15 
mg/kg I.M. during surgery and Albipen LA 15 mg/kg S.C. every 48h after surgery.
Evaluation of pre-implants
One month later, the remodelled tubes were harvested and evaluated. Ring pieces (h = ± 
5 mm) were transferred to PBS and immediately measured by tensile strength analysis by 
circular ring tests as described above. The hook spacing was 14.20 ± 1.45 mm. Ring pieces 
were transferred to 4% (v/v) formaldehyde (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 
fixation and subsequent embedding in paraffin for microscopic analysis. HE slides were 
scored by three independent observers (MS, PG, PdJ) for collagen and Vicryl® degradation, 
inflammation, tissue integration and vascularity. Averages of the independent scorings 
were calculated and combined into a scoring profile. Representative slides were used for 
confirmation by Masson’s Trichrome and immunohistochemistry.
Artificial urostomy implantation
In eight goats an urostomy was created as proof of principle: six goats received a pre-
implanted COL-Vicryl-EtO construct and two goats received a pre-implanted COL-Vicryl-γ 
construct. The flank incision created for harvesting the autologous graft was also used to 
create the urostomy. The procedure was performed as previously described under general 
anesthesia [17, 29]. In brief, the ureter was extraperitoneally approached, cut and spatulated 
conforming the size of the remodeled tubes. A tension-free side-to-end anastomosis was 
created. The distal end of the construct was connected the skin (ø 2.5 cm). A catheter (Cystofix 
Minipaed, B.Braun, Melsungen, Germany) was inserted and removed after maximally 10 days. 
Goats received Albipen LA (ampicillin) 15 mg/kg I.M. during surgery and Albipen LA 15 mg/kg 
S.C. every 48h until the catheter was removed.
Artificial urostomy evaluation
After maximally three months, goats were sacrificed by pentobarbital overdose. Radiological 
images were taken with the Veradius Mobile C-arm with FD (Model 718130, Philips, 
Amsterdam, The Netherlands) after instilling contrast fluid (Iomeron, Bracco Imaging, Monroe 
Township, NJ, USA) into the conduit with an 8 Fr ureter catheter (Vygon, Ecouen, France). 
Kidneys, urinary bladder, ureters, conduit and skin outlet were excised and macroscopically 
inspected. Subsequently, samples were fixed in 4% (v/v) formaldehyde in PBS and paraffin 
embedded for (immuno)histochemical analysis.
Immunohistochemistry
Expression of type IV Collagen (COLIV) and HIF1α was analyzed on paraffin-embedded 
material (5 µm thickness), mounted on Silane-coated slides (New Silane III, Muto Pure 
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Chemicals Co., Ltd., Tokyo, Japan). After deparaffinization and PBS washings, endogenous 
peroxidase activity was blocked by incubation in 1% (v/v) H2O2 in PBS for 20 min.
For COLIV, antigen retrieval was performed using 0.05% (v/v) proteinase in PBS (20 min, 37°C, 
Merck, Darmstadt, Germany). Slides were then washed with PBS/Tween and incubated with 
10% (v/v) swein serum (30 min) followed by incubation with the primary antibody (1h, rabbit-
α-human COLIV, 1:250, Abcam, Cambridge, UK). After washings, the sections were incubated 
with peroxidase-labelled swein-α-rabbit secondary antibody (30 min, SWARPO, 1:100, 
DakoCytomation, Glostrup, Denmark) followed by washings.
For HIF1α, heat-induced antigen retrieval was performed using sodium citrate (pH 6) followed 
by TBS/0,1%Tween20 washings. Blocking of endogenous biotin (and receptors) and avidin 
receptors (10 min, Vector Laboratories, Burlingame, California, USA) was performed with 
washing in between. After additional washing, endogenous proteins were blocked with 2% 
BSA (5 min), directly followed by incubation with the primary antibody (45 min, mouse-
α-human HIF1α, 1:500, BD Biosciences, San Jose, CA, USA). After washings, sections were 
incubated with a biotin-labeled secondary antibody (15 min, donkey-α-mouse, 1:500, 
Jackson ImmunoResearch, West Grove, PA, USA). Slides were then washed and 15 min 
incubated with peroxidase-labeled streptavidin/biotin complex (1:100 Avidin solution and 
1:100 Biotin solution, 30 min pre-incubation, Vector Laboratories, Burlingame, California, 
USA). An amplification step was performed after washings using biotinyl tyramide (15 min, 
DAKO, Heverle, Belgium). After washings, slides were incubated with peroxidase-labelled 
streptavidin (15 min, 1:250, Thermoscientific, Rockford, IL, USA) followed by washings.
For both COLIV and HIF1α, sections were developed with Bright-DAB (ImmunoLogic, Duiven, 
The Netherlands) and counterstained with hematoxylin (Klinipath, Duiven, The Netherlands).
RESULTS
Construct analysis
The macroscopic appearance of the COL-Vicryl-EtO and COL-Vicryl-γ constructs was 
comparable, showing a luminal diameter of approximately 1.5 cm (Figure 6.1A-B). 
Microscopic analysis by SEM and histology indicated integration of the Vicryl® polymer as 
indicated by visible collagen-Vicryl connections and a typical honeycomb structure (Figure 
6.1C-D). For the COL-Vicryl-EtO constructs, that required additional processing (freezing 
and freeze-drying), a thinner and compressed wall with smaller pores was observed (Figure 
6.1E-F). Cross-linking was successful as indicated by the decrease in free amine groups and 
was comparable for both groups: 35% for the COL-Vicryl-γ (reduced to 109 ± 15 nmol/mg) and 
37% for the COL-Vicryl-EtO (reduced to 202 ± 5 nmol/mg). The mechanical characteristics 
of the construct were compared to native goat ureter, the primary anastomosis site for the 
construct in an artificial urostomy and conform the animal model (Figure 6.1G-H). The 
ultimate tensile strength (UTS) of the ureter and both constructs was similar (ureter: 0.83 
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± 0.26 MPa, COL-Vicryl-EtO: 0.66 ± 0.39 MPa, COL-Vicryl-γ: 0.74 ± 0.28 MPa). The COL-Vicryl-γ 
Young’s modulus (2.31 ± 0.67 MPa) was approximately twice as high as the ureter (0.95 ± 0.39 
MPa) whilst the COL-Vicryl-EtO showed a Young’s modulus only 1.5x as high (1.57 ± 0.75 MPa).
Figure 6.1: Construct analysis. A-B) show the macroscopic overview of the COL-Vicryl-EtO and COL-Vicryl-γ, 
unit = 0.5 cm. C-D) show the SEM images, unit = 250 μm, pore size for COL-Vicryl-EtO is approximately 150-250 
μm and for COL-Vicryl-γ 200-300 μm, and E-F) show the histological overview of the construct, unit = 250 μm. 
The graphs in G-H represents the mechanical characteristics of the constructs. V = Vicryl polymer, * p<0.05, **** 
p<0.0001, ns = non-significant.
Degradation assay
Incubation in urine resulted in fast degradation (<7 days) of the Vicryl® polymer in both 
constructs (Figure 6.2A). Microscopic analysis revealed negative imprints of the multi-
filamented Vicryl® in the scaffold after 3 days. The collagen structure was barely affected 
in the COL-Vicryl-γ constructs. In contrast, swelling of collagen lamellae was seen in the 
urine-incubated COL-Vicryl-EtO constructs at day 28 (Figure 6.2A). Tensile strength analysis 
showed a strongly diminished UTS and Young’s modulus, already after 3 days (Figure 6.2B), 
regardless of sterilization method.
The effect of SBF was less severe, and Vicryl® remnants were still present at 28 days in both 
constructs, although their original multi-filamented structure was lost. Only in the COL-
Vicryl-EtO construct the collagen was substantially affected by SBF and showed swelling of 
collagen lamellae at 14 and 28 days. The UTS and Young’s modulus of the constructs in SBF 
were maintained for at least 14 days. At this evaluation point, COL-Vicryl-EtO showed a higher 
UTS and Young’s modulus then COL-Vicryl-γ, but after 28 days UTS and Young’s modulus of 
both constructs were similar.
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Figure 6.2: Degradation assay. A) shows the microscopic overview by HE of the degradation assay in urine 
and SBF, unit = 100 μm, V = Vicryl® polymer, * = collagen degradation. Urine day 28 is representable for day 14 
and 7. SBF day 3 is representable for day 7 and 14. B) Mechanical characteristics of the degraded constructs. 
Urine exposure resulted in immediate diminished mechanical properties of both construct at day 3, although 
the Vicryl® was still morphologically visible. In SBF prolonged mechanical stability was observed until day 14 
for both constructs. At day 28 the mechanical properties were lost and the polymer showed signs of severe 
degradation.
Effect of Subcutaneous pre-implantation
Subcutaneous pre-implantation was successful in all goats and for all constructs. After one 
month, a remodelled tissue grafts was formed regardless of the sterilization method. The 
tissue graft was encapsulated but easy to harvest from the subcutaneous pocket (Figure 
6.3A-D). The rims of the tissue, where scaffold material was absent, were fragile and ruptured 
easily and were therefore eliminated from analysis. After removal of the mandrel, the firm 
tissue was able to maintain an open lumen and was suitable for translocation to serve as 
an artificial urostomy. No clear macroscopic differences between the construct types were 
observed.
Ring pieces of both pre-implants were analysed by tensile strength analysis and compared 
to the native goat ureter (Figure 3E-F). After subcutaneous pre-implantation, the UTS of 
the COL-Vicryl-ETO was 0.28 ± 0.03 MPa, and 0.40 ± 0.25 MPa for the COL-Vicryl-γ. This was 
significantly lower than the UTS for the native goat ureter (0.83 ± 0.26 MPa). The Young’s 
modulus was similar for all groups (Ureter: 0.95 ± 0.39 MPa, COL-Vicryl-ETO: 0.56 ± 0.19 MPa 
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and COL-Vicryl-γ 0.87 ± 0.72 MPa). The UTS and Young’s modulus of the COL-Vicryl-γ pre-
implant approximated the native ureter more closely than the COL-Vicryl-EtO.
Figure 6.3: Pre-implantation. A) shows the overview of the washed constructs with the inserted mandrel, 
all units – 1 cm. COL-Vicryl-γ is the upper construct, COL-Vicryl-EtO is the lower construct. B) shows the 
subcutaneous pocket. C) shows the autologous tissue grafts one month after pre-implantation (same formation 
as in A). D) shows the open lumen after removal of the mandrel. E-F) shows the mechanical characteristics of 
the pre-implanted constructs compared to native goat ureter. *** p<0.005, **** p<0.0001, ns = non-significant.
(Immuno)histological analysis of the pre-implants
Detailed microscopic evaluation showed a clear difference between the COL-Vicryl-EtO and 
the COL-Vicryl-γ pre-implants (Figure 6.4 and Table 6.1). The pre-implanted COL-Vicryl-γ 
constructs were well integrated in the surrounding tissue and both collagen and the Vicryl® 
polymer were partially degraded. Ingrowing fibroblast-like cells from the surrounding tissue 
were present within the honeycomb structures of the collagen and between the Vicryl® 
filaments. In contrast, the COL-Vicry-EtO constructs did not successfully integrate in the 
surrounding tissue, resulting in a clear separation between the construct and tissue in some 
areas (Figure 6.4D). Degradation of collagen and Vicryl® was substantially less in the COL-
Vicryl-EtO constructs. In these less degraded areas of the COL-Vicryl-EtO constructs increased 
HIF1α+ expression was observed, indicating hypoxia. Although the amount of vascularity was 
comparable between groups, different vascular architecture was observed in the luminal 
area (Table 6.1 and Figure 6.5). In the COL-Vicryl-γ an organized layer of COLIV+ vasculature 
was formed, whilst in the COL-Vicryl-EtO this layer showed an aberrant architecture.
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COL-Vicryl-EtO (n=6) COL-Vicryl-γ (n=3) 
Collagen degradation + ++ 
Vicryl® degradation +/- + 
Inflammation + + 
Tissue integration + ++ 
Vascularity + + 
Table 6.1: Scoring profile. HE slides of pre-implanted COL-Vicryl-EtO and COL-Vicryl-γ constructs were scored 
independently to create a representative profile for each pre-implanted construct. Items were scored – (not 
present), +/- (sporadically present), + (moderately present), ++ (abundantly present) or +++ (excessively present).
Figure 6.4: (Immuno)histological analysis of the pre-implants. A-B) Macroscopic overview of ring pieces of 
COL-Vicryl-EtO and COL-Vicryl-γ by HE, bar = 5 mm. C-G, I) Masson’s Trichrome staining from indicated boxes, 
blue/green = collagen, collagen from constructs is indicated by arrows, light blue (V) = Vicryl® polymer, red/brown 
= cell nuclei, yellow line = construct/tissue separation, unit = 100 μm. G-H) shows area in construct material, with 
no presence of vasculature but high expression of HIF1α, indicating hypoxia. I-J) progressed regenerating area 
with presence of vascular structures (*) and less hypoxia. (HIF1α). Bar = 200 μm.
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Figure 6.5: Evaluation of vascularization in COL-Vicryl-EtO and COL-Vicryl-γ pre-implant. Luminal, middle 
and outer area of pre-implants were stained with COLIV to visualize the vasculature. Outer and central areas 
are comparable between construct types. However, the luminal area showed a thin organized architecture 
of vasculature in the COL-Vicryl-γ, which is comparable to native urinary tissue. The COL-Vicryl-EtO shows an 
aberrant vasculature in the luminal area. V = Vicryl, scalebar = 200 μm.
Artificial urinary conduit
In a pilot experiment we tested whether these sterilized and pre-implanted tubular scaffolds 
could be used as artificial urinary conduits. Six pre-implanted COL-Vicryl-EtO and two pre-
implanted COL-Vicryl-γ construct were used to create artificial conduits in goats (Figure 
6.6 and 6.7). Both animals with the COL-Vicryl-γ pre-implants and one animal with a 
COL-Vicryl-EtO pre-implant successfully completed the experiment. After 3 months a well-
functioning artificial conduit was formed with a skin-outlet of Ø 3 mm in these three animals. 
The X-ray analysis and macroscopic inspection revealed severe hydroureteronephrosis as a 
consequence of a stricture (Figure 6.5C) at the anastomosis. 
Five animals with a COL-Vicryl-EtO pre-implant was prematurely sacrificed at 1 week (n=2), 
2 weeks (n=1) or 3 weeks (n=2) due to conduit malfunction and suspicion of leakage at the 
anastomotic site. At necropsy, the ureter and implant were completely disconnected, which 
had resulted in complete closure of the ureter and the formation of a urine-filled reservoir.
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Figure 6.6: Artificial urostomy COL-Vicryl-γ. A) skin outlet of functional artificial urostomy, bar = 5 mm. B) 
X-ray analysis, K = kidney, U = ureter, arrow = stricture at anastomosis. C) Macroscopic reproduction of functional 
artificial urostomy, S = skin, U = ureter, arrow = anastomosis, bar = 5 mm.
Figure 6.7: Artificial urostomy COL-Vicryl-EtO (3 weeks). A) Macroscopic view of the artificial urostomy, ureter 
and kidney, showing disconnection/ rupture of the implant (white arrow) from ureter (U, black arrow). K = kidney, S 
= skin, bar = 1 cm. B) X-ray analysis, R = fluid filled reservoir.
DISCUSSION
Clinical implementation of biomaterials requires sterilization with EMA-FDA-approved 
techniques, like γ-irradiation or EtO-degassing. In the preclinical phase materials are 
generally tested in vitro and in vivo with non-validated, in-house disinfection or sterilization 
methods, to evaluate strength, cyto- and biocompatibility. This study shows that sterilization 
procedures are a crucial aspect in biomaterial evaluation: it significantly influences the 
functional outcome. Therefore, evaluation of the effects of the sterilization procedures should 
become standard in early biomaterial development. Moreover, we demonstrate that in vitro 
data cannot be solely used as predictive factors for material behaviour in vivo. Evaluation in 
a functional setting (i.e. large animal model) is required to facilitate clinical translation and 
registration as a medical device.
In the in vitro part of this study, we evaluated the mechanical and morphological characteristics 
of the hybrid tubular constructs. For urological tissue engineering and specifically the 
artificial urinary conduit, the addition of a reinforcing polymer to the collagen, e.g. Vicryl®, 
is desired to provide additional strength for template functionality and surgical handling 
[29]. Terminal sterilization of this hybrid tubular construct by EtO-degassing or γ-irradiation 
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did not show major differences in the morphological and mechanical characteristics, as 
has been described for collagen alone [30]. Other comparative studies already showed 
that γ-sterilization of collagen resulted in enhanced enzymatic degradation and reduced 
integrity and stability. In contrast, the structure and stability of EtO-sterilized collagen 
remained unaltered and was comparable to unsterilized scaffolds [30, 31]. The reporting on 
cytocompatibility was contradictory and either showed no influence of sterilization methods 
[13, 30], or a preference for EtO degassing [31].
Furthermore, we assessed the influence of a wet environment using either urine, mimicking 
direct implantation, or Simulated Body Fluid (SBF), mimicking subcutaneous pre-
implantation. Interestingly, exposure of both constructs to urine resulted in immediate loss 
of Vicryl® polymer integrity (3 days). This suggests that direct implantation of the construct in 
the urinary tract will lead to material collapse before sufficient tissue regeneration can occur 
and may therefore not be advisable. Pre-implantation may solve this by creating a (semi-)
autologous construct.
The biomechanical properties of absorbable multifilament sutures, like Vicryl®, have been 
previously evaluated in equine urine and similarly showed total loss of Vicryl® integrity albeit 
after 21 days [32]. The absence of any buffering capacity of both goat and equine urine may 
have influenced Vicryl® degradation by enhancing pH-dependent hydrolysis. Furthermore, 
bacterial infections from the urostomy exit may have resulted in subsequent enhanced 
enzymatic degradation and hydrolysis, of the Vicryl® polymer [33]. The higher degradation 
rate observed in our study was probably the consequence of additional γ-sterilization of the 
commercially available and already sterilized Vicryl® polymer mesh [34].
Exposing the construct to SBF instead of urine prolonged Vicryl® polymer stability up to two 
weeks. At this time, the strength and Young’s Modulus of the COL-Vicryl-EtO was significantly 
higher than the COL-Vicryl-γ. After 28 days, signs of collagen degradation (swelling) were 
observed in the EtO-sterilized construct and not in the γ-sterilized constructs. This may 
have been the consequence of the thinner and compressed wall in the COL-Vicryl-EtO. The 
γ-sterilization results in additional crosslinking of collagen and may explain this difference 
[35]. In contrast, it is well established that sterilization of Vicryl® by γ-irradiation results in 
enhanced degradability due to chain scissions [36]. Although this explains the lower Young’s 
modulus of the COL-Vicryl-γ, this in vitro assay only evaluated material degradation, whilst 
the creation of an autologous tissue graft is a balance between material degradation and 
tissue regeneration and requires in vivo analysis. 
Besides the slightly prolonged stability of the COL-Vicryl-EtO in a fluidic environment, 
neither of the constructs was absolutely superior in the in vitro analyses. Both constructs 
were therefore tested in a subcutaneous pre-implantation model. Interestingly, when the 
pre-implanted constructs were harvested, tissue ingrowth of pre-implanted COL-Vicryl-γ 
was much further developed compared to EtO-degassed constructs. In accordance with 
the in vitro data, the Vicryl® polymer in the EtO-sterilized constructs was less susceptible to 
degradation in vivo and contributed to prolonged strength over time. This is in agreement 
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with a previous study showing that γ-irradiation enhanced Vicryl® degradation when 
implanted in the lumbar muscle of rats [24, 35]. It is likely that the enhanced degradation rate 
of Vicryl® facilitates the ingrowth of surrounding tissue and the formation of an organized 
subluminal vasculature, comparable to normal urinary tissue. The prolonged and increased 
levels of hypoxia led to the formation of an aberrant vascular architecture in the COL-Vicryl-
EtO pre-implant.
Nevertheless, full comprehension of the sterilization effect required functional application 
as an artificial urinary conduit. Creation of an artificial conduit with remodelled COL-Vicryl-
EtO grafts was not as successful as anticipated. Earlier studies suggested that perhaps a 
prolonged stability for sustained mechanical stability would be important in the formation 
of the artificial conduit [17]. Indeed, our in vitro analyses showed that prolonged stability in 
a fluid could be accomplished by applying EtO-sterilization to the hybrid tubular construct. 
Nevertheless, this did not result in an improved outcome since other aspects like cellular 
ingrowth and vascularization are equally or even more important. Furthermore, mechanical 
analysis after pre-implantation did not indicate a difference in strength or elasticity, 
suggesting that the loss of construct integrity is compensated by tissue ingrowth, with no net 
loss of strength as a result.
The limited tissue growth in the COL-Vicryl-EtO construct was not sufficient to prevent 
harmful urine infiltrating and affecting the Vicryl® polymer. In vitro analyses already showed 
that exposure to urine results in degradation of the Vicryl® polymer within 3 days. In vivo, 
the polymer was degraded in less than a week with stoma failure as a consequence as 
indicated by 2 animals sacrificed after 1 week. In contrast, the advanced tissue ingrowth of 
the COL-Vicryl-γ construct contributed to the superior outcome. The enhanced remodeling 
and formation of autologous tissue probably secluded urine from the residual material and 
prevented degradation. The anastomosis resulted in ureter continuity and allowed safe 
passage of urine, directly after implantation.
Although the in vivo performance indicated superiority for the COL-Vicryl-γ, it is clear that 
larger studies with more animals and long-term evaluation is necessary to validate this 
statement. Nevertheless, the functional outcome should be improved as hydronephrosis 
and contraction at the anastomosis was still observed. Complete degradation of the polymer 
material during the pre-implantation phase may result in an even better outcome. This 
would require a longer pre-implantation phase, which would be clinically challenging due 
to the limited time between bladder cancer diagnosis and urinary conduit implantation [37]. 
Alternatively, Vicryl® degradation may be enhanced by increasing the γ-ray dose, although its 
effect on collagen may be substantial and could influence construct remodelling [38]. Finally, 
the collagen carbodiimide cross-linking, initially introduced to provide additional strength 
to the collagen, may be omitted since the Vicryl® mesh provides the required mechanical 
support. Any of these changes could result in the creation of a completely autologous tissue 
graft within 4 weeks with superior functional characteristics.
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Regeneration of urinary-like tissue may be achieved by the addition of a cellular component. 
Urothelial cells, adipose-derived stem cells or urine-derived stem cells may be seeded onto 
the construct before implantation and form a protective epithelial layer [39.40]. Combining 
the current construct with fibrin-cell suspension may be considered for adequate cell 
distribution and stimulation of angiogenesis during pre-implantation [41]. Angiogenesis 
may also be enhance by incorporation of extracellular matrix signalling cues, such as elastin 
peptides or growth factors [42-44].
EtO and γ-irradiation are two of the most commonly used and FDA-approved sterilization 
techniques and were therefore chosen as comparators. Recently, novel sterilization 
techniques, like supercritical carbon dioxide (scCO2), have come available and may we 
worthwhile to consider [45]. Our study shows that for full comprehension of the effect of a 
novel sterilization method on in vivo biomaterial behaviour a complete panel of analyses 
ranging from mechanical characterization to implantation in a functional setting in a large 
animal model is essential.
CONCLUSIONS
Thorough analysis of the in vitro and in vivo behaviour of sterilized collagen-Vicryl tubular 
scaffolds shows that the effect of final sterilization is considerable. Subcutaneous pre-
implantation of a γ-sterilized hybrid construct resulted in better tissue remodelling which 
probably contributed to an improved outcome when functionally implanted in a goat 
model, compared to EtO-sterilized constructs. This study shows that sterilization affects the 
functional outcome that cannot be predicted by in vitro analyses alone. Clinical translation of 
tissue engineered biomaterials can only be achieved when EMA-FDA-approved sterilization 
methods are included in a full panel of in vitro and in vivo analyses.
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SUMMARY & DISCUSSION
Acquired bladder pathologies like bladder cancer, or congenital abnormalities like neurogenic 
bladders may require a surgical intervention. Although the creation of a neobladder may be 
considered as the ultimate goal, the majority of patients receives an ileal conduit. For both 
approaches gastrointestinal tissue (GIT) is the best clinically available option, but this tissue 
is far from optimal for urine transport. For patients with an ileal conduit, an acceptable quality 
of life can be accomplished in the simplest clinical cases. The risk of complications at the 
conduit or donor site is high. The subsequent care and (re)hospitalization have a significant 
impact on patients and are a financial burden on healthcare systems.
A tissue engineering and regenerative medicine (TERM) approach may omit the use of bowel 
tissue and reduce complications and healthcare costs. This thesis describes the current 
knowledge on urological tissue engineering (urinary bladder and urinary diversion) using 
systematic reviews and continues with the development of the artificial urinary conduit as a 
replacement for bowel tissue in the ileal conduit.
Animal models and systematic reviews
In the first part of this thesis, systematic reviewing techniques were used to assemble all 
available data on tissue engineering approaches for the urinary bladder (chapter 2) and 
urinary diversions (chapter 3) in animal models. The identification of a suitable animal 
model is essential to facilitate clinical translation. The advantage of a systematic approach, 
compared to conventional reviews, is the design of a specific but extensive search strategy 
which minimizes the risk of unintentional excluding of studies. Specifically for the preparation 
of research proposals, this method will provide all available data on any topic of choice and 
will prevent duplication of animal experiments. The meta-analyses will identify previously 
unnoticed research gaps and provide insight in the appropriate design of preclinical animal 
studies.
In chapter 2, a large subarea of urological tissue engineering, i.e. TERM for the urinary 
bladder, was subjected to a systematic research strategy to evaluate the clinical translational 
value of preclinical animal experimentation. Bladder tissue engineering aims to restore 
bladder volume and the results of the meta-analysis of this systematic review indicated 
that this is indeed achievable in healthy large animals, such as dogs and pigs. Large animals 
resemble the human anatomy more closely and allow evaluation at a clinically relevant site 
with constructs of a comparable size to humans [1, 2]. Phase I clinical studies for bladder 
tissue engineering were based on the promising outcome of such healthy animal models. 
The results the phase I trial were promising, but they were not substantiated in further clinical 
trials. This may have been caused by the different clinical backgrounds of the patient groups 
[3]. The systematic review suggested that the choice of animal was affected by financial 
considerations, experience, and ethical and practical considerations, but that the predictive 
value of an animal model was not part of the decision making.
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A similar systematic approach was used to create a detailed overview of the preclinical work 
on artificial urinary diversions in chapter 3. This systematic review aimed to investigate all 
preclinical evidence with animal models evaluating TERM products for urinary diversion, 
to identify a suitable animal model for this application. Although the in vitro experimental 
work on the artificial urinary conduit is substantial, the amount of preclinical animal studies 
is negligible. The limited amount of published studies may have been the consequence of 
the novelty of this specific research field. The included studies (7 in total) were all feasibility 
studies with a short follow-up period and high heterogeneity in choice of animal model and 
biomaterial. Meta-analyses indicated successful experimentation in large animals, but no 
specific predictive animal model could be identified. Therefore, relevant information could 
be obtained from larger and related fields, like tissue engineering for the urinary bladder 
(chapter 2).
To facilitate clinical translation, new tissue engineering approaches should be evaluated in 
healthy animals first, and second in diseased animal models, For both is a long-term follow-
up required. Evaluation in diseased animals is important since it may result in a significantly 
different outcome [4-6]. As the design of an artificial urinary conduit is still relatively new, 
large and healthy animal models were therefore used in subsequent experiments.
Biomaterials
In a pioneering study, the feasibility of an artificial urinary conduit was established in a large 
porcine model, using a scaffold of combined type I collagen and a semi-biodegradable 
polymer mesh [7]. The mesh was not biocompatible and therefore the construct required 
improvements. Novel reinforcement strategies were designed and evaluated in an inter-
animal comparison, in which all three construct types were simultaneously connected 
to the full bladder defects of 11 Landrace pigs (chapter 4). Collagen was reinforced with 
either 1) a semi-biodegradable polymer mesh (Vypro II [7]), 2) a fast-biodegradable mesh 
(Vicryl) or 3) an additional collagenous layer. Vicryl is commercially available and FDA-
approved suturing material containing 90% glycolide and 10% lactide. In clinical practice, 
Vicryl meshes are already used for abdominal wall repair and breast reconstruction [8, 9]. 
The applicability for the reconstruction of the esophagus and diaphragmatic hernias is 
currently being investigated [10, 11]. In this study the hybrid construct of collagen type I and 
a biodegradable Vicryl mesh was superior in surgical handling, biocompatibility and bladder 
tissue regeneration. It was therefore chosen as the optimal construct for the engineering of 
the artificial urinary conduit. Moreover, considering that Vicryl is already clinically applied, 
translation to humans is expected to be less complicated.
Artificial urinary conduit
The hybrid construct was implanted as a urinary conduit in pigs, using three different 
approaches: 1) direct implantation of a basic construct, 2) direct implantation of a construct 
combined with cells and 3) subcutaneous pre-implantation of a basic construct to create an 
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autologous graft for the conduit (chapter 5). The latter approach showed the best outcome. 
The conduit created from an autologous graft was capable of urinary drainage with limited 
hydroureteronephrosis and partial urinary tissue regeneration as a result. During the pre-
implantation phase remodeling may occur without interference of harmful urine. 
The pre-implantation can be performed through a minimal-invasive and low-risk procedure 
in the (outpatient) clinic. Considering the time between bladder cancer diagnosis and radical 
cystectomy which is limited to three months, a time window for pre-implantation exists [12]. 
At the time of surgery, the autologous graft can be harvested through a simple incision and 
used to create an artificial conduit, omitting the use of bowel tissue. Although this approach 
is quite successful, severe contraction of the implant and formation of hydroureteronephrosis 
was observed. We hypothesized that the cause of these undesirable side effects was two-
sided. First, young porcine animals were used, known for their fast regenerative capacity, 
growth pattern and specific skin properties [13, 14]. Second, the choice of sterilization 
may have significantly influenced the final outcome, since γ-sterilization enhances Vicryl 
biodegradability [15].
The effect of sterilization
Therefore, in a follow-up study (chapter 6), the effect two validated sterilization methods 
(γ-irradiation and ethylene oxide (EtO) degassing) on the in vitro and in vivo performance 
was investigated. In vitro analyses did not reveal any preference for a specific type of 
sterilization. However, immediate contact with urine resulted in fast Vicryl degradation and 
loss of structural integrity in both sterilized constructs. Structural integrity is required for 
long-term strength and tissue regeneration. Direct implantation (without pre-implantation) 
of the construct in the urinary tract is therefore not advisable. Urine has no buffering capacity 
and therefore cannot prevent pH-dependent hydrolysis of Vicryl [16]. Furthermore, bacterial 
infections may have facilitated enzymatic degradation [17]. These phenomena explain the 
results of chapter 5, in which direct implantation of the constructs in the urinary tract (with or 
without cells) resulted in a worse outcome than the pre-implanted group.
In an adult goat model, the constructs were pre-implanted and subsequently used to create 
artificial urinary conduits. Subcutaneous pre-implantation of a γ-sterilized hybrid construct 
resulted in better tissue remodeling and improved outcome when functionally implanted, 
compared to EtO-sterilized constructs. Tissue remodeling of the EtO-sterilized construct was 
less advanced in the subcutis and thus construct material was still excessively present at 
the time of conduit creation. This study showed that the effect of sterilization on construct 
behavior was substantial and could not be predicted by in vitro analyses alone. Thus a full 
panel of in vitro and in vivo analyses, including a validated sterilization method is needed for 
a successful clinical translation of biomaterials.
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CONCLUSIONS
This thesis describes the recent developments in urological tissue engineering using 
systematic reviewing techniques and the development of an artificial urinary conduit. 
A systematic search strategy created an overview of all the published clinical data on 
urological tissue engineering. These studies indicated that an artificial urinary conduit 
should be evaluated in consecutive healthy and diseased large animals. Furthermore, this 
thesis describes the development of an artificial urinary conduit – from biomaterial, animal 
model, implantation strategy to sterilization method. Subcutaneous pre-implantation of a 
γ-irradiated hybrid construct from type I collagen and a biodegradable Vicryl polymer mesh, 
is the initial step in the creation of an artificial urinary conduit.
FUTURE PERSPECTIVES
Before clinical translation can be considered, several adjustments can be envisioned to 
improve the functional outcome and generation of urinary tissue to provide long-term 
satisfaction for patients requiring an urinary conduit.
Regeneration of urological-like tissue
The primary concern in creating an artificial urinary conduit is the maintenance of urinary 
flow to prevent kidney damage (hydronephrosis). Although urinary flow was present in 
the artificial conduits some degree of hydronephrosis, the consequence of contraction at 
the implantation site, occurred. This can be partly attributed to the presence of toxic urine 
which may harm the regenerating process and formation of new tissue [18]. It is important 
to quickly establish an epithelial layer to protect the new tissue and prevent contraction 
and subsequent hydronephrosis. The well-vascularized graft has already shown to be a 
good template for epithelial growth, but this process only starts after implantation. The 
feasibility of combining pre-implantation with cell seeding was demonstrated previously in 
a rabbit model. A tubularized bladder acellular matrix was seeded with epithelial cells and 
pre-implanted in the omentum. The epithelialized graft was subsequently used to create 
successful artificial conduits [19]. The combination of subcutaneous pre-implantation with 
cell-seeding is the first step to improve the artificial urinary conduit.
In artificial urinary conduits, urine will passively flow into the urine collection (urostomy) bag 
by itself. Urinary drainage can be further enhanced by the development of a peristaltic muscle 
layer in the conduit to facilitate active drainage. An in vivo bioreactor, like the subcutis, is a 
recommendable approach to create such a muscle layer. Alternatively, an in vitro bioreactor 
imitating urinary flow could aid in maturation of a muscle layer, and even the formation of an 
epithelial layer, before in vivo implantation [20]. The disadvantage of this approach is the lack 
of a formed vascular network, probably inducing hypoxia, cell death and contraction after 
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implantation. Furthermore, the addition of a cellular component requires GMP regulations 
for clinical implementation, which is an expensive and labor-intense procedure [21]. For 
bladder pathologies care must be taken with the use of bladder cells, like epithelial cells, 
since they may be unsuited due to pre-malignancy [4, 22]. Therefore. for future application of 
cells in the artificial urinary conduits other cell sources should be explored such as adipose-
derived stem cells, urine-derived stem cells or bone-marrow derived cells [23].
Vascularization
Survival of the newly formed tissue or seeded cells in the artificial conduit is dependent 
on the formation of a perfused vasculature. Subcutaneous pre-implantation results in 
a well-vascularized autologous tissue, but required disruption of the vasculature stalk for 
transposition. The omentum is an alternative pre-implantation site in which the vasculature 
can be preserved during transposition. Nevertheless, this surgical procedure is more 
invasive and may result in and extremely fibrous graft with abdominal (bowel) adhesions 
[24]. Optimization of vascularization in the subcutaneous pre-implantation is therefore 
recommended. We hypothesized that the emergence of hypoxic signals after transposition 
results in inosculation and perfusion of the created vasculature in the graft. This effect may 
be enhanced by the incorporation of extracellular matrix signaling cues like growth factors 
or elastin [25]. Addition of signaling cues to the construct or pre-implant may improve 
vasculogenesis and/or inosculation after functional implantation.
Evaluation techniques
The in vivo monitoring of product performance and tissue regeneration is one of the major 
issues concerning evaluation of novel TERM products in large animals. Blood or urine 
analyses provide valuable information regarding kidney function, but additional methods are 
needed for quantitative and qualitative evaluation of tissue remodeling in the same animal. 
Hence, real-time and non-invasive imaging techniques are necessary. Many techniques, such 
as magnetic resonance imaging (MRI) rely on perfusion of newly formed vascular structures 
in the graft, using a magnetic contrast agent [26]. The vascular structures formed during pre-
implantation makes this non-invasive in vivo analysis possible. To investigate the fate of the 
construct material in an earlier stage, when no vasculature is yet present, the construct can 
be conjugated with ultra-small super-paramagnetic iron oxide (USPIOs) [27]. Optimization 
of functionalized construct material for imaging and the development of suitable imaging 
techniques is thus desirable.
Industrialized production
To maximize clinical translation, preparation of the hybrid tubular constructs was performed 
in a clean room facility (EMCM B.V., Nijmegen, The Netherlands) using medical grade collagen 
(Collagen Solutions, Glasgow, Scotland). The final product is a combination of collagen and 
the Vicryl polymer mesh, packaged in ethanol and sterilized by γ-irradiation. The Vicryl woven 
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mesh is a commercially available and FDA-approved product, but it is only available as a 2D 
rectangular mesh (Ethicon, Inc., Somerville, NJ, USA). For this thesis, the Vicryl mesh was 
manually tubularized and sutured under semi-sterile conditions. An industrialized, controlled 
and sterile environment is required for large scale production of tubular meshes to maximize 
clinical implementation. For instance electrospinning. This techniques uses an electric field 
to process polymers, like Vicryl (a PGA/PLA copolymer), in fibers on a cylindrical mold [28]. 
Alternatively, coupled helical coils can be created using winding and curing techniques of a 
copolymer around a cylindrical mold. After fusing of the polymer intersections at the curing 
temperature a stable mesh/coil can be created [29]. The aforementioned strategies may 
aid in the manipulation of the Vicryl degradation time, since a fully degraded construct is 
necessary for a successful clinical outcome. Increased γ-ray dosage during sterilization or 
decreased collagen cross-linking efficiency may also be advantageous as these contribute to 
construct degradation.
Urine collection (ostomy) bags
Focus should be directed to application of an ostomy bag for further optimization and 
clinical application of the artificial urinary conduit. The eversion of bowel tissue in the 
classical treatment (ileal conduit) allows perfect application of such bags. Eversion of the 
pre-implants was used on several occasions, but could not be maintained as a consequence 
of tissue regeneration. Redesign of the traditional stoma application bags may therefore be 
required.
Large and long-term animal studies
Correct approximation of the feasibility and applicability in a human situation requires, 
standardized, controlled and comparable preclinical animal studies using large animals from 
different species, ages and sexes. This also requires optimization of the pre-implantation time 
in different animals (pigs. vs goats) to generate a fully autologous tissue graft. The systematic 
researches performed in this thesis did not reveal a particular animal model that adequately 
predicted the clinical outcome, but a trend towards more successful experimentation in large 
animals. Nevertheless, the literature mainly describes pigs and dogs, while other large animals 
may be equally suitable. Furthermore, long-term evaluation (> 1 year) is important to identify 
all potential outcomes and possible difficulties since conduits need to last the lifetime of the 
patients. The outcomes should be compared to animals receiving the classical treatment, i.e. 
the ileal conduit, to fully appreciate the advantage of TERM for urinary diversion.
Clinical translation
The optimized pre-implanted tubular construct might be suitable for the frail (adult) 
patient population with bladder cancer, awaiting radical cystectomy and subsequent 
urinary diversion. Clinical implementation of the artificial conduit however, requires further 
optimization of the results from this thesis. Nevertheless, lessons learned from this research 
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can be translated to pediatric patients or patients with other tubular organs pathologies. 
In pediatric patients, autologous grafts may be used to create a temporary conduit or even 
a Mitrofanoff-stoma. Mitrofanoff stomas function as a drainage system for the bladder. The 
bladder itself remains intact and therefore the chance of hydronephrosis is minimal. The 
procedure is less invasive an probably most suitable for a first clinical trial [30]. Autologous 
tissue grafts may be also used for other urological tubular structures including the ureter [31] 
or urethra [32] or large tubular organs such as the esophagus [33] or trachea [34].
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Voor patiënten met verworven of aangeboren blaasafwijkingen, zoals een blaastumor of een 
neurogene blaas, kan een chirurgische ingreep de beste behandeling zijn om een adequate 
urineafvoer te realiseren. Er zijn meerdere mogelijkheden voor de constructie van een 
urinederivatie, maar in principe gaat de voorkeur uit naar een neoblaas. In deze procedure 
wordt een nieuwe urineblaas gemaakt van lichaamseigen darmweefsel, waarmee de patiënt 
normaal kan urineren. Echter, in de praktijk wordt er bij de meeste patiënten een incontinente 
urostoma aangelegd. Dit is een derivatie van darmweefsel tussen de ureteren (urineleiders) 
en de buikwand, waarbij urine in een stomazakje wordt opgevangen. Hoewel patiënten met 
een urinederivatie een acceptabele kwaliteit van leven ervaren, is darmweefsel in principe 
niet geschikt voor de afvoer van urine. Daarnaast gaat het gebruik van darmweefsel gepaard 
met een hoog risico op complicaties. In sommige gevallen leidt het zelfs tot een heropname 
in het ziekenhuis met grote (financiële) gevolgen voor de patiënt en de gezondheidszorg.
Mogelijkerwijs kan Tissue Engineering en Regeneratieve Geneeskunde (TERM) het gebruik 
van darmweefsel overbodig maken en daarmee de complicaties en medische kosten 
beperken. In dit proefschrift worden eerst de meest recente ontwikkelingen over urologische 
tissue engineering (urineblaas en urinederivatie) beschreven. Daarna wordt dieper ingegaan 
op de ontwikkeling van een kunststoma als alternatief voor het gebruik van darmweefsel bij 
de incontinente urostoma.
Diermodellen en systematische reviews
In het eerste gedeelte van dit proefschrift is getracht om via een systematische zoekstrategie 
een overzicht te maken van al het beschikbare bewijs van TERM voor de urineblaas (hoofdstuk 
2) en urinederivatie (hoofdstuk 3) in diermodellen. De selectie van een geschikt diermodel 
is essentieel om uiteindelijk de klinische vertaalslag te kunnen maken. Het voordeel van 
een systematische review, ten opzichte van een conventionele review, is de specifieke 
doch uitgebreide zoekstrategie. Deze methode minimaliseert het risico op onopzettelijke 
uitsluiting van relevante studies. Ter voorbereiding van een onderzoek(svoorstel) kan deze 
werkwijze de onderzoeker van een gedegen achtergrondkennis voorzien en duplicatie van 
dierexperimenten voorkomen. Een meta-analyse van de verzamelde data kan vervolgens 
onopgemerkte hiaten identificeren en inzicht geven in een passend ontwerp van preklinische 
dierstudies.
Om de waarde van dierexperimenten voor de klinische translatie te bepalen, is in hoofdstuk 
2 de literatuur over TERM voor de urineblaas systematisch onderzocht. TERM voor de 
urineblaas is een groot thema binnen de urologische tissue engineering en heeft als doel het 
blaasvolume te herstellen. Hoofdstuk 2 liet zien dat dit inderdaad haalbaar is in gezonde grote 
dieren, zoals honden en varkens. Dit kan verklaard worden door de anatomische gelijkenissen 
tussen mensen en grote dieren. TERM producten van een realistische grootte kunnen in grote 
dieren op een klinisch relevante wijze worden bestudeerd [1,2]. Gebaseerd op de goede 
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uitkomst in de gepubliceerde studies met grote dieren is een fase I klinische trial gestart 
die een evenzeer veelbelovend resultaat liet zien. Echter, deze goede resultaten konden in 
verdere studies niet worden bevestigd. De klinische verschillen tussen de patiëntengroepen 
uit deze studies kunnen hieraan hebben bijgedragen [3]. Uit de systematische review blijkt 
dat de keuze voor het diermodel werd beïnvloed door ervaring en financiële, ethische en 
praktische overwegingen. De klinische voorspellende waarde is onvoldoende meegenomen 
in de besluitvorming.
In hoofdstuk 3 is een zelfde systematische zoekstrategie gebruikt om een overzicht te geven 
van alle diermodellen waarin TERM-constructen voor urinederivatie werden getest. Het 
doel was om hieruit een diermodel te identificeren met de grootste klinisch voorspellende 
waarde. Hoewel er een aanzienlijke hoeveelheid in vitro experimenteel werk is verricht, is 
het aantal gepubliceerde dierstudies over dit onderwerp beperkt. Waarschijnlijk is dit het 
gevolg van de noviteit van dit zeer specifieke onderzoeksveld. De studies (n=7) waren allen 
haalbaarheidsonderzoeken met een korte follow-up periode en grote onderlinge variatie in 
gebruikte diermodellen en biomaterialen. De beste resultaten werden behaald in grote dieren, 
maar een specifieke diersoort kon met deze review niet worden geïdentificeerd. Daarom 
is ervoor gekozen om relevante informatie uit vergelijkbare en grote onderzoeksvelden te 
halen, zoals tissue engineering voor de urineblaas, zoals beschreven in hoofdstuk 2. 
Deze review laat zien dat TERM-constructen voor urinederivatie in eerste instantie in gezonde 
dieren moeten worden geëvalueerd. In een volgende fase zullen de beste constructen 
in pathologische dieren moeten worden getest omdat de uitkomst significant door het 
ziektebeeld kan worden beïnvloed [4-6]. In beide gevallen is een lange follow-up periode 
gewenst. Het ontwikkelen van een kunststoma staat nog in de kinderschoenen en de 
experimenten zoals verder beschreven in dit onderzoek zijn daarom in grote, gezonde dieren 
uitgevoerd.
Biomaterialen
Baanbrekend onderzoek in varkens heeft al eerder laten zien dat een kunststoma kon 
worden gemaakt van een tubulair hybride construct van collageen met een semi-afbreekbare 
polymeer mesh [7]. Echter, de gebruikte polymeer mesh was niet biocompatibel en behoefde 
verbetering. In hoofdstuk 4 zijn daarom nieuwe hybride collageenconstructen ontwikkeld 
met een snel-afbreekbare polymeer mesh (Vicryl) óf een extra verstevigende laag van 
collageen. De biocompatibiliteit van de vernieuwde constructen is vervolgens vergeleken met 
het originele construct [7] in blaasdefecten van varkens. De experimenten uit dit hoofdstuk 
laten zien dat het hybride construct van collageen en de snel-afbreekbare Vicryl mesh 
superieur is qua chirurgisch gebruik, biocompatibiliteit en weefselregeneratie. Vicryl is een 
commercieel verkrijgbaar hechtmateriaal, bestaande uit 90% glycolide en 10% lactide. In de 
klinische praktijk wordt dit type meshes al gebruikt voor borst- en buikwandreconstructies 
[8,9]. Momenteel wordt de toepassing van deze mesh ook voor de reconstructie van de 
slokdarm en hernia’s van het diafragma nog onderzocht [10,11]. Klinische translatie van deze 
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materiaalcombinatie zal daarom minder gecompliceerd zijn dan van een niet-commercieel 
verkrijgbaar materiaal.
Kunststoma
In hoofdstuk 5 werd het superieure hybride construct uit hoofdstuk 4 middels drie 
verschillende technieken als kunststoma in varkens getest. In de eerste groep werd het 
construct direct als kunststoma geïmplanteerd. In de tweede groep werd het construct eerst 
gecombineerd met blaascellen en daarna direct als kunststoma geïmplanteerd. In de laatste 
groep werd het construct eerst in de onderhuid geïmplanteerd, waarna het resulterende 
lichaamseigen weefsel (graft) werd gebruikt om een kunststoma te maken. Deze laatste 
methode was het meest succesvol vanwege de beperkte hydroureteronephrose (uitzetting 
van nieren en ureteren, nierschade) en gedeeltelijke regeneratie van urologisch weefsel. 
Tijdens een subcutane implantatie vindt eerst afbraak en regeneratie van het biomateriaal 
plaats zonder interactie met schadelijke urine. Hierdoor wordt een volledig lichaamseigen en 
gevasculariseerde graft gevormd die als kunststoma kan worden geïmplanteerd.
Tussen de diagnose van blaaskanker en het verwijderen van de blaas (radicale cystectomie) 
zit een periode van (maximaal) drie maanden, waarin deze onderhuidse implantatie 
poliklinisch kan plaatsvinden [12]. De procedure is minimaal-invasief met een gering risico 
op complicaties. Ten tijde van de radicale cystectomie kan de graft worden verwijderd via 
een simpele incisie en als kunststoma worden geïmplanteerd. Het gebruik van darmweefsel 
wordt hierdoor overbodig.
Hoewel een onderhuidse implantatie resulteerde in een succesvolle kunststoma, werd 
desondanks hydroureteronephrose en contractie van de kunststoma geobserveerd. 
Twee oorzaken kunnen hieraan ten grondslag liggen. Ten eerste zijn er jonge varkens 
gebruikt. Deze dieren staan bekend om een snel weefselherstel, snelle groei en specifieke 
huideigenschappen [13,14]. Ten tweede kan de keuze van sterilisatie van de materialen de 
uitkomst significant hebben beïnvloed aangezien γ-straling de degradeersnelheid van Vicryl 
verhoogt [15].
Het effect van sterilisatie
Derhalve is in een vervolgstudie (hoofdstuk 6) het effect van twee gevalideerde 
sterilisatietechnieken op het construct onderzocht. Hiervoor zijn zowel in vitro (buiten 
het lichaam) als in vivo (binnen het lichaam) experimenten uitgevoerd. Op basis van in 
vitro experimenten was er geen duidelijke voorkeur voor sterilisatie met γ-bestraling 
of ethyleenoxide gas (EtO). Daarentegen, directe blootstelling van zowel EtO- als γ 
-gesteriliseerde constructen aan urine resulteerde in een snelle degradatie van het Vicryl 
polymeer en een sterk verminderde structurele integriteit. Structurele integriteit is nodig om 
genoeg weerstand aan de omliggende weefsels te bieden voor een goede urine doorstroom 
en om weefselregeneratie te bevorderen. Directe implantatie in de urinewegen is daarom 
niet wenselijk. Urine heeft geen buffercapaciteit en kan daardoor pH-afhankelijke hydrolyse 
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van Vicryl niet voorkomen [16]. Daarnaast kunnen bacteriën vanuit de stoma-uitgang ook 
bijdragen aan enzymatische degradatie van Vicryl [17]. Deze observaties kunnen de resultaten 
uit hoofdstuk 5 verklaren; directe implantatie van het construct (met en zonder cellen) als 
kunststoma liet een slechtere uitkomst dan de kunststoma van lichaamseigen weefsel.
Na de in vitro experimenten, zijn beide gesteriliseerde constructen onderhuids geïmplanteerd 
en als kunststoma getest in een geitenmodel (in vivo). De γ-gesteriliseerde constructen 
lieten een betere uitkomst zien dan de EtO-gesteriliseerde constructen. Na onderhuidse 
implantatie van het EtO-gesteriliseerde construct was de weefselregeneratie in deze graft 
volledig. Het nog aanwezige Vicryl polymeer in deze groep werd derhalve direct blootgesteld 
aan schadelijke urine in de kunststoma, wat resulteerde in een snel verlies van structurele 
integriteit en een slechtere uitkomst. De kunststoma gemaakt van een γ-construct liet een 
betere uitkomst zien, alsmede door de vergevorderde regeneratie. Deze studie laat zien dat 
sterilisatie een significant effect op de uitkomst kan hebben. Een combinatie van in vitro én 
in vivo analyses van gesteriliseerde constructen is nodig voor een succesvolle vertaling naar 
de klinische toepassing.
CONCLUSIES
Dit proefschrift beschrijft de meest recente ontwikkelingen op het gebied van systematische 
zoekstrategieën voor urologische tissue engineering en de ontwikkeling van een kunststoma. 
Een systematische zoekstrategie creëert een overzicht van alle gepubliceerde preklinische 
data over urologische tissue engineering. Hieruit blijkt dat een kunststoma gedurende lange 
tijd moet worden getest in grote, gezonde en pathologische, dieren. Aansluitend presenteert 
dit proefschrift de ontwikkeling van een kunststoma – van biomateriaal, diermodel, 
implantatiestrategie tot en met de sterilisatiemethode. De onderhuidse implantatie van het 
γ-gesteriliseerde hybride construct, van collageen en een biodegradeerbaar Vicryl polymeer, 
is de eerste stap richting de ontwikkeling van een kunststoma.
TOEKOMSTIGE ONTWIKKELINGEN
Verdere verbetering van de kunststoma, zoals gepresenteerd in dit proefschrift, is nodig voor 
het maken van de klinische vertaalslag naar de patiënt.
Regeneratie van urologisch weefsel
De grootste uitdaging voor de ontwikkeling van een kunststoma is het behouden van 
de urineafvoer en het voorkomen van hydroureteronephrose (nierschade). Ondanks de 
adequate urineafvoer in de kunststoma’s uit dit proefschrift, werd een zekere mate van 
hydroureteronephrose geobserveerd. Dit kan gedeeltelijk worden verklaard doordat urine het 
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regeneratieproces verstoorde en zo contractie van het construct of de graft veroorzaakte [18]. 
Het is daarom van groot belang om zo spoedig mogelijk een beschermende bekleding van 
epitheelcellen aan de binnenkant van de kunststoma te creëren. De gevasculariseerde graft 
uit de onderhuid heeft al bewezen een goede basis te zijn voor de groei van epitheelcellen, 
maar dit proces start pas na anastomose met de ureter. Recentelijk is in een konijnenmodel 
een gedecellulariseerde tubulaire matrix met epitheelcellen in het omentum geïmplanteerd. 
In de graft werd een epitheellaag gevormd die bijdroeg aan een verbeterde uitkomst van de 
kunststoma na aansluiting [19]. Het combineren van onderhuidse implantatie met (epitheel)
cellen is de eerste stap om de kunststoma te verbeteren.
In patiënten met een kunststoma vloeit de urine normaal gesproken vanzelf in een 
stomazakje (urostomiezakje). Dit proces kan worden verbeterd door de ontwikkeling van een 
peristaltische spierlaag in de wand van de kunststoma die zorgt voor een actieve afvoer van 
urine. Een in vivo bioreactor, zoals de onderhuid of het omentum (vetschort), is een aanbevolen 
methode om deze spierlaag te creëren. Een andere mogelijkheid is een in vitro bioreactor die 
de vloeistofstroom nabootst. Hierdoor kan de spierlaag, en eventueel de epitheellaag, zich 
ontwikkelen voordat deze in vivo wordt geïmplanteerd [20]. Het nadeel van deze techniek is 
het gebrek aan bloedvaten, wat kan leiden tot hypoxie (zuurstoftekort), celdood en contractie 
van de kunststoma. Om een TERM-construct met cellen te combineren moet de procedure 
voldoen aan strikte GMP-voorschriften. Dit is een erg kostbaar en arbeidsintensief proces [21]. 
Bovendien zijn de lichaamseigen blaascellen van patiënten met een blaasafwijking mogelijk 
ongeschikt vanwege het risico op maligniteit [4,5]. Daarom moeten ook andere celbronnen 
worden onderzocht, zoals stamcellen uit vet, urine of beenmerg [22].
Vascularisatie
Het voortbestaan van nieuw gevormd weefsel of van geïmplanteerde cellen is afhankelijk van 
de bloedvoorziening in het construct of de graft. Onderhuidse implantatie resulteert in een 
gevasculariseerde en lichaamseigen graft, maar voor transpositie naar de ureter worden de 
vasculaire structuren verbroken. Het omentum is een alternatieve locatie, waar de gevormde 
bloedvaten intact kunnen blijven tijdens transpositie. Daar tegenover staat dat deze ingreep 
invasiever is en dat er een risico bestaat op een zeer fibrotische graft en adhesie aan de 
omliggende darmen [23]. Optimalisatie van de vascularisatie in de onderhuid geniet daarom 
de voorkeur. Het vermoeden bestaat dat het ontstaan van hypoxie na implantatie van de 
kunststoma zal leiden tot verbinding met het bestaande vasculaire netwerk. Dit effect kan 
worden versneld door het toevoegen van groeifactoren en/of elastine, signaalmoleculen die 
normaal gesproken in de extracellulaire matrix voorkomen [24].
Evaluatie technieken
Het evalueren van de constructen na implantatie in grote dieren is een uitdaging. Analyse 
van bloed en urine geeft waardevolle informatie over de nierfunctie, maar aanvullende 
technieken zijn nodig voor het verkrijgen van meer kwalitatieve en kwantitatieve data. Real-
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time en niet-invasieve beeldvormingstechnieken zijn nodig om een construct in één en 
hetzelfde dier te volgen. Dit kan mogelijk leiden tot een reductie in het aantal benodigde 
proefdieren. Technieken als magnetic resonance imaging (MRI) maken gebruik van een 
contrastmiddel met magnetische deeltjes [25]. De vaatstructuren die in de graft worden 
gevormd, maken deze niet-invasieve in vivo analyse mogelijk. Om de functionaliteit van 
het construct ook in een vroeger stadium te onderzoeken, wanneer er nog onvoldoende 
vaatstructuren zijn gevormd, kan collageen worden geconjugeerd met ultra-small super-
paramagnetic iron oxide (USPIO’s) [26]. Verdere optimalisatie van het construct in combinatie 
met de ontwikkeling van bruikbare beeldvormingstechnieken is daarom wenselijk.
Geïndustrialiseerde productie
Om de klinische translatie te bevorderen, zijn de constructen uit dit proefschrift gemaakt 
met collageen van medische kwaliteit (Collagen Solutions, Glasgow, Scotland) in de 
gecontroleerde omgeving van een clean room (EMCM B.V., Nijmegen, The Netherlands). 
Het eindproduct van deze studie bestaat uit een combinatie van collageen en Vicryl, 
verpakt in blisters met ethanol en gesteriliseerd met γ-bestraling. Vicryl is een commercieel 
verkrijgbaar product, maar als mesh alleen verkrijgbaar in een 2D rechthoekige vorm. Voor 
de dierstudies uit dit proefschrift is de mesh handmatig en onder semi-steriele condities 
gehecht. Voor grootschalige productie van tubulaire meshes, is een geïndustrialiseerde 
methode in een gecontroleerde en steriele omgeving vereist. Een voorbeeld hiervan is 
electrospinning. Deze techniek maakt gebruik van een elektrisch veld om polymeren zoals 
Vicryl (PGA/PLA polymeer) in ultradunne vezels om een tubulaire mal te spinnen [27]. Een 
andere mogelijkheid is het maken van coupled helical coils (CHC). In dit proces worden 
polymeerdraden om een mal gedraaid en aan elkaar vast gesmolten waardoor een stabiele 
mesh/spiraal ontstaat [28]. Deze strategieën kunnen tevens bijdragen aan de manipulatie 
van de degradatietijd van Vicryl. Dit is belangrijk aangezien een volledige degradatie nodig is 
voor een goede functionele uitkomst. Het verhogen van de γ-straling tijdens sterilisatie of het 
beperken van collageen cross-linking zou de degradatie ook kunnen versnellen.
Opvang van urine
Eén van de essentiële punten om klinische translatie naar de patiënt mogelijk te maken is 
het ontwerp van een passend opvangzakje (urostomiezakje) voor de urine uit de kunststoma. 
In de huidige methode wordt een stukje darm geëverteerd zodat deze precies aansluit op 
het urostomiezakje. Everteren is bij verschillende kunststoma’s uit dit proefschrift toegepast, 
maar door weefselregeneratie kon dit niet worden gehandhaafd. Een nieuw ontwerp van de 
traditionele urostomiezakjes is dus nodig om deze toepasbaar te maken voor de kunststoma.
Langdurige en grote dierstudies
Om de prestatie van de kunststoma in patiënten nauwkeurig te kunnen voorspellen zijn 
gestandaardiseerde, gecontroleerde en vergelijkbare preklinische dierstudies nodig met 
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dieren die verschillen in soort, leeftijd en geslacht. In hoofdstuk 4,5 en 6 is een verschil gezien 
in de weefselregeneratie tussen varkens en geiten. Om een lichaamseigen graft toepasbaar 
te maken voor verschillende diersoorten en mensen, is optimalisatie van de onderhuidse 
implantatietijd nodig.
De systematische zoekstrategieën uit dit proefschrift konden geen optimaal klinisch-
voorspellend diermodel identificeren. Desalniettemin kon een trend worden geobserveerd 
van succesvolle experimenten in grote dieren. In de literatuur zijn vooral varkens en honden 
gebruikt, hoewel andere grote dieren wellicht even geschikt kunnen zijn. Lange-termijn 
evaluaties (>1 jaar) zijn van groot belang om alle mogelijke uitkomsten en nadelige effecten te 
inventariseren. Zodoende kunnen we inzicht krijgen hoe een kunststoma zich zal gedragen in 
patiënten. Tevens zullen er ook dieren moeten worden behandeld met de huidige standaard 
techniek, om het voordeel van een kunststoma ten opzichte van darmweefsel zo volledig 
mogelijk te kunnen vaststellen.
Klinische translatie
Een geoptimaliseerde kunststoma kan het aantal complicaties beperken voor 
blaaskankerpatiënten die in aanmerking komen voor een radicale cystectomie. De resultaten 
van dit proefschrift kunnen daarnaast ook worden vertaald naar andere patiëntengroepen, 
zoals jonge patiënten met urologische problemen of patiënten met problemen aan andere 
tubulaire organen. In kinderen kan een kunststoma worden gebruikt als een tijdelijke 
urinederivatie of zelfs als Mitrofanoff-stoma. Bij een Mitrofanoff-stoma blijft de urineblaas 
intact en wordt de stoma direct aan de blaas vastgemaakt. De blaas wordt dan via een 
stoma-katheter geleegd, waardoor er een verminderd risico op hydroureteronephrose 
is. De procedure is minder invasief en waarschijnlijk het meest geschikt voor een initiële 
klinische trial [29]. De lichaamseigen grafts kunnen ook voor andere (urologische) tubulaire 
toepassingen worden gebruikt, zoals de ureter (urineleider [30]), urethra (plasbuis [31]), 
oesophagus (slokdarm [32]) of trachea (luchtpijp (33]).
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DANKWOORD
Ik ben erg trots op het werk wat nu voor u ligt. Daarom zou ik graag samen met u willen 
terugblikken op een mooie periode van samenwerkingen, leermomenten en vriendschappen. 
Weet, dat als ik u hier ben vergeten te noemen, ik u hoe dan ook ontzettend dankbaar ben 
voor uw bijdrage aan dit proefschrift. 
Geachte Prof. Feitz, beste Wout. Je optimistische benadering van problemen, die jij als 
uitdagingen beschouwt, zijn een inspiratie. Je hebt me laten zien dat het slechts kleine 
opstapjes zijn in de vertaling van onderzoek naar een klinische toepassing. Een doel wat 
nooit uit het oog verloren moet worden. De mogelijkheden en ideeën binnen dit onderzoek 
waren oneindig en daarvoor wil ik je heel graag bedanken. 
Beste Egbert, de afgelopen jaren heeft jouw deur altijd open gestaan. In die zeldzame 
momenten dat ik het overzicht verloor, kon jij me helpen en vroeg je wat er voor nodig 
was om het op te lossen. Het schrijven van mijn eerste manuscript ging niet zonder slag of 
stoot. Na het figuurlijk verscheuren van mijn eerste introductie duurde het nog even voor 
mijn leerproces ten einde was. Volgens mij ben ik er nog steeds niet maar het heeft ertoe 
bijgedragen dat mijn schrijven in ieder geval is verbeterd. Ontzettend bedankt voor deze 
investering in mij en de dagelijkse bereidheid tot het beantwoorden van al mijn vragen. 
Beste Paul, toen je me vlak na mijn aanstelling vertelde dat je had besloten een ander pad 
in te slaan, vond ik dat enorm jammer. Tijdens mijn bachelor stage was de begeleiding en 
samenwerking al heel prettig en dus was jij één van de redenen om voor dit project te kiezen. 
Gelukkig kan ik nu zeggen dat er na je vertrek eigenlijk niks veranderde. Van onze gesprekken 
op vrijdag kreeg ik hernieuwde energie en gewapend met nieuwe ideeën kon ik de week 
daarop weer verder. Zelfs tijdens de laatste fase van dit onderzoek heb je me wekelijks 
geholpen. Bij jou thuis aan de keukentafel hebben we in de avonduren de laatste hand aan 
de hoofdstukken gelegd. Paul, ontzettend bedankt voor je enthousiasme en mentorschap. 
Lieve collega’s van de tissue engineering groep, voor jullie een speciaal plekje in dit 
dankwoord. Paul (De Jonge, red.), onze onderzoeken zijn sinds het begin nauw met elkaar 
verbonden geweest. Ik was daarom ook heel blij om te horen dat jij na je stage ons TE team 
kwam versterken. We hebben mooie tijden doorgemaakt bij het CDL, op de boerderij en in 
de clean room. Ik heb altijd veel plezier aan onze samenwerking beleefd! Peter, there are 
too many good stories and memories to write down here, so I’ll save some for your defense. 
Next to my U-mate, you have become my friend in and outside the lab. I loved our coffee and 
ice cream meetings and of course ‘Prosit mit einem Weißbier‘. Dorien, ontzettend bedankt 
voor je hulp en vrolijkheid tijdens dit project. Als stabiele factor binnen de groep was je altijd 
bereid tot hulp en een luisterend oor als het nodig was. Silvia, you are an example how to 
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combine personal life with ambitions. Thanks for your input in the last phase of this research. 
Alejandra, Brontë and Rayna, thanks to you guys for great times in and outside the lab! Linde, 
Tamar, Peter en Wouter, hartelijk dank voor jullie bijdrage als student aan dit werk. 
Uiteraard was deze ervaring niet hetzelfde geweest zonder het complete lab en de arts-
onderzoekers van de afdeling urologie: Gerald, Ola, Onno, Cindy, Jasmijn, Mirjam, Dick, 
Tilly, Dorien, Kees, Jeanette, Elze, Marion, Nicolien, Vicky, Anglita, Sebastian, Boy, Rianne, 
Allert, Caroline, Hans, Tom, Siebren en Max. Met menigeen heb ik een hoop uurtjes boven 
een kop koffie of een biertje mogen kletsen of lachen. Beste Jack, hoewel je op inhoudelijk 
vlak minder met dit proefschrift te maken hebt gehad, ben ik ontzettend blij dat ik de kans 
heb gekregen om in deze fantastische groep te werken. Ik heb me altijd welkom gevoeld, 
waardoor ik kan terugkijken op een hele mooie periode. Er zijn maar weinig professoren die 
met zoveel charme en humor hun afdeling leiden. 
Mijn dankbaarheid gaat ook uit naar de fijne collega’s van het CDL. Alex, Maikel, Wilma, 
Conrad en Tom. Zoals een voorganger van mij ooit zei: ‘jullie maken het onaangename 
aangenamer’ en niets is minder waar. Vele uren hebben we samen in de OK’s of op de 
boerderij doorgebracht en ik heb gezien dat jullie allemaal je werk vol passie en met respect 
uitvoeren. Maikel, de busritten naar de boerderij waren legendarisch. 
Vasilis, I am very grateful for you input and contribution to this thesis. You were indispensable 
to the early phases of this work. Wout, Barbara, Robert en Luc, jullie waren altijd bereid tot 
een bijdrage aan dit onderzoek ondanks jullie drukke schema’s. Zelfs op hele korte termijn 
viel er altijd iets te regelen. Ontzettend bedankt daarvoor, zonder jullie hadden deze studies 
niet plaats kunnen vinden. 
Beste vrienden van de Biochemie afdeling. Henk, Luuk, Corien, Michiel en René, jullie wil ik 
uiteraard bedanken voor de goede samenwerking maar nog meer voor de extra curriculaire 
activiteiten. Vele grappen in een niet nader te noemen groepsapp en de biertjes in de 
Aesculaaf, tijdens de vierdaagse of boven een pizza van Romagna. Goeie tijden! 
Willeke, gedurende mijn project was je mijn mentor en het was altijd erg leuk om je te updaten 
over de voortgang van mijn project. Bedankt voor je interesse en begeleiding. 
Lieve vriendinnetjes die ik al zo lang ken. Steffanie, Lotte, Hilda en Anne. We hebben samen 
al zo veel beleefd sinds de middelbare school en daarom ben ik enorm blij dat ik ook deze 
ervaring met jullie heb kunnen delen. Bedankt voor jullie luisterend oor. 
Superßeta’s (Daan, Sander, Arne, Wouter, Siroon, Inge en Renee), niemand kan zo goed de 
ervaringen van een PhD-student begrijpen als jullie. Onze kerstmeetings zijn altijd weer een 
mooi moment om elkaar op de hoogte te stellen van onze struggles en ambities. Stiekem 
denk ik dat onze aanhang er gierend gek van wordt. 
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Fiducia-la-la-la-la, mijn feestbeestjes, therapeutjes, vakantiemaatjes en culi-fanaatjes: 
Renee, Annemieke, Joyce, Lisanne, Mirjam en Inge. Alle ervaringen, goed of minder goed, 
kunnen altijd tot in detail worden besproken. Na elke jaarclubavond ga ik weer met een goed 
gevoel naar huis en kan ik de hele wereld weer aan. Jullie waren/zijn onmisbaar! 
De bende van Gennep! Dick, Wilma, Monique, Mark, Noa, Mara, Project X, Bianca, Jeroen en 
Julian. Ik voel me helemaal thuis in de familie Postema en ik wil jullie graag bedanken voor de 
interesse die jullie in mij en dit project hebben getoond. De goede basis die ik nu in Gennep 
heb, heeft ertoe bijgedragen dat ik dit project in alle rust heb kunnen afronden. Natuurlijk 
ook bedankt aan Jim, Wiesje, Maryn, Britt, Sam, Elske, Kevin en Nick voor de nodige afleiding 
van die rust. 
Renee, je komt al twee keer voor in dit verhaal, maar toch wil ik graag in het bijzonder jou 
bedanken voor je steun de afgelopen jaren. Als huisgenootje stond je een tijd lang in de 
eerste vuurlinie van mijn verhalen. Ik kon ze altijd bij je kwijt en zelfs na een drukke dag als co-
assistent  was je altijd geduldig en geïnteresseerd. Ik ben daarom ook zo blij dat je vandaag 
als paranimf naast me staat. 
Lieve Lysanne, mijn kleine zusje. Links en rechts ben je me altijd voorbij gestreefd, maar 
vandaag sta je naast me. Als paranimf. Ik help jou, jij helpt mij. Hou je vandaag mijn handje 
vast? Ik vind het een beetje spannend. 
Lieve papa en mama, Frenk en Hetty. Al van jongs af aan hebben jullie mij mijn gang laten 
gaan in alles wat ik wilde doen en zo gestimuleerd om het beste uit mezelf te halen. Jullie 
zijn altijd trots op mij en ik geniet jullie onvoorwaardelijke steun. Dit proefschrift is voor jullie.
Lieve Derk, mijn laatste woord richt ik aan jou. Hoewel ons werk verschilt als dag en nacht 
(soms letterlijk) kun je mij op de juiste momenten op de belangrijke dingen in het leven 
wijzen. Bij jou heb ik een thuis gevonden en onvoorwaardelijk steun in wat ik doe. Je zou me 
volgen naar het einde van de wereld. Ik ben je daarvoor eeuwig dankbaar. Ik hoop dat we 
samen nog een heleboel mooie herinneringen gaan maken. Jij en ik. Ik hou van je.
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 Geutjes P, Roelofs L, Hoogenkamp H, Walraven M, Kortmann B, De Gier R, Farag F, 
Tiemessen D, Sloff M, Oosterwijk E, Van Kuppevelt T, Daamen W, Feitz W. Journal of 
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10. Improving the cell distribution in collagen-coated poly-caprolactone knittings. 
 Sun W, Tiemessen DM, Sloff M, Lammers RJ, De Mulder EL, Hilborn J, Gupta B, Feitz 
WF, Daamen WF, Van Kuppevelt TH, Geutjes PJ, Oosterwijk E. Tissue Engineering Part C 
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PHD PORTFOLIO
Name PhD candidate: M. Sloff
Department: Urology
Graduate School: Radboud Institute for Molecular Life 
Sciences
PhD period: 01-02-2012 – 27-7-2016
Promotor(s): Prof. W.F.J. Feitz
Co-promotor(s): Dr. E. Oosterwijk, 
Dr. P.J. Geutjes
Year(s) ECTS
TRAINING ACTIVITIES
a) Courses & Workshops
- Graduate Course
- Animal Course
- Presentation Skills
- Management for PhD’s
- FRAME training school
- Loopbaan management
- Academic Writing
- Histopathology
- Solliciteren en Netwerken
- Wetenschapsjournalistiek
- Embloyability outside Academia – PCDI 
(Utrecht)
2012
2012
2012
2012
2012
2013
2013
2014
2014
2014
2015
2
3
3
3
0,75
1
3
0,75
0,75
3
1
b) Seminars & lectures
- Technical Fora (16x)
- Seminars (12x)
- NCMLS Spotlight (4x)
- Radboud Research Rounds (9x)
- MMD Masterclass
- BMM Lecture Series
2012-15
2012-15
2012-15
2012-15
2013
2013
1,6
1,2
0,4
0,9
0,1
0,4
c) Symposia & congresses
- PhD Retreat (2 posters, 1 oral)
- TERMIS  world congress (2 poster, 2 orals) 
- EAU congress (2 posters)
- New Frontiers (1 poster)
- NBTE congress (1 poster, 2 orals)
- Minisymposium Systematic Reviews, RIMLS
- REFORM symposium, RIMLS
- Inspirational day on Systematic Reviews and 
Animal studies, KNAW (Laptop presentation)
- KNAW Stem Cell Forum 
2013-15
2012-15
2013-14
2013-14
2012-14
2012
2013
2014
2014
2,25
5,5
3,5
1,25
2,25
0,5
0,25
0,5
0,25
d) Other
- Journal Club (10x)
- PhD Committee Member
- Organization PhD Retreat (3x)
- Reviewing articles (2x)
2012-2015
2012-2015
2013-2015
2014
2,5
2
6
0,2
TEACHING ACTIVITIES
e) Lecturing
- Bijzondere Heelkunde bij Kinderen
- College 5KMP8
2014-2015
2014
1
0,25
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f) Supervision of internships / other
- Graduation Internship Technical Medicine, TU 
Twente
- Graduation Internship HLO, HAN
- Bachelor Internship Biomedical Sciences, RU
- VWO Profielwerkstuk, VWO, Karel de Grote 
College 
2013-2014
2012
2014
2015-2016
4
1
1,75
1
TOTAL 61,8 ECTS
^Indicate oral or poster presentation
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CURRICULUM VITAE 
Marije Sloff werd op 24 oktober 1987 geboren in Best. Na het behalen van haar VWO-diploma 
aan het Heerbeeck College Best in 2006, is ze Moleculaire Levenswetenschappen (MLW) gaan 
studeren aan de Radboud Universiteit in Nijmegen. Tijdens de bachelorstage van MLW kwam 
ze voor het eerst in aanraking met het begrip tissue engineering in de groep van Prof. Dr. 
W.F.J. Feitz (Urologie, Radboudumc, Nijmegen), wat uiteindelijk zelfs leidde tot de keuze voor 
het onderzoek. Maar dit werd niet voortgezet voor ze een semester aan UVM (Universitas 
Viridis Montis) had gestudeerd in Burlington, Vermont, USA. Daarna heeft Marije voor de 
afronding van haar MLW studie een half jaar onderzoek gedaan naar drug delivery systemen, 
in de groep van Prof. J. Hilborn aan Uppsala Universitet in Uppsala, Zweden.
Begin 2012 is Marije gestart met een promotieonderzoek op de afdeling Urologie van het 
Radboudumc, onder leiding van Prof. Dr. W.F.J. Feitz, Dr. E. Oosterwijk en Dr. P.J. Geutjes. 
De resultaten van dit onderzoek zijn gepresenteerd op (inter)nationale congressen en 
gepubliceerd in hooggewaardeerde tijdschriften. Tijdens haar PhD project is ze lid geweest 
van PhD Progam Committee en was ze onder meer betrokken was bij de organisatie van de 
jaarlijkse PhD-retraite en een aanspreekpunt was voor nieuwe PhD-studenten. 
Momenteel is Marije werkzaam als postdoctoraal onderzoeker bij de Universiteit van 
Maastricht (UM) en het Maastricht Universitair Medisch Centrum (MUMC+) op de afdeling 
Biomedische Technologie van Prof. T. Delhaas, onder leiding van Dr. B.M.E. Mees. Het project 
is gericht op het ontwikkelen van een nieuwe vaattoegang voor dialyse patiënten (XS-
graft). Het project is onderdeel van InSciTe, een publiek-privaat instituut voor biomedische 
materialen ontstaan uit de samenwerking tussen de Technische Universiteit Eindhoven en 
Royal DSM (Chemelot, Geleen).
